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DRUG MILK TO SERUM RATIO PREDICTION AND ONTOGENY OF CYP3A 
CLEARANCE PATHWAY AS A MODEL OF DRUG EXPOSURE IN THE 
DEVELOPING RAT  
 
 Transfer of drugs into milk and the clearance of drugs in neonates are critical 
determinants of the exposure of infants to drugs in breast milk.  Models predicting both 
parameters have been proposed.  The objective of this dissertation is to test two models 
predicting milk to serum ratio and an ontogeny clearance model predicting clearance in 
the neonate. 
 Predicted milk to serum ratio (M/S) values were generated according to the 
Atkinson and Begg model.  The model did not adequately predict M/S when comparing 
the predicted values to observed values in the literature. 
  The Fleishaker model was also tested.  The model was able to predict whether the 
drugs appeared in milk by passive diffusion only or whether active transport processes 
were involved.  This model, together with appropriate animal models, is useful in 
understanding the mechanism of drug transfer into milk. 
 An ontogeny model that predicts clearance was proposed earlier by our 
laboratory.  In order to test the model prediction and assumptions of constant microsomal 
protein and constant Km for an enzyme-substrate system with age, the male rat was used 
as an animal model.  The ontogeny of Cyp3a1, Cyp3a2, Mdr1a and Mdr1b mRNA was 
examined in the male rat liver and intestine.  The ontogeny pattern of Cyp3a2 mRNA, 
protein and in vitro Cyp3a activity were found to be similar in male rat liver.  The 
microsomal protein content was found to vary with age in the liver.  Km was found to be 
constant with age for the midazolam 4-hydroxylation by male rat liver microsomes.  
Scaling factors that extrapolate adult clearance to infant clearance were calculated from 
in vitro data.  The model did not predict the in vivo oral clearance of midazolam for day 7 
and 21 age groups from the 112 day age group (adult).  The assumption that intestinal 
availability in the rat pups and adults was equal to unity might not be true resulting in 
overprediction of rat pup clearance when compared to the adult.  Intestinal first pass 
effect for midazolam in adult rats might be significant.  More experiments are needed to 
further test the model adequacy in clearance prediction. 
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Chapter 1. Introduction 
Lactation is the ideal source of nutrition for a newborn.  The exposure of neonates 
to drugs or other xenobiotics through maternal milk has been demonstrated.  No 
conclusive approach is currently available to determine the extent of exposure that poses 
a risk to the neonate, due to the lack of data about the different factors affecting the 
exposure level.  Ethical and logistical concerns hinder the direct determination of this risk 
in neonates in vivo via clinical trials.  Several in vitro approaches and empirical models 
have been proposed in the literature for this purpose.  In this dissertation we examine 
models for prediction of two critical factors in determining infant exposure, namely the 
maternal milk to serum ratio of a xenobiotic and infant clearance. 
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Chapter 2. Background 
1 Lactation: 
 
Xenobiotic exposure imposes potential risk to lactating neonates through mother’s 
milk.  It has been shown to have numerous health and emotional benefits for both the 
mother and the infant.   Lactation protects the infant against various infections, enhances 
vaccine response, protects against allergies and enhances development and intelligence 
(AAP 1997).  As for the mother it has been demonstrated to decrease risks of breast and 
ovarian cancer, improve bone remineralization and enhance bonding with the baby.  
Moreover, there are benefits for society in terms of reduced health care costs and reduced 
employee absenteeism due to child illness (AAP 1997). 
Healthy People 2010 sponsored by U.S. Department of Health and Human 
Services (http://www.healthypeople.gov) aims at the increase of breastfeeding mothers 
from the baseline of 1998 of 64% in the early postpartum period to 75%, 29% at 6 
months to 50% and 16% at 1 year of age to 25%. 
Lactating mothers frequently take medications during lactation.  It has been 
reported that 90-99% of lactating mothers will receive a medication in the first week 
postpartum, 17-25% by 4 months and 5% will need chronic administration of a 
medication (Bennett and World Health Organization. Regional Office for Europe. 1988). 
Since the medications are more than likely to appear in the mother’s milk, there is 
always a concern about the safety of the neonate.  The risk versus benefit for both the 
mother and the infant are usually weighed by clinicians before administering medications 
during breastfeeding.  However, sometimes the mother opts to either temporarily or 
totally stop breastfeeding when taking a medication or not to take the medication 
altogether.  There is a dearth of knowledge about the safety of most of the drugs 
appearing in the milk to the neonate.  The extent to which many of the drugs appear in 
the milk as well as the newborn handling of these drugs is largely unknown.  In order to 
afford the mother a needed pharmacotherapy during breastfeeding or the infant a much 
needed healthy nutrition, more studies are needed which address the risks of exposure. 
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The American Academy of Pediatrics (AAP) classifies drugs taken during 
breastfeeding in terms of infant exposure and safety into the following classes (AAP 
2001): 
1-Cytotoxic drugs that may interfere with cellular metabolism of the nursing 
infant (e.g. cyclophosphamide and cyclosporine). 
2-Drugs of abuse for which adverse effects on the infant during breastfeeding 
have been reported. (e.g. amphetamine and cocaine). 
3-Radioactive compounds that require temporary cessation of breastfeeding (e.g. 
Iodine 131). 
4-Drugs for which the effect on nursing infants is unknown but may be of concern 
(e.g. anti-anxiety, anti-depressants, antipsychotic and other drugs such as 
chloramphenicol). 
5-Drugs that have been associated with significant effects on some nursing infants 
and should be given to nursing mothers with caution (e.g acebutolol and lithium). 
6-Maternal medication usually compatible with breastfeeding. 
The list detailing the drugs that are usually compatible with breastfeeding is the longest.  
Most of the effects cited for all of the above classes are either possible effects anticipated 
in the newborn, concerns about the concentration of the drug in either the milk or infant 
serum post the maternal dose or acute side effects in the infant (e.g. sedation, irritability, 
increased bowel movement…etc.).  Although many of the drugs that might be of concern 
(class 4) are chronic drugs taken by the mother (anti-anxiety and antidepressants), no 
reported or possible effects are reported in the AAP publication.  The long term effects of 
chronically taken drugs on the infant are lacking in the literature and in publications 
intended for guiding clinicians in prescribing drugs during breastfeeding (Riordan and 
Riordan 1984; AAP 2001; Hale 2004).  More studies are needed to follow up on the 
chronic exposure of infants to drugs via breast milk and the possible risks associated. 
The Food and Drug Administration has released a draft for the Guidance to 
Industry on Clinical Lactation Trials in 2005 
(http://www.fda.gov/cber/gdlns/clinlacstud.pdf ) which recommended mother-infant pair 
and mother only clinical trials on drugs.  While these trials would be beneficial, there are 
many cases in which the risk of the drug in question is unknown and many logistical 
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hindrances in terms of having a significant number of subjects in the study who are 
taking the same medication under similar conditions to have definitive results. 
Although some clinical data is currently available in the literature concerning the 
extent of appearance of some of the drugs in the milk and the serum levels and/or toxicity 
in the neonate, the scope is usually narrow and most of the time there are case study 
reports that are far from conclusive. 
 
2 Infant Exposure: 
 
Drug exposure of the infant through suckling has been described in the literature 
in various terms: Milk-to-serum ratio, dose in the mother’s milk, neonatal serum 
concentration and exposure indices (McNamara and Abbassi 2004). 
Milk-to-serum concentration ratio (M/S) has been reported in the literature 
frequently as a single-time point determination, or more usefully and less frequently, after 
steady state is reached in the milk and serum or as a ratio of AUCmilk/AUCserum following 
a single dose (Wilson 1983; Wilson, Brown et al. 1985). 
M/S is a step towards an estimate of the dose to which the infant is exposed but 
not a real measure of infant exposure.  M/S is a reflection of the distribution of drug 
between maternal milk and serum both by passive diffusion and active transport 
mechanisms.  Concentraton of a drug passively diffusing into milk is a function of an 
unbound, unionized concentration gradient set up by drug protein-binding in milk and 
serum, unionized fraction in milk and serum (function of pKa of drug and pH of medium) 
and partitioning into milk fat.  Active transport is dependent on the interaction of drug in 
serum and the transporter proteins present on the mammary epithelial barrier. 
The absolute dose which is administered to the neonate in milk reflects 
gastrointestinal and not necessarily systemic exposure.  The dose is a function of drug 
milk concentration and the volume of milk consumed by the infant per time interval. 
Hence, lower milk consumption in general means lower dose exposure. It has been 
implied in the literature that if the percentage of the infant dose is 10% or lower than that 
of the mother then little or no risk is expected (Begg, Duffull et al. 2002).  However, such 
an arbitrary cut-off has no evidence based clinical trials to support it. 
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The neonatal serum concentration best correlates with pharmacological effects 
and toxicity of the drug and thus is the determinant of systemic exposure.  Understanding 
how much drug actually gets in to the circulation determines the extent/risk of exposure 
assuming that the pharmacodynamic effects of a drug in the neonate or infant are the 
same as those in adults.  Such effects have not been very well studied in neonates (Berlin 
2003).  To be able to estimate the neonatal serum concentration either actual 
measurements have to be performed or accurate predicitions are needed.  Actual 
measurements impose both ethical and logistical hindrances.  If the drug is not meant for 
pediatric use or not expected to be used chronically by lactating mothers, there are ethical 
concerns about the justification of clinical studies in neonates.  However, this does not 
mean that neonates and infants will not be exposed to such types of drugs. If the drug is 
actually measured in the neonatal serum then the frequency and volume of sampling are 
concerns, hence scarce sampling is usually employed and the need of rigorous analysis of 
such data arises to be able to understand the pharmacokinetics in such a population.  
Predicting neonatal serum concentration entails understanding the factors influencing 
these concentrations. 
Systemic exposure can be expressed in terms of maximum serum concentration 
Cmax, average serum concentration at steady state, or area under the concentration time 
curve AUC after a single dose. 
For simplicity average serum concentration at steady state will be discussed to 
elucidate the factors affecting systemic exposure.  It can be described by Equation 1: 
                     
 
 
where   C infantserum      is the infant serum steady state concentration of a given drug , F
infant is 
the oral bioavailability of that drug since the drug is orally ingested via milk, Dinfant     is 
the dose of the drug ingested and infantsystemicCl  is the systemic clearance of the drug in the 
infant.  Since the dose of the drug is ingested via milk, Equation 1 can be rewritten as 
Equation 2: 
 
Equation 1 
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where maternalmilkC  is the steady state concentration of the drug in the mother’s milk  and 






τ
milkV  is the infant’s  milk consumption rate.  Since the mother’s milk concentration can 
be expressed in terms of maternal serum concentration and maternal milk to serum ratio 
as follows: 
 
 
where maternalserumC  is the steady state concentration of the drug in the mother’s serum, S
M is 
the milk–to-serum concentration ratio of the drug. Assuming linear pharmacokinetics in 
the mother and infant equation 3 can be expressed as: 
 
 
Equation 4 illustrates the different factors influencing average serum 
concentration.  How each factor affects the infant serum concentration and the interplay 
between these factors have been previously discussed (Bailey and Ito 1997; McNamara 
and Abbassi 2004). It is evident that the infant serum concentration is dependent upon 
maternal and infant clearance, maternal and infant bioavailability, maternal dose, 
maternal milk-to-serum ratio, and the rate of milk consumption.  An increase in the infant 
dose and bioavailability without other changes would increase the systemic serum 
concentration.  An increase in maternal dose alone, or M/S alone would also increase the 
concentration.  However, a high M/S ratio or a high maternal dose does not imply an 
increase in the infant serum concentration.  If the systemic clearance in the neonate for 
such a drug is efficient, then the infant serum concentration might still be low.  Hence, 
both the maternal and neonatal pharmacokinetics need to be understood.  Although the 
pharmacokinetics for the drugs available in the market is readily available, how these 
parameters change in lactating mothers due to hormonal changes is largely lacking. 
 
Equation 2 
Equation 3 
Equation 4 
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3 Exposure Indices: 
 
Exposure indices have been reported in the literature to assess exposure in terms 
of maternal dose  (EIdose) or maternal serum concentration (EIconc) (Ito and Koren 1994; 
McNamara and Abbassi 2004).  Exposure indices can be described by the following 
Equations: 
 
 
 
 
The EIconc  (concentration exposure index) was proposed by Ito and Koren (Ito 
and Koren 1994) and is more useful since it reflects systemic exposure.  Using the above 
indices assumes steady state concentration in the mother and infant and linear 
pharmacokinetics. 
The use of EIconc  is hindered by the fact that some of the parameters used to 
calculate it are missing. The maternal serum concentration can be measure and is reported 
in the literature for some drugs.  However, the reported values are usually a Cmax or 
levels after a single dose.  The infant consumption rate has been reported to be  150 
ml/kg/day (Wilson, Brown et al. 1985).  Trends of milk consumption have been also 
reported (McNamara and Abbassi 2004).  The parameters that are harder to find and that 
would enable us to determine the risk associated with xenobiotic ingestion in the neonate 
are the M/S ratio and the infant systemic clearance.  Hence, we are attempting to address 
the problem both at the maternal and the infant levels by examining M/S ratio and infant 
clearance predictions by models previously proposed in the literature.  
 
4 Milk to Serum Ratio Predictions: 
  
Milk to serum ratios (M/S) are based on total drug concentrations in their 
respective spaces.  It would be beneficial if M/S ratios were accurately predicted by 
models, especially when drug administration to nursing mothers and infants is of ethical 
concern. Several models have been introduced in the literature to predict M/S ratios 
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(Rasmussen 1958; Rasmussen 1959; Meskin and Lien 1985; Fleishaker, Desai et al. 
1987; Atkinson and Begg 1990; Agatonovic-Kustrin, Ling et al. 2002).  These models 
assume that the appearance of most drugs in milk is dependent only on passive diffusion 
and hence correlate the observed M/S values in the literature to the physicochemical 
properties of the drug.  If the drug passively diffuses into milk without the aid of 
transport, then it is assumed that only the free unbound, unionized drug in serum is 
capable of diffusion. Since both serum and milk have proteins, then M/S will depend on 
the extent of binding in both phases.  Serum and milk have different pH values: serum pH 
is 7.4 and milk pH is 7-7.2 (Fleishaker, Desai et al. 1987). Due to that difference in pH, 
the degree of ionization of a drug will be different.  Milk has high lipid content while 
serum lipids are generally lower, hence lipid partitioning will play a role in the M/S 
value. 
Rasmussen (Rasmussen 1958; Rasmussen 1959) demonstrated that the extent of 
appearance of total drug concentration in the milk not only depends on protein-binding in 
serum and milk, but also depends on changes in pH. Basic drugs experience more 
ionization in the slightly more acidic milk pH in what is called “pH trap” or “ion trap”. 
Meskin and Lien (Meskin and Lien 1985) introduced a quantitative structure 
activity relationship (QSAR) analysis of  M/S ratios for a number of drugs where the M/S 
ratio was reported in the literature.  They correlated the log M/S ratios available in the 
literature with Log P (log octanol-water partition coefficient, reflecting the degree of 
lipophilicity of a drug), the degree of ionization of a drug (log undissociated/dissociated 
drug) and the square root of the molecular weight since the lower the molecular weight, 
the easier it is for the drug to diffuse through biological membranes.  They chose the best 
two linear regression correlations for basic and acidic drugs.  Unexpectedly, the M/S 
ratios for both acidic and basic drugs showed negative dependence on LogP.  They 
explained this phenomenon by the fact that the more lipophilic the drug, the more it will 
bind to serum proteins and the less it will be available unbound drug for diffusion into 
milk.  However, they concluded that the confidence in the predictive power of such 
regression models should not be high since the M/S ratios used to build the correlations 
are from a variety of sources and experimental setups which might not be rigorous. 
Further criticism of the model is that the predictors used in the model are relevant only to 
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diffusion across membranes and do not take into account steady state conditions in milk 
and serum (Atkinson and Begg 1990). 
Fleishaker et al (Fleishaker, Desai et al. 1987) proposed a model to predict M/S 
ratios based on the assumptions of passive diffusion and that the drug is at steady state 
condition in both milk and serum.  The model is described by the following equation: 
,
,
1un ss
m un m
ffM
SS f f
W
                                                                                        Equation 7 
where M/S is the milk to serum ratio, fs, fm are the free fraction of drug in serum and milk 
respectively, fun,s fun,m are the unionized fractions in the serum and milk respectively and 
S/W is the ratio of the drug concentration in skim to whole milk.  S/W reflects not only 
lipid partitioning, but also takes into account protein binding as well, since only unbound 
drug is free to partition into lipids.  In the above model, it is assumed that at steady state 
the free unbound, unionized, non-partitioned drug concentrations in serum and milk are 
equal.  Fractions unionized in serum and milk are calculated using a rearranged 
Henderson-Hasselbach equation while the serum and milk protein binding and the skim 
to whole milk drug concentration ratio are measured in vitro.  The advantage of this 
model is that it can account for the variability in M/S ratios due to differences in protein 
binding and milk composition reflected by S/W ratios. However, this approach may not 
account for any transport component and the in vitro determinations for the M/S 
predictions can be cumbersome because of all the parameters that need to be measured. 
Atkinson and Begg established an empirical model (Atkinson and Begg 1990) to 
predict M/S values.  To be consistent, we have modified Atkinson and Begg 
nomenclature from M/P (milk-to-plasma ratio) to M/S.  The model assumes passive 
diffusion of drugs as well. It proposes a phase distribution equation that is dependent on 
the physicochemical characteristics of the drug where all the parameters can be predicted 
empirically from a further set of equations developed by the authors.  The phase 
distribution equation is: 
   phase s u u m appM/S f M /S 0.955/f 0.045 milk lipid P                                   Equation 8 
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Equation 9 
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where fm and fs refer to the unbound fractions in milk and serum, Mu/Su is the ratio of 
unbound concentrations in milk and serum predicted from the Henderson-Hasselbach 
equation, and milk lipid Papp is the partitioning of drug into the milk lipid.  The 
coefficients of fm and  milk lipid Papp  represent the ratios of the aqueous phase and the 
lipid phase in milk respectively.  Since the above phase equation assumes equal 
contribution of each factor to the predictive power of the equation, the authors modified it 
to a log-transformed model (Equation 9) so that multiple linear regression analysis can be 
carried out and each factor weighted accordingly.  The M/S values gathered from the 
literature to build the model were either ratios of AUC (area under the curve) in milk to 
AUC in serum or single point measurements that were consistent in the literature and 
across different studies in order to satisfy the assumption of steady state conditions.  The 
observed M/S values in the literature were correlated to the right-hand of Equation 9 to 
obtain the regression coefficients for a set of acidic drugs and a set of basic drugs.  The 
equation obtained for basic drugs was further validated and modified for better prediction 
with a set of drugs that were not previously used to build the model (Begg, Atkinson et 
al. 1992).  In general the equation for acidic drugs was reported to overpredict M/S ratio 
while for basic drugs M/S ratio values were underpredicted. 
In vivo animal M/S models exist.  The benefit of in vivo models is to identify the 
extent of accumulation of drugs in milk, whether it is high or low, but may not directly 
predict the human M/S ratios.  The advantage of using an animal model over in vitro 
systems is that it accounts for all the biological changes during lactation and all the  
processes that can influence the M/S ratio that are absent in vitro (e.g. tissue binding). 
Animal models that have been previously used in the literature are cow, goat, rabbit, 
mouse and rat.   The interest in cows and goats stems from the fact that they are dairy 
animals and their milk is consumed by humans.  In our laboratory the rabbit and rat 
models have been used.  The rabbit model has failed since it did not exhibit active 
transport for drugs that were actively transported in rats and humans (McNamara, Burgio 
et al. 1992).  The rat proved to be more constant with human observations.  Drugs that 
have high M/S ratio in humans that cannot be explained by passive diffusion alone and 
have to rely on active transport exhibited similar properties in rats (Pons, Rey et al. 1990; 
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McNamara, Burgio et al. 1992; McNamara, Meece et al. 1996a; Kari, Weaver et al. 1997; 
Gerk, Kuhn et al. 2001; Gerk, Oo et al. 2001).   Knockout mouse models have proved 
valuable in demonstrating the role of specific transporters in drug transfer into milk 
(Jonker, Merino et al. 2005; Merino, Alvarez et al. 2006). 
The use of passive diffusion models along with the appropriate animal model can 
predict active transport processes of drugs into human milk. For all the other drugs where 
active transport is absent or not significant, passive diffusion M/S prediction models are 
useful in estimating M/S values where clinical trials are lacking. 
 
5 Neonatal Drug Clearance: 
 
In addition to M/S ratio, the infant systemic clearance is the other signifcant 
parameter in Equation 6 that is difficult to measure in vivo.  For the majority of drugs 
systemic clearance can be described by the sum of  hepatic and renal clearances 
(Equation 10) assuming that no other organs are involved (e.g. lungs). 
  
where Cl is total body clearance, ClH is hepatic clearance and CLR is renal clearance. 
 
5.1 Hepatic Clearance: 
 
Hepatic clearance is described by the well-stirred model (Equation 11). (Rowland, 
Benet et al. 1973; Wilkinson and Shand 1975; Pang and Rowland 1977) 
 
 
where HQ  represents hepatic blood flow, uf  is the fraction of drug unbound in plasma 
and intCl  is intrinsic clearance.  According to this model, drugs can be broadly classified 
into 3 types.   High extraction ratio drugs are those whose hepatic clearance is limited by 
hepatic blood flow.  In this case intClfQ uH    and  Intermediate 
extraction drugs have hepatic clearances of about 0.3-0.7 of hepatic blood flow and 
hepatic clearances are dependent on hepatic blood flow, fraction unbound and intrinsic 
clearance and essentially the equation applies.  Low extraction drugs have hepatic 
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clearance dependent on intrinsic clearance which is the rate limiting step ( intClfQ uH  ) 
and Equation 11 reduces to .ClfCl intuH    For high extraction ratio drugs, ClH  is 
dependent on hepatic blood flow in the infant, values of which have been previously 
documented (Edginton, Schmitt et al. 2006b).  For the other 2 classes, intrinsic clearance 
and fraction unbound are critical in determining hepatic clearance.  A model has been 
developed to predict the unbound plasma fraction of a drug in infants (McNamara and 
Alcorn 2002).  Intrinsic clearance is dependent on both the ontogeny of hepatic enzymes 
and transporters.  Hepatic clearance is usually described in terms of phase I, phase II and 
phase III reactions.  Phase I and phase II are enzymatic reactions while phase III is 
clearance by hepatic transporters (Ishikawa 1992).  Phase I is mediated by microsomal 
enzymes where the drug molecule is modified by addition or removal or exposure of a 
functional group.  Cytochrome P450 enzymes are the superfamily responsible for the 
majority of the phase I reactions.  Phase II enzymes conjugate the drug molecule or 
metabolite formed in phase I.  Acetylation, glucuronidation, sulfation, methylation, 
glutathione conjugation and amino acid conjugation are reactions by which phase II 
enzymes make the drug molecule or metabolite mostly more water soluble.  Transporters 
are now found to play an important role in hepatic clearance and hence have been 
designed as phase 0 and phase III metabolism (Ishikawa 1992; Vavricka, Van Montfoort 
et al. 2002).  No chemical reaction occurs; the drugs are either taken up into the hepatic 
cells for interaction with enzymes, phase 0, or effluxed from the cells and away from the 
enzymes and made available to bile for excretion, phase III.  The interplay between drug 
transporters and metabolizing enzymes is still under investigation (Wacher, Silverman et 
al. 1998; Benet, Cummins et al. 2004; Kurnik, Wood et al. 2006) and has not been very 
well characterized.  
 The ontogeny of hepatic enzymes and transporters needs further investigation for 
a full understanding of how these ontogeny processes affect neonatal clearance.  In vitro 
and in vivo studies (Rich and Boobis 1997; Tanaka and Breimer 1997) have been 
performed to measure clearance or explore the underlying processes affecting clearance 
ontogeny (enzyme activity, protein and RNA ontogeny).   In vivo experiments always 
suffer from ethical and logistical limitations (Rowell and Zlotkin 1997).  It has to be 
noted that most of the work cited is for term neonates.  However, preterm infant 
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clearance has been followed.  For a number of pathways in a preterm infant, it has been 
shown from both in vitro and in vivo experiments that activity for a specific hepatic 
pathway is at most half of that in a full term infant (Edginton, Schmitt et al. 2006a).  In 
this work we are interested in following hepatic enzyme ontogeny. 
 
5.1.1 Cytochrome P450 Enzymes and Ontogeny:  
 
The major cytochrome P450 enzymes in the adult human liver are CYP1A2 
(12.7% ), CYP2A6 (4%), CYP2B6 (0.2%), CYP2C (18.2%), CYP2D6 (1.5%), CYP2E1 
(6.6%), CYP3A (28.8%) (Shimada, Yamazaki et al. 1994) where the numbers represent 
percentages of liver cytochrome P450 content.  The contributions to drug metabolism 
have been determined to be CYP3A (52%), CYP2D6 (31%), CYP2C9 (10%), CYP1A2 
(3%), CYP2E1( 2%), CYP2A6 (2%), and CYP1A2 (3%) (Goodman, Gilman et al. 1996). 
To be able to understand the development of hepatic clearance in the neonate, the 
ontogeny processes of different enzymes need to be understood on the functional level in 
vitro and in vivo and on the protein and mRNA levels. The molecular ontogeny of the 
enzymes gives an insight regarding the triggers of developmental processes. 
Ontogeny of human hepatic enzymes has been extensively reviewed (Hakkola, 
Tanaka et al. 1998; de Wildt, Kearns et al. 1999; de Wildt, Kearns et al. 1999; Ring, 
Ghabrial et al. 1999; Gow, Ghabrial et al. 2001; Hines and McCarver 2002; McCarver 
and Hines 2002; Alcorn and McNamara 2002c; Johnson 2003). 
Cresteil (Cresteil 1998) has classified the enzymes into 3 groups according to 
their ontogeny pattern. Fetal enzymes where the enzymes are detected in the fetal liver 
(CYP3A7 and CYP4A1), early neonatal enzymes that surge within hours after birth 
(CYP2D6, CYP2E1), and neonatal enzymes that develop later; CYP3A4 and CYP2C 
develop weeks after birth and CYP1A2 is the latest enzyme to develop. 
Vieira et al (Vieira, Sonnier et al. 1996) investigated the ontogeny of CYP2E1. 
Protein levels were absent in fetuses but rose immediately after birth then gradually 
increased to reach adult levels in the age group of 1 to 10 years of age. CYP2E1 RNA 
was detectable in fetal samples. The surge in RNA was seen in the age group 1-3 months 
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and reached 50% of the adult levels at 3-12 months. Chlorzoxazone hydroxylation 
mirrored protein levels, reaching adult activity at 1-10 years. 
Lacroix et al (Lacroix, Sonnier et al. 1997) demonstrated the decline of CYP3A7 
and the surge of CYP3A4 after birth.  The antibody used for protein quantification was 
found to be non-specific.  Hence, total CYP3A was quantified. Protein levels were 
constant from early fetal stages (12 weeks) to adulthood.  Fetal CYP3A4 RNA was 10% 
that of the adult, then reached a plateau at 1 week.  The ability to differentiate between 
the development of CYP3A7 and CYP3A4 was achieved by using selective substrates. 
The 16-α-hydroxylation of testosterone was found to be selective for CYP3A7 over 
CYP3A4. This activity was high in fetal stages and reached a maximum at 1 week of age 
then declined to reach adult levels that were 10% those of the fetus. On the other hand, 
the 6-β-hydroxylation of testosterone, which was selective for CYP3A4, was low in the 
fetus and increased after birth to 30-40% of the adult activity from 8 days to 12 months, 
to reach adult levels by 1 year of age. 
Treluyer et al (Treluyer, Jacqz-Aigrain et al. 1991) studied the development of 
CYP2D6 in human liver. Protein levels in fetuses and newborns less than 1 day of age 
had 5% CYP2D6 levels compared to adults.  Subsequently, CYP2D6 level began to rise 
and was about 50% that of adult in age group 28 days-5years. CYP2D6 RNA 
development was different, it increased to levels higher than that of the adult from 1 day 
of age to 5 years of age in the samples used, then declined to adult levels.  The activity of 
dextromethorphan o-demethylation was not more than 25% that of the adult at 1 week to 
five years of age.  
Koukouritaki et al (Koukouritaki, Manro et al. 2004) studied the human hepatic 
ontogeny of CYP2C9 and CYP2C19.  Protein and catalytic activity agreed for each 
enzyme. CYP2C9 was low in early fetal stages (1-2% of adult values) to reach 30% in 
the third trimester.  From birth to 5 months of age, 50% of the samples measured had 
values similar to the adult.  CYP2C19 had a different pattern.  At 8 weeks gestation fetal 
levels were 12-15% that of the adult and did not change at birth.  There was then a linear 
increase with age until 5 months of age. Adult values were reached after 10 years of age. 
Sonnier and Cresteil (Sonnier and Cresteil 1998) showed the delayed ontogeny of 
CYP1A2 in the human liver.  Protein and function represented by methoxyresorufin 
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demethylation where probed in human liver microsomes. At 1 month of age, CYP1A2 
protein represented only 3% of the adult levels and reached 50% by one year of age. 
Methoxyresorufin demethylation appeared to mirror CYP1A2 protein ontogeny.  
These in vitro experiments involved livers from infants where the exact 
circumstances of sample retrieval and storage are not very well documented (Stevens, 
Hines et al. 2003).  The age groups used to characterize in vitro ontogeny also had wide 
ranges.  The ages studied in the above studies were fetal less than 30 weeks, fetal greater 
than 30 weeks, neonatal less than 24 hours, 1-7 days, 1-3 months, 3-12 months, 9-12 
months and greater than 1 year.  In human studies, the available samples dictate the age 
ranges studied.   In older children, the ranges even become wider (years).  However, 
these wide ranges may obscure important developmental milestones especially in early 
stages when the infant is nursing (0-1 year).  The shortcomings of such studies limit the 
use of and makes it difficult hard to extrapolate to in vivo clearance values (Burtin, Jacqz-
Aigrain et al. 1994). 
In vivo ontogeny of metabolism of cytochrome P450 substrates has been studied 
(Brash, Hickey et al. 1981; Pons, Carrier et al. 1988; Davis, Killian et al. 1989; Burtin, 
Jacqz-Aigrain et al. 1994; Jacqz-Aigrain, Bellaich et al. 1994; Falcao, Fernandez de Gatta 
et al. 1997; de Repentigny, Ratelle et al. 1998; Ito, Gow et al. 1998; Anderson, Gunn et 
al. 1999; Lee, Charles et al. 1999).  The age ranges are usually limited to the infants that 
are on the investigated medication during the time of the study.  The age ranges used are 
usually 1-7 days 7-28 days, 1-3 months and 3-12 months. Many times it is just one age 
range, as in the case of premature neonates that need medications directly after birth and 
can be observed until one month of age.  Again, these wide ranges again limit the ability 
to fully characterize the developmental activity of a certain pathway.   In addition, limited 
drugs are administered to neonates and hence more than one specific probe for the same 
pathway might not be feasible to study.   The limitations of both the in vitro and in vivo 
studies in humans create the need for an animal model where the developmental 
processes can be extensively studied.  
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5.1.2 Phase II Enzymes and Ontogeny: 
 
Phase II enzymes are classified into glucuronosyltransferases (UGTs), 
sulfotransferases (STs), N-acetyltransferases (NATs), glutathione-S-transferases (GSTs), 
O-,S- and N-methyltransferases (MTs) (Johnson 2003). 
 The development of UGTs has been reviewed by de Wildt et al (de Wildt, Kearns 
et al. 1999).  According to their summary of UGT in vitro ontogeny, UGT1A1 can be 
described as an early neonatal enzyme.  UGT1A3 in fetal and early neonatal activity is 
around 30% of the adult.  UGT1A6 is present in the fetus up to 10% that of the adult and 
reaches 50% by 6 months of age.  There is little known about the in vivo development of 
UGTs.  
Pacifici et al (Pacifici, Franchi et al. 1988) studied fetal hepatic GSTs. The 
method used was non-specific to individual GST enzymes.  It was reported that the fetal 
GST activity was around 60% that of the adult. Strange et al (Strange, Howie et al. 1989) 
studied the ontogeny of GSTA1, GSTA2, GSTM and GSTP1. GSTA1 and GSTA2 were 
detectable as early as 10 weeks gestation and increased to adult levels within 1-2 years of 
age. GSTM was lower during gestation and increased to adult levels at birth.  GSTP1 was 
high in fetal samples and decreased towards birth and was not detectable in adults. 
Pacifici et al (Pacifici, Franchi et al. 1988) examined sulfotransferase activity by 
the sulfation of 2-naphthol.  The fetal activity was about 33% that of the adult. SULT1A3 
expression and activity were found to be higher in fetal liver than adults (Cappiello, 
Giuliani et al. 1991; Pacifici, Kubrich et al. 1993). SULT1A1, however was higher in 
adult livers and probably had delayed ontogeny (Cappiello, Giuliani et al. 1991; Gilissen, 
Hume et al. 1994). SULT2A1 activity and protein increased in the second half of 
gestation to close to adult levels in the newborn (Barker, Hume et al. 1994). 
There is little known about the ontogeny of NATs, despite their known 
importance in drug metabolism. Fetal livers were shown to have NAT activity of p-
aminobenzoic acid that was 28% of adults (Pacifici, Bencini et al. 1986). 
It is clear from the above studies that the development of cytochrome P450 and 
phase II  enzymes in the liver is different from one enzyme to the next, even within the 
same family.  Consequently, ontogeny of clearance of a certain xenobiotic will be 
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dependent on the elimination pathway and cannot be generalized for all drugs.  Most of 
the studies targeted at studying ontogeny were in vitro studies and hence several 
approaches are taken to extrapolate the in vitro activities to in vivo clearance that can be 
useful in determining infant exposure. 
 
5.2 Renal Clearance: 
 
 Renal clearance is described by three mechanisms; glomerular filtration, renal 
secretion and renal reabsorption.  Glomerular filtration is a passive diffusion process 
through the glomeruli of unbound molecules.  Renal secretion and reabsorption are 
carried out by the tubules and involve transport processes. 
The ontogeny of glomerular filtration rate (GFR) in human fetuses and neonates 
has been studied.  GFR development is dependent on nephrogenesis in utero that starts at 
8-9 weeks gestation and reaches completion at 36 weeks.  Postnatal GFR is dependent on 
blood flow (Robillard JE 1999; Kearns, Abdel-Rahman et al. 2003; Solhaug, Bolger et al. 
2004). GFR  is 2 to 4 ml/min/1.73m2, normalized to adult body surface area in neonates, 
and is lower in preterm neonates.  It increases rapidly in the first 2 weeks postnatal and 
then assumes a gradual increase to reach adult levels by 1 year of age (Arant 1978; van 
den Anker, Schoemaker et al. 1995; Kearns, Abdel-Rahman et al. 2003).  However, when 
normalized to bodyweight, GFR in the neonate appears to have similar values to that in 
the adult (Rodvold, Everett et al. 1997).  Renal tubular secretion represented by para-
aminohippuric acid clearance follows a similar pattern (Kearns, Abdel-Rahman et al. 
2003).  The ontogeny of transporters in renal tubules is not very well studied.  The 
ontogeny patterns of each transporter will affect elimination rate of the involved drugs. 
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5.3 Models for Predicting In Vivo Clearance: 
 
5.3.1 In Vitro In Vivo Correlation: 
 
In vitro in vivo correlation has been widely used to predict hepatic clearance of 
drugs (Hoener 1994; Iwatsubo, Hirota et al. 1997; Ito, Iwatsubo et al. 1998; Obach 1999; 
Zuegge, Schneider et al. 2001; Shiran, Proctor et al. 2006). 
The prediction of hepatic clearance of a compound by a certain enzyme starts by 
determining the in vitro intrinsic clearance of that compound, which is independent of 
other physiological factors.  Assuming that the clearance of this compound is 
independent of hepatic transporters, then the in vitro intrinsic clearance can be scaled to 
liver intrinsic clearance and in vivo clearance by a variety of scaling factors: liver weight, 
blood flow, hepatocyte number and microsomal protein yield. In addition to scaling 
factors, a liver model is needed to predict the in vivo clearance (Houston 1994).  Limiting 
factors to in vitro in vivo correlations are the presence of pathways not accounted for in 
the correlation, interindividual variability, transport processes in the hepatocytes, invalid 
assumptions by the model used to scale intrinsic clearance to hepatic clearance e.g. rapid 
equilibrium of drug between blood and hepatocytes (Iwatsubo, Hirota et al. 1997).  Other 
limitations are dependent on the system used to predict intrinsic clearance, e.g. 
microsomes versus hepatocytes. 
The in vitro intrinsic clearance is typically calculated from enzyme kinetics, as the 
ratio of the terms of Michaelis-Menten enzyme kinetics parameters Vmax (maximum 
enzyme rate) and Km (substrate concentration at half the maximum velocity and indicates 
the molecule-enzyme affinity) in the linear range of the reaction. 
Other approaches for in vitro in vivo extrapolation have been described (Obach 
1999; Lau, Sapidou et al. 2002; Niro, Byers et al. 2003). 
Obach (Obach 1999) had showed good agreement between in vitro predicted 
clearance values and in vivo observed values for neutral, acidic and basic compounds, 
using both the hepatic well-stirred model and the parallel tube model when protein 
binding in microsomes and blood were considered.  Several other studies demonstrated 
the applicability of in vitro in vivo correlation methods for hepatic clearance prediction 
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(Hoener 1994; Iwatsubo, Hirota et al. 1997; Carlile, Hakooz et al. 1999; Soars, Burchell 
et al. 2002; McGinnity, Soars et al. 2004). 
In vitro in vivo extrapolation methods were also examined for the possible 
application in the fields of enzymatic induction and drug-drug interactions (Burtin, Jacqz-
Aigrain et al. 1994; Bertz and Granneman 1997; Kedderis 1997; Andersson, Bredberg et 
al. 2004; Ito, Brown et al. 2004).  
These extrapolations are mostly applied to predict adult in vivo clearance for a 
certain drug.   In this dissertation we are examining an ontogeny model that applies in 
vitro in vivo extrapolation priniciples to predict in vivo infant clearance from adult 
clearnance for a specific pathway. 
 
5.3.2 Physiologically Based Pharmacokinetic (PBPK) Models: 
 
Physiologically based pharmacokinetic (PBPK) models describe the 
pharmacokinetics of a drug in the context of physiologically and anatomically based body 
compartments.  The body compartments are based on body organs, tissues, fluids and 
systems and the flow between the compartments is based on blood flow to the different 
organs (Nestorov 2003).  The equations describing these models involve the description 
of mass transport of a compound between these compartments.  Parameters used include 
body weight, organ weight/volume, organ blood flow, tissue composition, interstitial 
spaces, tissue permeability, binding and partition of the compound (Edginton, Schmitt et 
al. 2006b).  These models assume flow rate limited drug distribution and are useful in 
prediction of drug concentrations in various tissues especially for lipophilic drugs. They 
require intrinsic clearance estimation to be able to predict hepatic clearance. A 
disadvantage of these types of models is that it is compound specific and hence a model 
needs to be developed for each compound (Andersen 1995).   
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5.3.3 Allometric Scaling: 
 
Allometric scaling employs the basic allometric equation: 
Y=a BW b                                                                                               Equation 12 
where Y is the biological variable, BW is body weight, a is the allometric 
coefficient and b is the allometric exponent.  Allometric scaling has been employed to 
extrapolate animal data to human data, recognizing the similarities between species in the 
aspect that various biological variables are correlated to body weight (Hu and Hayton 
2001).  In vivo clearance in humans has been extrapolated from animal in vivo clearance 
using allometric scaling (Boxenbaum 1982; Lave, Dupin et al. 1997; Wajima, Fukumura 
et al. 2003; Ward and Smith 2004; Ito and Houston 2005; Mahmood 2005).  Allometric 
scaling has been employed to predict clearance in neonates and children as well where 
clearance for example can be calculated from adult clearance based on the ratios of body 
weights  (Hayton 2000; Knibbe, Zuideveld et al. 2005; Bjorkman 2006; Johnson, 
Rostami-Hodjegan et al. 2006).  However, in many cases, in vitro correlations and 
physiologically based pharmacokinetic (PBPK) modeling were found to be superior in 
predicting clearance (Ito and Houston 2005; Johnson, Rostami-Hodjegan et al. 2006). 
 
 
5.3.4 Ontogeny Model: 
 
The model examined in this dissertation is a clearance ontogeny model that was 
proposed in our lab to predict infant intrinsic clearance based on in vitro infant and adult 
data (Alcorn and McNamara 2002d).  The model utilizes the in vitro in vivo correlation 
approach to predict in vivo clearance in neonates from in vitro data from both neonates 
and adults. 
For a hepatically cleared, low extraction ratio drug, hepatic clearance can be 
described as follows according to the well-stirred model and assuming clearance by 
multiple pathways: 
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Intrinsic clearance has been defined in terms of enzyme kinetics as follows: 
 
 
where Clint(j) is the intrinsic clearance for a given pathway j, Vmax (j) is the maximal 
enzyme activity for this pathway and Km is the drug concentration at half maximal 
activity, fu is the fraction unbound of drug and C is the drug concentration. Under linear 
conditions Km>>fu C and hence equation 14 reduces to: 
  
 
To extrapolate the in vitro intrinsic clearance to in vivo intrinsic clearance, a 
hepatic scaling factor (HSF) is needed.   In vitro Vmax values are normalized to mg 
microsomal protein.  If the Vmax and Km measurements determined in vitro are 
performed in a microsomal system, then the scaling factor is mg microsomal protein per 
gram liver normalized to body weight.  Thus Vmax is now normalized to whole body and 
the intrinsic clearance for the whole body (in vivo intrinsic clearance) is expressed as: 
 
 
The above equation is valid for both infants and adults: 
 
   
 
 
 
Assuming Km(j) to be similar for both infant and adult, and dividing Equation 17 
by Equation 18 and rearranging, the infant intrinsic clearance is calculated as: 
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where RHSFt is the relative hepatic scaling factor for a given age t.  Since Vmax is 
assumed to be proportional to the amount of active enzyme present and proportional from 
one substrate to the next for the same enzyme, then the ratio of Vmax of the infant to that 
of the adult is considered to reflect the ontogeny of activity for that pathway and is 
termed ontogeny scaling factor (OSF).  Equation 19 can then be written as: 
 
 
where ISF (j,t) is the infant scaling factor and is equal to the product of RHSF and OSF, 
for a certain pathway j at a certain age t. 
The model further proposed modeling liver and body weight as a function of age.  
ISF for a certain pathway would also be modeled as a function of age using existing in 
vitro data such that no in vitro experiments would be required to predict clearance for a 
certain age in which in vitro parameters were not determined.  
 Hence the model assumptions can be summarized as follows: 
1. Drug has a low extraction ratio. 
2. Infant and adult share the same enzymes and transporters in metabolizing the 
same drug. 
3. Microsomal protein content normalized to liver weight is constant and 
independent of age. 
4. Km for an enzyme-substrate system remains constant throughout development. 
5. Vmax reflects the amount of functional enzyme and is proportional from one 
substrate to the next for the same enzyme along development. 
6. Hepatic Clearance is governed by hepatic metabolic enzymes and not hepatic 
transporters. 
 The validity of assumptions 3 and 4 will be examined in this dissertation. 
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6 Experimental Evidence:  
 
6.1 Rat as an Animal Model for Ontogeny Model Validation: 
 
 Rat and human cytochrome P450 orthologues share some substrate specificity 
and regulatory mechanisms, yet major differences exist (Zuber, Anzenbacherova et al. 
2002).  The rat is widely used as an animal model in toxicology studies (NTP 2007a; 
NTP 2007b; NTP 2007c).   However, the purpose of using the rat is not to extrapolate rat 
ontogeny data into human ontogeny data.  The rat will be used as a well studied animal 
model in drug metabolism to verify the assumptions of the model with defined age 
groups and exhaustive sampling.  Performing such studies in humans is very difficult if 
not impossible.  Thus using the rat as a model is a proof of concept for the model 
assumptions. 
 
6.2 Cytochrome P450 3A and P-glycoprotein: 
 
Cytochrome P450 3A is the focus of this research. In humans, it represents 28.8% 
of the liver cytochrome P-450 content and metabolizes 52% of the xenobiotics (Shimada, 
Yamazaki et al. 1994; Goodman, Gilman et al. 1996).  In the human intestine, although 
CYP3A is around only 1% that of the liver, it still reperesents 82% of the total P450 
content and contributes significantly to first pass metabolism for orally administered 
drugs (Paine, Hart et al. 2006). 
P-glycoprotein (P-gp, ABCB1) is a drug efflux transporter of the ATP Binding 
Cassette (ABC) family.  It is responsible for drug resistance in tumor cells and was first 
identified in drug resistant mutated Chinese hamster ovary cells (Juliano and Ling 1976). 
P-gp has a wide role in drug disposition in the body due to its wide expression and wide 
substrate specificity.  It is expressed in tumor cells and in normal tissue in hepatocytes on 
the canalicular surface, the apical surface of renal tubular epithelial cells, brush border of 
intestine, placenta and the apical surface of endothelial cells forming blood-brain barrier 
(Thiebaut, Tsuruo et al. 1987; Cordon-Cardo, O'Brien et al. 1990).  The role of P-gp in 
drug pharmacokinetics has been elucidated using Mdr1a/1b knockout mice (Schinkel, 
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Mayer et al. 1997), where biliary and intestinal excretion of [H3]-digoxin were shown to 
be decreased. Therefore, the levels of P-gp in liver, intestine and kidney, have an effect 
on drug elimination. 
CYP3A4 and P-gp share a wide substrate similarity (Wacher, Silverman et al. 
1998) and hence the interplay of CYP3A4 and P-gp in both intestine and liver affects 
drug disposition (Wacher, Silverman et al. 1998; Benet, Cummins et al. 2004). Therefore, 
in addition to characterizing the ontogeny of Cyp3a in the rat, P-gp RNA development 
will also be characterized to examine if there is any correlation between the 
developmental pattern of their transcripts. 
The equivalent rat isoforms of human CYP3A4 are both Cyp3a1 and Cyp3a2.  It 
has been demonstrated that Cyp3a2 is sex-dependent, being predominant in adult male rat 
livers and absent in adult female rat livers (Ribeiro and Lechner 1992). There are 
substrate specificity similarities between human CYP3A4 and rat Cyp3a1/ Cyp3a2 e.g. 
midazolam, 6β-hydroxylation of testosterone (Kobayashi, Urashima et al. 2002) and 
tamoxifen (Kim, Suzuki et al. 2003). Induction by dexamethasone was observed for both 
human and rat CYP3A isoforms (Lu and Li 2001).  Several studies focusing on the 
ontogeny of Cyp3a1/2 in the rat were conducted. Inducibility and postnatal development 
were studied (Johnson, Tanner et al. 2000; Kawai, Bandiera et al. 2000).  There have 
been conflicting reports about hepatic enzyme levels of Cyp3a1 and Cyp3a2. Cyp3a1 was 
reported to be constitutive in adult male and female rat livers (Simmons and Kasper 
1989), while in other reports it has been reported to be totally inducible (Gonzalez, Song 
et al. 1986). For postnatal development of Cyp3a2, studies have shown that protein and 
mRNA levels in male neonate rat livers (22 days) are comparable to (Kawai, Bandiera et 
al. 2000) or higher than (Wright, Edwards et al. 1997) male adult levels.  Another study 
(Gonzalez, Song et al. 1986) reported Cyp3a2 mRNA levels to be lower than adult male 
levels.  More studies need to be done to clarify the ontogeny of Cyp3a1 and Cyp3a2 in 
rats. P-gp mRNA, expressed by Mdr1a/Mdr1b in the rat, was detected in rat kidney, liver, 
small and large intestine and brain (Brady, Cherrington et al. 2002). Ontogeny of P-
glycoprotein mRNA levels has been studied in male Wistar rats (Matsuoka, Okazaki et 
al. 1999; Rosati, Maniori et al. 2003).  Characterization of parallel development of P-
glycoprotein with Cyp3a in the rat is our current goal. 
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6.3 Midazolam as a Probe for Cyp3a: 
 
Midazolam has been widely used as a probe for Cyp3a metabolism in human and 
rat in vitro and in vivo (Kobayashi, Urashima et al. 2002; Galetin and Houston 2006; 
Krupka, Venisse et al. 2006; Kumar, Mann et al. 2007; Matsuda, Nishimura et al. 2007; 
Ryu, Song et al. 2007; Zhang, Tan et al. 2007).   It has the advantages of being specific to 
Cyp3a and not endogenous (unlike testosterone) and not affected by transporters (unlike 
erythromycin).  Kobayashi et al (Kobayashi, Urashima et al. 2002) have shown that in 
rat-expressed enzyme systems the 4-hydroxylation of midazolam is specific to Cyp3a2 
and formed to a less extent by Cyp3a1 (at least 2.5 fold). Midazolam has been shown to 
be a highly permeable substrate of P-gp (Tolle-Sander, Rautio et al. 2003) and hence its 
permeability is not affected by P-gp expression.  Another property needed for the drug to 
be used as a probe to predict clearance of a certain pathway is that it should have a low 
extraction ratio in order to be able to calculate intrinsic clearance from in vitro data. 
Midazolam has an intermediate extraction ratio (Paine, Shen et al. 1996) and thus hepatic 
blood flow would have an effect on clearance.  To be able to calculate intrinsic clearance 
in vitro and correlate it to in vivo clearance without measuring hepatic blood flow, 
midazolam will be administered orally.  Midazolam is known to be extensively 
metabolized by intestinal CYP3A in humans such that the intestinal availability after oral 
administration (FG) is about 0.5 (Gorski, Vannaprasaht et al. 2003).   In rats, FG has been 
reported to be 1 (Kotegawa, Laurijssens et al. 2002; Uhing, Beno et al. 2004; Kanazu, 
Okamura et al. 2005) which will enable the prediction of oral clearance based only on 
hepatic intrinsic clearance. 
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Chapter 3. Hypotheses and Specific Aims 
 
We are proposing here to experimentally examine models that have been 
previously developed in our lab to predict M/S ratio and neonatal clearance.  Additionally 
an empirical model predicting M/S ratio from the literature will be examined.  The 
purpose is to test the validity of the underlying assumptions of the models and/or their 
predicitivity when compared to observed values in the literature. 
To test the M/S and ontogeny clearance models we propose the following 
hypotheses: 
 
Hypothesis 1: 
 Most drugs diffuse into milk passively and their milk to serum ratios can be 
readily predicted using passive diffusion models. 
 
Specific aim 1A: To test the predictivity of the Atkinson and Begg model by 
calculating the M/S ratios for a number of drugs not used in building the model and 
comparing them to observed M/S values from the literature.  The model should predict 
the observed M/S values provided that no active transport mechanism exists for these 
drugs.  If successful, the model could be a great asset in assessing neonatal exposure to 
drugs appearing in the milk by passive diffusion without having to perform experimental 
measurements. 
 
Specific aim 1B: To compare calculated M/S ratios of a number of drugs based 
on in vitro determination of serum and milk unbound fractions and skim to whole milk 
ratios using Fleishaker’s model, to observed M/S ratios in vivo from the literature.  If 
drug appearance in milk were limited to passive diffusion, the parameters in the model 
should account for the relatively high M/S ratio.  An additional value of this model is that 
it can account for interindividual differences in milk and serum composition. 
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Hypothesis 2: 
mRNA expression levels of Cyp3a1, Cyp3a2, Mdr1a and Mdr1b increase with 
age in male rat liver and intestine.  The mRNA expression ontogeny of Cyp3a2 and 
Mdr1b follow the same pattern. 
 
Specific aim 2A: Determine mRNA levels of Cyp3a1, Cyp3a2, Mdr1a and 
Mdr1b in rat liver and intestine in different developmental stages and in adults. Cyp3a 
in the rat was chosen since it is the major cytochrome p450 in the liver and intestine 
and is responsible for the metabolism of the majority of xenobiotics. Mdr1a and 
Mdr1b are the genes expressing the P-glycoprotein (P-gp) transporter that plays a 
major role in drug disposition in both the liver and intestine and shares similar 
substrate specificity with Cyp3a.  RNA levels were examined since they might 
provide insights as to developmental triggers for a pathway, and to examine whether 
Cyp3a and P-gp share the same triggers.  Liver and intestine are the two major organs 
responsible for drug elimination when the drug is orally administered, as in the case 
of drug exposure via lactation. 
 
Hypothesis 3: 
Cyp3a protein expression and in vitro activity in male rat liver follow the same 
ontogeny pattern as mRNA expression. 
 
Specific aim 3A:  Determine protein levels of Cyp3a normalized to 
microsomal protein in rat liver and intestine via specific antibodies across 
developmental stages to adulthood.  This will help assess if protein levels follow the 
RNA developmental pattern. 
Specific aim 3B: Measure in vitro activity of Cyp3a in rat intestine and liver 
microsomes using a specific substrate (midazolam) across developmental stages to 
adulthood.  These determinations will enable the calculation of Vmax and Km values 
for Cyp3a in rat.  Vmax values will allow the calculation of an in vitro clearance. Km 
values will be used to validate the assumption that Km values do not change with age 
for an enzyme-substrate combination. 
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Hypothesis 4: 
 Age-specific in vivo clearance for a drug can be predicted from an ontogeny 
model based on the developmental pattern of its clearance pathway based on in vitro 
measurements. 
 
Specific aim 4A: Determine microsomal protein content in rat liver across 
developmental stages to adulthood.  The microsomal protein content will then be 
normalized to liver weight and body weight to examine the assumption that 
microsomal protein content does not vary with age. 
 
Specific aim 4B: Model the in vitro Vmax values normalized to the different 
scaling factors to predict in vivo oral clearance for Cyp3a in rats throughout 
development. 
 
Specific aim 4C: Measure in vivo oral clearance for midazolam in rats across 
different developmental stages and evaluate the predictivity of the in vivo clearance 
by the model. 
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Chapter 4. Materials and Methods 
 
1 In Vitro M/S: 
 
1.1 M/S Prediction: 
 
The equation used to describe the Atkinson and Begg model (Atkinson and Begg 
1990; Begg, Atkinson et al. 1992)( To be consistent, we have modified Atkinson and 
Begg nomenclature from M/P to M/S)  is: 
   phase s u u m appM/S f M /S 0.955/f 0.045 milk lipid P                        Equation 21  
where fm and fs refer to the unbound fractions in milk and serum, Mu/Su is the ratio of 
unbound concentrations in milk and serum predicted from the Henderson-Hasselbach 
equation, and milk lipid Papp is Clipid/Cultrafiltrate and calculated by:   
app applog milk P  = 1.29 log octP  - 0.88.                                               Equation 22                                        
Atkinson and Begg predicted fraction unbound in milk in terms of fraction 
unbound in serum (Atkinson and Begg 1988) as described by                                       
Equation 23:                
fm = fs0.448 / (0.000694 0.448+ fs0.448  )                                                            Equation 23                                    
The phase distribution model equation was: 
   phase s u u m appln M/S ln f ln M /S ln 0.955/f 0.045 milk lipid P              Equation 24 
Reported regression analysis for acidic and basic drugs were obtained, respectively 
as: 
u u sAcidic drugs: ln M/S = -0.405 + 9.36 ln(M /S ) - 0.69ln f - 1.54 ln K           Equation 25 
       
u u sBasic drugs: ln M/S = 0.02477 + 2.28 ln(M /S ) + 0.886 ln f + 0.505 ln Ku u sBasic drugs: ln M/S = 0.02477 + 2.28 ln(M /S ) + 0.886 ln f + 0.50  ln K     Equation 26 
where K is defined as: (0.955/fm) + 0.045 milk lipid Papp.   
To evaluate the whole model, M/S values for a number of drugs not used in 
building the model were calculated based on the above equations and compared to 
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reported M/S values in the literature. Log P and pKa were obtained from ACD/Lab, 
version 6.0, (Advanced Chemistry Development, Inc., Toronto ON, Canada, 
www.acdlabs.com, 2002). Free fraction in serum was obtained from the literature.  
 
1.2 M/S Calculation 
1.2.1 Materials: 
 
H3-Acyclovir, C14-Ascorbic acid, H3-Citalopram, and H3-Nicotine were obtained 
from Perkin Elmer Life Sciences, Inc Boston MA. C14-Ciprofloxacin was obtained from 
Moravek Biochemicals Inc. Brea CA. Non-labeled acyclovir, ascorbic acid, 
ciprofloxacin, citalopram, nicotine, potassium dihydrogen phosphate and disodium 
hydrogen phosphate were obtained from Sigma-Aldrich Co. St. Louis MO. 
 
1.2.2 Samples: 
 
The protocol of the study was approved by the University of Kentucky’s 
Institutional Review Board. The samples were collected in the facilities of the General 
Clinical Research Center (GCRC) at the University of Kentucky on different days. Single 
blood and milk samples were obtained from eight healthy non-smoking white lactating 
females after signing a consent form. Milk samples were obtained by an electric pump. 
The first few milliliters were set aside as fore-milk, then about a 100 mL were pumped. A 
single 30 mL sample of blood was obtained. Volunteers were not on any current 
medications and were instructed to abstain from having any analgesics or antihistamines 
one week prior to the study and abstain from having any alcohol or caffeine 48 hours 
prior to the study. 
 
1.2.3 Serum Collection: 
 
Blood samples were left to stand for at least 45 minutes then centrifuged at 
3000xg for 15 minutes.  Serum was collected and stored in a glass vial at –20° C or 
processed immediately. 
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1.2.4 Skim Milk Collection: 
 
Two 13 mL aliquots of milk samples were centrifuged in plastic centrifuge tubes 
at 1800xg for 15 minutes.  The skim milk was collected and the top fat layer was 
discarded.  The skim milk was again centrifuged for 15 minutes at 1800xg to ensure the 
least amount possible of fat in the skim milk.  Skim milk was collected and kept in a 
glass vial. 
 
1.2.5 Crematocrit: 
 
The crematocrit was determined in triplicate for fresh milk samples. Whole milk 
from each sample was drawn in 3 capillary tubes and centrifuged at 5125xg for 15 
minutes.  The volume percentage of the fat layer was then determined.  Two and a half 
milliliters each of whole milk, skim milk and serum for each of the five drugs was spiked 
with the non-labeled drug to obtain therapeutic levels (acyclovir 6.5 µg/mL, ascorbic acid 
17.6 µg/mL, ciprofloxacin 0.21 µg/mL, citalopram 0.28 µg/mL, nicotine 0.028 µg/mL). 
Radio-labeled drug was added to obtain an activity of 2000 dpm/150 μL solution.  The 
added radiolabeled drug did not significantly contribute to the mass of the nonlabeled 
drug. 
 
1.2.6 Skim to Whole Milk Ratio (S/W): 
 
Skim to whole milk ratios were obtained in triplicate by adding drug to fresh 
aliquots of the whole milk, mixed and then centrifuged to obtain skim milk. 
Concentrations of the drugs in both the whole milk and the skim milk were obtained by 
liquid scintillation counting.  Ratios of whole to skim milk concentrations were obtained.  
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1.2.7 Protein-Binding: 
 
Binding to milk and serum proteins was determined using an equilibrium dialysis 
method.  All experiments were done in triplicate.  Two-half plexiglass cells were 
separated by Spectra/Por® membrane tubing, molecular weight cut off 6000-8000. On 
one side, the 400 μl half chambers were filled with either the serum or the skim milk 
spiked with the drug, and dialyzed against 0.133 M sodium/potassium phosphate buffer, 
adjusted to either pH 7.2 or 7.4 respectively, in the other half-chamber. 
Equilibrium dialysis was done in water bath at 37 °C for 8 hours for acyclovir, 
ascorbic acid and nicotine and for 14 hours for both ciprofloxacin and citalopram.  The 
equilibrium time was determined from preliminary studies.  One hundred and fifty 
microliter aliquots from both the milk or serum and the buffer sides were obtained at the 
end of equilibrium and the concentrations of the drugs analyzed using liquid scintillation 
counting.  Free fraction in serum and milk (fs and fm respectively) were then calculated.  
 
1.2.8 Unionized Fractions: 
 
The values for unionized fraction in serum and milk (fun,s and fun,m respectively) 
were calculated from the following equations: 
For weak acids (acyclovir, ciprofloxacin and ascorbic acid): 
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                                                                                         Equation 27  
For weak bases (nicotine and citalopram): 
 
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f


                                                                                           Equation 28 
where the pH is 7.4 for serum and 7.2 for skim milk. 
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1.2.9 M/S Calculation: 
 
The above values were used to calculate predicted milk to serum ratio for the 
drugs under investigation, using the following equation (Fleishaker, Desai et al. 1987): 
,
,
1unss
m unm
ffM
SS f f W
=                                                                                          Equation 29  
 
1.2.10 Statistics: 
 
The 95% CI of the M/S observed values were calculated for drugs where the 
standard deviations were reported.  In the case of the other drugs the observed M/S ratio 
was either reported from a case study or the standard deviation and the individual values 
were not reported.  Drugs where active transport contributes about 50% to their transfer 
will have an M/S observed 50-200% of that predicted.  Hence, the 95% CI of the 
predicted values and of the 50-200% of the predicted values were calculated as well. The 
observed M/S ratios were then compared to both intervals, where the later is a more 
rigorous approach. 
 
 
 
 
 
 
 
34 
 
2 In Vitro and  In Vivo Cyp3a Ontogeny: 
 
2.1 Materials: 
 
RNAlater (RNA Stabilization Reagent) and RNeasy kit were obtained from 
Qiagen, (Valencia, CA). Potassium chloride (KCl), sodium phosphate dibasic 
(Na2HPO4), Tween 20, ethidium bromide  and acetonitrile HPLC grade were obtained 
from Fisher Scientific (Fair lawn , New Jersey).  Calcium chloride (CaCl2),   histidine,  
sodium edetate (Na EDTA),  potassium phosphate monobasic (KH2PO4),  potassium 
phosphate dibasic (K2HPO4), sodium citrate, phenylmethylsulfonyl fluoride (PMSF), 
butyrated hydroxytoluene (BHT),  trizma base, tris HCl, bovine serum albumin (BSA), 2-
mercaptoethanol, ammonium phosphate monobasic and 4-hydroxymidazolam were 
obtained from Sigma Chemicals (St. Louis, MO).  Sodium chloride (NaCl) was obtained 
from EM Sciences and sucrose from MCB Reagents.  DC Protein Assay Kit, 96-well 
PCR plates and i-Cycler iQ™ Optical Tape were obtained from Bio-Rad Laboratories 
(Hercules, CA). SYBR Green PCR Core Reagent system was purchased from Applied 
Biosystems (Foster City, CA). SuperScript III First-Strand Synthesis System, LDS 
Sample Buffer, Sample Reducing Agent,  Magic MarkXP, 4-12% NuPage  Bis-Tris gel, 
MOPS Running Buffer,  PVDF membranes, NuPage Transfer Buffer were obtained from 
Invitrogen Life Technologies (Carlsbad, CA). NADPH Regenerating System, Cyp3a2 
and Cyp3a1 Supersomes™ were obtained from BD Biosciences (Woburn, MA). 
Midazolam was obtained as midazolam hydrochloride for injection from Bedford 
Laboratories (Bedford, OH). Agarose (SeakemTM LE agarose,) was from BMA 
(Rockland, ME). Primary antibodies Anti-Cytochrome P450 Enzyme CYP3A1 and 
CYP3A2 (anti-rat raised in rabbit) were obtained form Chemicon International Inc. 
(Temecula, CA). SuperSignal West Pico Chemiluminescent Substrate and ImmunoPure 
Goat Anti-Rabbit IgG (H+L) peroxidase Conjugated secondary antibody were obtained 
from Pierce Biotechnology, Inc. (Rockford, IL).  HPLC column SUPELCOSIL ABZ+ 
Plus column (25 cm X 4.6 mm, 5 µm) and gurad column SUPELCOSIL™ ABZ+Plus 
Supelguard® Cartridge (5 cm X 4.6 mm, 5 µm) were obtained from Sigma-Aldrich 
Biotechnology LP. 
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2.2 Methods: 
 
2.2.1 Animals: 
 
Male Sprague-Dawley rats were used for all experiments.  The studies were done 
under approval of the IACUC at The University of Kentucky.  Animals were procured 
from Harlan (Indianapolis, IN).  Age groups: 1, 7, 21, 42, 77 and 112 days were used for 
in vitro experiments. Four animals per age group were used. For age groups 1, 7 and 21 
days pregnant dams were ordered and male rats from litters were used.  Older animals 
were ordered directly from the supplier.  The age groups were chosen based on 
developmental stages: Neonatal (1 and 7 days), weanling (21 days), pubertal (42 days), 
young adults (77 days) and adults (112 days).  Animals were kept in the College of 
Pharmacy animal facility for at least 3 days for acclimatization before performing 
experiments.  Standard rat chow (Harlan Teklad Global Rodent Diet 2018) and water 
were provided ad libitum.  Animals were kept in a controlled environment of temperature 
and humidity and 12 hours light-dark cycle. 
 
2.2.2 Tissue Collection: 
 
On the day the animals became of age (according to the date of birth observed or 
supplied by Harlan), animals were weighed, then sacrificed under isoflurane anesthesia 
by exsanguination.  Whole livers were excised, washed by saline, blotted and weighed.  
A portion of the tissue was cut in pieces less than 0.5 cm thick and kept in at least 10 
volumes of its weight of RNAlater at 4 °C for subsequent RNA extraction.  The rest of 
the tissue was then flash frozen in liquid nitrogen and transferred to a -80 °C freezer. 
The proximal third of  the small intestine was collected and kept on ice in 100 mL 
Weiser solution A (Weiser,1973) (KCl 1.5 mM; NaCl 96 mM; sodium citrate 27 mM; 
KH2PO4 8 mM; Na2HPO4 5.6 mM; pH to 7.4)  with phenylmethylsulfonyl fluoride 
(PMSF) at 40 µg/mL and the intestinal mucosa was immediately collected as described 
below. 
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2.2.3 Tissue Processing: 
 
2.2.3.1 Intestinal Mucosa and Microsomal Preparation: 
 
The procedure was adapted from a number of previously used methods (Weiser 
1973; Bonkovsky, Hauri et al. 1985; Cotreau, von Moltke et al. 2000; Johnson, Tanner et 
al. 2000). 
The collected intestinal segments were flushed with fresh Weiser Solution A 
(Weiser 1973) on ice then dissected longitudinally and washed in Weiser Solution A.  
The tissue was then blotted and weighed.  To collect the intestinal mucosa the dissected 
segment was spread on an ice cold glass plate with the mucosal side upwards.  The 
mucosa was then gently scraped using a microscope slide.  The scraped mucosa was 
weighed on a clean slide, and a portion weighed and kept in RLT buffer (RNeasy 
MiniKit) with 2-mercaptoethanol for RNA extraction, homogenized using a rotor-stator 
homogenizer and kept at -80 °C.  The rest of the mucosa was homogenized in a 15 mL 
centrifuge tube in 10 mL of  Weiser Solution C (Weiser 1973) (histidine 5 mM, pH 7.0; 
sucrose 0.25 M; NaEDTA 0.5 mM; pH to 7.4) with PMSF at 40 µg/mL by sonication, 7 
cycles, 10 seconds each.  The homogenates were placed into two clean ultracentrifuge 
tubes.  The total homogenate was then centrifuged at 15,000xg for 10 minutes.  The 
supernatant was carefully transferred to a clean centrifuge tube.  For each 7 mL of 
supernatant collected, 1.25 mL of 52 mM CaCl2 was added.  Tubes were gently shaken 
for 20 seconds and then allowed to stand for 15 minutes on ice.  Fractions were then 
centrifuged at 25,000xg for 10 minutes.  If the pellet formed was not compact, the above 
step was repeated.  Pellets were resuspended in 0.25 M Sucrose/0.02 M Tris buffer by 
sonication.  The protein concentration was determined using DC Protein Assay in 
microplate format and the microsomal suspension aliquoted and frozen at -80 °C for later 
use. 
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2.2.3.2 Liver Microsomal Protein Preparation: 
 
All steps are performed on ice or in the cold room at 4 °C. Half of a gram of the 
frozen liver tissue was homogenized in 2 mL homogenization buffer (0.154 M potassium 
chloride prepared in 0.25 M potassium phosphate buffer (pH 7.4).  Butyrated 
hydroxytoluene (BHT) was directly added before homogenization to a final concentration 
of 2.5µL BHT/mL buffer (BHT solution 10mg/mL in 100% ethanol).  Homogenization 
was done by a stirrer type homogenizer (Potter-Elvehjem) by performing 10 strokes.  The 
homogenate was then poured in ultracentrifuge tubes kept on ice.  The homogenizer tube 
and head were then rinsed with 2 mL homogenization buffer and the rinse added to the 
ultracentrifuge tubes.  The volume of the homogenate in the ultracentrifuge tubes was 
then completed to 7.5 mL as recommended by the manufacturer.  The tubes were then 
centrifuged at 6860xg (10,000 rpm) for 15 minutes, 4 ºC in the Ti 70.1 Beckman rotor. 
The supernatant was then transferred to clean, cooled tubes and balanced with the 
homogenization buffer and ultra-centrifuged at 84,035xg (35,000 rpm, Ti 70.1 Beckman 
rotor) for 30 minutes, 4 ºC. Two mL of 0.154 M potassium chloride solution were added 
to the pellet, which was resuspended in the ultracentrifuge tube with the head of the 
homogenizer by three strokes.  The tubes were filled with the KCl solution until the 
recommended filling level and balanced then ultra-centrifuged at 84,035xg (35,000 rpm, 
70.1 Ti Beckman rotor) for 30 minutes at 4 °C.  The supernatant was discarded and the 
pellet resuspended in buffer (0.25 M Sucrose prepared in 0.02 M Tris buffer pH 7.4) by 
sonication for 5 cycles 10 seconds each.   The protein concentration was determined 
using DC Protein Assay in the microplate format.  The microsomal suspension was then 
aliquoted and kept at -80 °C for future use. 
 
2.2.3.3 RNA Isolation and Quantification: 
 
Thirty micrograms of the liver tissue stabilized in RNAlater at 4 °C was 
transferred to RLT buffer (600µL RLT plus 6 µL of 2-mercaptoethanol of RNeasy 
MiniKit) and homogenized using a rotor stator homogenizer.  The intestinal mucosa 
samples previously homogenized in RLT buffer and frozen at -80 °C were thawed at 
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37°C for 5 minutes.  RNA was then extracted from the liver and intestinal mucosa 
samples according to the manufacturer’s protocol (RNeasy Mini kit Handbook, Animal 
Tissue Protocol, Qiagen Valencia, CA).  Briefly, the samples were mixed with equal 
volume of 70% ethanol, centrifuged at maximum speed and the supernatant applied to an 
RNeasy spin column (RNA retention column).  The column was washed with RW1 and 
RPE buffers from the kit.  The RNA was eluted using 40 µL of DNase free water.  The 
RNA concentration of each sample was determined using NanoDrop Spectrophotometer 
(NanoDrop Technologies Inc.).  RNA was stored at -80 °C. 
 
2.2.3.4 RNA Integrity: 
 
A few microliters of the RNA samples were diluted in the range of 100 to 400 
ng/µL   and supplied to the University of Kentucky Microarray Core Facility to check 
RNA integrity.  Agilent chips were used and Agilent 2100 analyzer and 2100 Expert 
software for analysis.  Integrity was reported in terms of RIN (RNA Integrity Number) 
from 0-10, 10 being the best quality.  Absorption peaks as well as RNA bands for 18s and 
28s ribosomal RNA were also reported. 
 
2.2.4 Reverse Transcription: 
 
 The RNA reverse transcription was performed using the SuperScript III First-
Strand Synthesis System.  One microgram of RNA was used per reaction unless the RNA 
concentration did not permit (8 µL RNA solution maximum per reaction).  The procedure 
was done according to the manufacturer’s protocol.  One µg of RNA , 1 µL of each of  50 
µM Oligo dt, 10 mM dNTP mix  and DPEC treated water to 10 uL per reaction were 
heated to 65°C for 5 minutes then placed on ice for at least 1 minute.  The synthesis 
mixture (2 µL of each of 10X RT buffer  and 0.1 M DTT, 4µL of 25 mM MgCl2  and 1 
µL of each of RNaseOUT (40 U/µL) and SuperScript III RT (200 U/µL)) was then added 
and heated for 50 min at 50°C and the reaction ended at 85 °C for 5 minutes and cooled 
on ice.  The reaction was centrifuged and 1 µL of RNase H added and incubated at 37 °C 
for 20 minutes.  The cDNA was then stored at -20 °C for later use in quantitative-PCR. 
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2.2.5 Quantitative PCR 
 
2.2.5.1 Primers: 
 
Quantitative PCR was performed for 5 rat genes Cyp3a1, Cyp3a2, Mdr1a, Mdr1b 
and villin.  Primers were either adopted from the literature or designed as described 
below. 
Primer design: For primers that had no satisfactory sequences in the literature, the 
mRNA sequence was obtained from NCBI Gene database and using Primer 3 online 
software (http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi) to design primers. 
For Cyp3a1, sequence alignment with Cyp3a2 mRNA was first performed using NTI 
Vector Suite Software version 9.0.0 (Informax) to choose a target sequence that was 
unique to Cyp3a1 and that would not amplify Cyp3a2 cDNA. 
The primer sequences were then compared against the available genome 
sequences using Nucleotide BLAST (The Basic Local Alignment Search Tool, http://0-
www.ncbi.nlm.nih.gov.library.vu.edu.au/blast/index.shtml) on the NCBI website to 
ensure that the primers were unique to the target gene sequences. 
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Table 1: Primer sets used for Quantitative PCR 
1-Designed by Primer 3 
2-(Meredith, Scott et al. 2003) 
3-(Kwan, Sills et al. 2003) 
  
2.2.5.2 Primer Optimization: 
 
The primer concentration was set at 1 µM and the conditions to be optimized 
were the annealing temperature (55-64°C) and MgCl2 concentrations (2.5-4.5 µM) at two 
starting cDNA dilutions (10-2 and 10-4).  Male Sprague-Dawley rat liver cDNA was used 
for optimization of all primers and subsequently for standard curves, except for Mdr1a 
and villin.  Male Sprague-Dawley rat brain and intestinal cDNA were used for Mdr1a and 
villin respectively. 
The reaction mixture was as follows made from SYBR Green PCR Core Reagent 
system (Applied Biosystems, Foster City, CA): 
1 uL of cDNA, 5 µL of 12.5 mM dNTP mix with dUTP, 5 µL of  10 x SyBR 
Green Buffer, 0.5 µL of Fluorescein Calibration Dye (1 µM) (Bio-Rad Laboratories, 
Hercules, CA), 0.25 µL of  5 U/µl Taq Polymerase, 1 µL of each of forward and reverse 
primers (10 µM), MgCl2 (25 mM)  up to the desired concentration, and DNAse free water 
Gene Primer Sequence 
Sequence 
Source 
Product 
size 
Cyp3a1 1 
Left: AAA GAA TCT CAT ACA GCC CTA TCC 
Right:  CTG CTG GTG GGT TCA TAT CC 
NM_173144 100 
Cyp3a2 2 
Left: GCTTTCAGCTCTCACACTGGAAA 
Right:   TCTATGGGTTCCAAGTCGGTAGA 
NM_153312 89 
Mdr1a 3 
Left: GATGGAATTGATAATGTGGACA 
Right:  AAGGATCAGGAACAATAAA 
NM_133401 351 
Mdr1b 3 
Left: GAAATAATGCTTATGAATCCCAAAG 
Right:  GGTTTCATGGTCGTCGTCTCTTGA 
NM_012623 326 
Villin 1 
Left: GATGGAATTGATAATGTGGACA 
Right:  AGTGCTCCTTCTCGCCTATG 
XM_237288 157 
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to complete reaction volume to 50 µL.  Reaction mixtures were loaded in a 96 well plate 
and covered with an optical film.  The reaction was then run using the iCycler Real-Time 
PCR Detection System (Bio-Rad Laboratories, Hercules, CA).  
The protocol for thermal cycling was: 
  
Cycle  1: (  1X)  
 Step  1:  95.0ºC for 05:00 
Cycle  2: ( 50X)  
 Step  1: 95.0ºC for 00:45 
 Step  2: gradient 55-64ºC for 01:00 
 Step  3: 72.0ºC for 01:00 
 Data collection and real-time analysis enabled. 
Cycle  3: (  1X)  
 Step  1:  95.0ºC for 02:00 
Cycle  4: (100X)  
 Step  1:  95.0ºC for 00:30 
 Decrease setpoint temperature by 0.5ºC 
 Melt curve data collection and analysis enabled.  
The reactions were run for 50 cycles (Cycle 2 in the above protocol) except for 
villin (40 cycles). 
To ensure the correct product formation, the product was then run on 2-3% 
agarose gel with a reference DNA ladder (Invitrogen Life Technologies, Carlsbad, CA) 
depending on the product size and stained with ethidium bromide for UV visualization 
using Kodak  imaging station 2000 MM and Kodak Molecular Imaging Software 
(Eastman Kodak Company, Rochester, NY).  The optimum conditions were chosen based 
on the lowest threshold cycle number needed for a product to be visualized by SYBR 
green intercalating dye for the dilutions of the reference cDNA used given that the 
agarose gel showed a positive product at the correct band size and no primer pairs. 
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2.2.5.3 Sample Analysis: 
 
 The conditions used for each primer pair are described in Table 2.  The reaction 
mixture and the thermal cycling protocol were similar to primer optimization except at 
Cycle 2 Step 2 where the temperature used was the annealing temperature.  Each sample 
was run in triplicate using the proper dilution to fit within the standard curve.  Standard 
curve dilutions of 1 to 10-4 of the proper cDNA (indicated above) were run 
simultaneously on the plate with the samples.  Standard curve cDNA was from animals 
other than the test animals.  Results were analyzed using the  i-Cycler IQ Software 
System v3.1.7.  Results were normalized to 1µg RNA used in the reverse transcription 
reaction and expressed in terms of the starting quantity of RNA in comparison to the 
standard curve used. 
  
Table 2: Quantitative PCR Conditions for each primer set 
Gene 
Annealing Temperature 
(°C) 
Magnesium Chloride 
Concentration (mM) 
Cyp3a1 62 3.5 
Cyp3a2 62 3.5 
Mdr1a 58.2 4 
Mdr1b 55 3.5 
Villin 62 4.5 
 
2.2.5.4 Statistical Analysis: 
 
The results obtained for each gene were statistically compared to the adults (112 
days) by one-way ANOVA using GraphPad Prism.  If statistical significance was found a 
post-hoc analysis was done using Dunnett’s test. 
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2.2.6 Western Blotting: 
 
Primary antibody specificity was first tested before running the samples against 
individual Cyp3a1 and Cyp3a2 SupersomesTM.  The tested antibodies were rat anti-
Cyp3a1 from Research Diagnostics and anti-Cyp3a2 from Daiichi and anti-Cyp3a1 and 
anti-Cyp3a2 form Chemicon.  To further characterize the specificity/interaction of the 
antibodies against the respective proteins, the anti-Cyp3a1 and anti-Cyp3a2 antibodies 
from Chemicon were used to probe mixtures of the proteins and the net intensities of the 
bands were analyzed.  
Liver microsomal protein and intestinal microsomal protein, 5 and 10 µg 
respectively, were used.  Standards were 3 different amounts of Cyp3a2 Supersomes™; 
1.16, 0.58 and 0.12 ng.  Samples and standards were mixed with 5 µL LDS Sample 
Buffer and 2 µL Sample Reducing Agent and water to complete the volume to 20 µL. 
The mixture was then heated at 70 °C for 10 minutes in a water bath. 
The samples and standards in duplicate and a protein ladder (Magic MarkXP) 
were then loaded on a 4-12% NuPage  Bis-Tris gel and run at 150 Volts constant for 55 
minutes using MOPS Running Buffer.  The proteins were then transferred to PVDF 
membranes (for 1 hour and 15 minutes at 30 volts constant using NuPage Transfer 
Buffer).  The membrane was then blocked for 1 hour in the blocking solution (3% Bovine 
Serum Albumin in Tris-Buffered Saline-Tween 20 (TBST): 10 mM tris Buffer pH 7.4, 
150 mM NaCl and 0.05% Tween 20).  The membrane was rinsed in TBST and incubated 
with a 1:1000 dilution of the primary antibody (Chemicon anti Cyp3a1 or Cyp3a2) in 
TBST overnight at 4 °C.  For detection the membrane was rinsed 3 times for a total of 20 
minutes in TBST and incubated with a 1:8000 dilution of the secondary antibody (ant-
rabbit Ig-G-HRP conjugated) in TBST for 1 hour.  The membrane was rinsed as 
described above and incubated for 5 minutes with SuperSignal® West Pico 
Chemiluminescent Substrate.  All the above incubations were done while shaking at room 
temperature unless otherwise indicated.  The chemiluminescent imaging was done using 
Kodak imaging station 2000 MM and Kodak Molecular Imaging Software (Eastman 
Kodak Company, Rochester, NY).  Analysis was done using the Kodak Molecular 
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imaging software using the standards run on the same gel for a standard curve.  Results 
for each band are expressed in mass units (ng) per 5 ug protein for the liver. 
 
2.2.7 Activity Determination: 
 
2.2.7.1 Vmax: 
 
2.2.7.1.1 Microsomal Incubation: 
 
Linearity of product formation with respect to time and intestinal or liver 
microsomal protein were first performed as well as the midazolam concentration at which 
Vmax is reached.  For liver, the incubation mixture consisted of 50 µg protein per sample 
per 200 µL reaction mixture, 50 µL of 0.2 M Tris buffer (dilutes to 0.05 M in a final 
volume of 200 uL pH 7.4), 12 µL of NADPH Regenerating System (10 µL of Solution A 
and 2 µL of Solution B), a final concentration of 60 µM Midazolam and water to 
complete reaction volume to 200 µL.  The reactions were done in duplicate per sample per 
day.  The reaction mixture was similar for intestinal microsomes except that the total 
protein amount per reaction was 200 µg.  The reaction mixture was pre-incubated for at 
least 5 minutes at 37 °C before starting by adding the NADPH Regenerating System and 
stopped after 5 minutes for the liver microsomes and 10 minutes for intestinal 
microsomes by adding 200 µL ice-cold acetonitrile.  The incubations were done in a 
shaking 37 °C water bath.  The reaction tubes were kept on ice for 5 minutes and then 
vortexed for 5 minutes.  Protein was precipitated by centrifuging at 1800xg for 15 
minutes.  A 50 µL sample of the supernatant was then analyzed in duplicate for the 4-
hydroxymidazolam metabolite using HPLC-UV.  Standard Curves and controls were 
made of 4-hydroxymidazolam in 1:1 0.05M Tris buffer:acetonitrile.  Vmax 
determinations were performed twice on two different days and the Vmax value was 
taken as the average of all determinations.  
 
 
 
45 
 
2.2.7.1.2 HPLC Analysis of 4-Hydroxymidazolam: 
 
A LC-10ADvp Shimadzu LC pump, SCL-10Avp system controller, SIL-10ADvp 
auto injector, and a SPD-10Avp UV-VIS detector were used to analyze 4-
hydroxymidazolam in the incubation mixture.  The mobile phase consisted of 60% 0.05 
M Ammonium Phosphate monobasic and 40% acetonitrile HPLC grade.  The column 
used was an alkylamide derivatized  SUPELCOSIL ABZ+ Plus column (25 cm X 4.6 
mm, 5 µm).  The flow rate was set at 1 mL/min and UV detection at 254 nm. 
Since 1’-hydroxymidazolam metabolite is also formed in the rat, a standard of  1’-
hydroxymidazolam was injected to ensure that the chromatographic method separated the 
2 metabolites and that the peak obtained at 6.9 minutes was solely that of 4-
hydroxymidazolam. 
  
2.2.7.2 Km determination: 
 
Pooled protein samples from each age group were used for the Michaelis-Menten 
constant (Km) determination.  An equal amount of protein from each rat (N=4) was 
combined within an age group.  Protein concentrations were determined in the pooled 
sample prior to the microsomal incubations to ascertain that the correct amount of protein 
was used.  The incubations were done for liver microsomes as described under Vmax 
determination except that a range of midazolam concentrations  (1-500 µM) were used to 
generate the Michaelis-Menten profile of Cyp3a enzyme kinetics.  The reactions were 
done in duplicate for each midazolam concentration.  The 4-hydroxymidazolam 
concentrations were determined by HPLC as described above.  The Michaelis-Menten 
kinetics were modeled using GraphPad Prism v.4.01 (Graph Pad Software, San Diego 
CA) using a hyperbolic one-binding site model on data from 1-60 µM midazolam only, 
since Vmax is reached at 60 µM.  Km and Vmax mean values and standard errors are 
generated from a fitted line of the data according to a hyperbolic one-binding site model 
(Michaelis-Menten kinetics).  The Km’s generated for each age group were statistically 
compared using the non-parametric Kruskal-Wallis test to determine if Km significantly 
varied with age.  To further confirm if Km varied or not with age, the data for all the age 
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groups was fitted to  the Michaelis-Menten profile using WinNonlin 4.1 (Pharsight 
Corporation, Mountain View, CA) simultaneously.  The fitting was done twice, once 
assuming different Km values and once assuming a single Km value.   The Vmax values 
for both fittings were then plotted against age for comparison. 
 
2.2.8 In Vivo Clearance Determination: 
 
2.2.8.1 Animals: 
 
In order to test the model prediction of Cyp3a ontogeny, the in vivo oral clearance 
of midazolam was determined in 3 age groups.  Animal studies were approved by the 
University of Kentucky IACUC committee.  Male Sprague-Dawley rats ages 7, 21 days 
(from litters of untimed pregnant females) and adult males (112 days) were obtained from 
Harlan (Harlan Inc., Indianapolis, IN).  Adult animal clearance was used as the reference 
used to predict infant clearance.  Seven and 21 day old groups were chosen since the 
former represents a neonatal age group and the latter is at the weanling stage.  Animals 
were kept in an environment of controlled temperature and humidity and 12-hour light, 
12-hour dark cycle.  Food and water were supplied ad libitum.  Animals were left to 
acclimatize for at least 4 days before the study.  On the day of the study 21 and 112 day 
old animals were fasted 6-8 hours before dosing, water was provided.  Seven day old 
animals were fasted 2 to 3 hours prior to dosing and were returned to the mother’s cage 
2-3 hours after dosing.  While away from the mother, the neonatal rats were kept on a 37 
°C heating pad to avoid heat loss.  Due to limited blood volume in rat pups 7 and 21 days 
old, a destructive sampling design was adopted where a terminal blood sample was 
obtained from each animal.  Although multiple sampling is feasible in adults, destructive 
blood sampling was employed as well to avoid any difference in clearance of midazolam 
that could be triggered by anesthesia and catheter implantation surgery and recovery 
(Uhing, Beno et al. 2004).  Four animals were used per sampling time point per age 
group. Midazolam was dosed at time zero at 20 mg/kg using oral intubation.  The size of 
the oral tube was suitable for the age group.  From preliminary studies, the following 
sampling times were deemed appropriate for a full pharmacokinetic profile along with 
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minimizing the number of animals used.  For the 7 and 21 day age groups sampling time 
points were: 0 (no dose),  5, 10 and 30 minutes, 1, 1.5, 2 ,3 , 4 , 6 and 8 hours.  For 112 
day rats sampling times were 0, 10 ,20 and 30 minutes, 1, 1.5, 2, 3, 4 and 6 hours.  At the 
time of sampling the animals were anesthetized using isoflurane inhalational anesthesia 
and blood was collected by cardiac puncture.  Blood samples were kept at room 
temperature for at least 30 minutes after which serum was collected by centrifugation at 
3000xg for 15 minutes at 4 °C then serum samples were stored at -20 °C until analysis. 
 
2.2.8.2 LC/MS/MS Assay of Midazolam in Serum: 
 
2.2.8.2.1 Sample Preparation: 
 
Midazolam concentration in rat serum was determined by an LC/MS/MS method. 
Serum samples were prepared by solid phase extraction.  Either 25 (7and 21 days) or 50 
(adults) µL of the serum sample was extracted.  The serum sample was diluted with 470 
µL of water and 70 µL of 100 ng/ml of flurazepam in acetonitrile as the internal standard. 
The sample was loaded by vacuum on preconditioned Oasis HLB solid phase extraction 
columns (Waters), the column was then washed with 1 mL of each of water and 5% 
methanol in water.  The sample was then eluted by 2 X 1 mL of methanol.  The methanol 
eluate was then evaporated under nitrogen gas and the residue was reconstituted in either 
100 or 200 µL of mobile phase (80% aqueous and 20% organic). 
The mobile phase used for the assay was 1 mM ammonium formate in water, pH 
adjusted to 3.8 using formic acid, as the aqueous phase and acetonitrile as the organic 
phase. Gradient elution was used starting at 80% aqueous, 20% organic. 
 
2.2.8.2.2 LC/MS/MS Conditions: 
 
LC/MS/MS was performed on a Varian Prostar Model 210 LC system coupled to 
a 1200 L Quadropole MS/MS Varian mass spectrometer equipped with an electrospray-
ionization source (Varian Inc., Palo Alto, CA). A Fusion RP-80A, 4 µm, 50 x 2 mm 
column (Phenomenex, Torrance, CA) was used for separation.  The mobile phase 
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consisted of solvent A (1 mM ammonium formate pH 3.8) and solvent B (acetonitrile), 
using linear gradients of 20-90% B (v/v) over 13 min.  The flow rate was 0.25 ml/min.    
Positive–ion mass spectra was acquired.  Positive-ion ESI was performed using an ion 
source voltage of 40 V and a capillary offset voltage of 86.0 V.   Nebulization was aided 
with coaxial nitrogen sheath gas provided at a pressure of 20 psi and a capillary 
temperature of 300 °C.  Mass spectra were recorded in a tandem MS mode with a 
collision Argon gas at a pressure of 2.02 m Torr.   Selective ion monitoring (SIM) width 
was set at 0.7 amu for m/z 326 (M+, midazolam) and monitoring its first daughter ion at 
m/z 291.  Peak areas of midazolam peaks in serum samples were normalized based on the 
area of the recovered internal standard peak (flurazepam). 
Initially there was a problem encountered with the analysis.  The sensitivity 
greatly dropped after 10-13 injections as determined from the drop of the peak area of the 
internal standard.  Repeated injection of the same control revealed that sensitivity 
dropped disproportionately for midazolam and flurazepam such that the concentration of 
a control appeared to significantly drop when injected twice once at the beginning of the 
run and another at the end of the run.  To rule out that this disproportionate drop with 
time is due to a stability problem of midazolam, the same control was injected the next 
day after the ionization chamber of the mass spectrometer was cleaned with methanol. 
The midazolam concentration and the sensitivity appeared to be regained.  To further 
explore if cleaning the ionization chamber was the solution to the disproportionate 
sensitivity drop, controls were injected (13 injections), the ionization chamber was 
cleaned with methanol after allowing it to cool, and meanwhile the LC flow was not 
interrupted and was diverted away from the mass spectrometer.  After cleaning, the same 
controls were reinjected for a second run.  This was performed for a total of three runs 
and two cleanings inbetween in the same day.   It appeared that the concentration of the 
controls for the three runs where within a 20% range.   This procedure was applied to 
sample analysis by injecting all the controls in the first run along with samples and then 
two of the controls were reinjected in the subsequent two runs along with the rest of the 
samples to ensure that sensitivity was not significantly dropping for midazolam.  The 
runs were deemed acceptable if the concentrations of the controls where within 20%. 
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2.2.8.2.3 Pharmacokinetic Analysis: 
 
 Non-compartmental analysis of the concentration-time profile for all the age 
groups was performed using WinNonlin 4.1 (Pharsight Corporation, Mountain View, 
CA). The model independent parameters: AUC, Cmax and tmax were determined. For 
model dependent parameters, clearance (Cl/F), volume of distribution (Vd) and 
absorption rate constant (KA), a one compartment, first order absorption model was 
assumed.  Analysis was performed using NONMEM (University of California, San 
Fransisco)   using population kinetics approach since each time point comes from a 
different animal (limited sampling). 
 
2.2.8.3 Midazolam Serum Protein Binding: 
 
Midazolam serum protein binding was determined by ultrafiltration.  Blank serum 
from 7, 21 and 112 day old animals (not exposed to midazolam) was pooled from at least 
3 animals per age group.  The serum was spiked with midazolam to a final concentration 
of 5000 ng/mL. For ultrafiltration, disposable Millipore Centrifree ® micropartition 
devices (Millipore Corporation, Bedford, MA) were used, containing YMT memebranes. 
The devices were loaded with 400 µL of serum in duplicate for 7 day age group and 
triplicate for the other two age groups.  Centrifugation was performed in a Sorvall RT 
6000D centrifuge at 37 °C for 20 minutes at 2000xg.  The free fraction was determined 
by assaying midazolam in the ultrafiltrate using HPLC.  
 
 
HPLC Analysis of Midazolam in Ultrafiltrate: 
 
A LC-10ADvp Shimadzu LC pump, SCL-10Avp system controller, SIL-10ADvp 
auto injector, and a SPD-10Avp UV-VIS detector were used to analyze midazolam in the 
ultrafiltrate.  The mobile phase composition was obtained by contacting Ultrafine 
Chemicals (Manchester, UK).  The mobile phase consisted of 60% 0.05 M Ammonium 
Phosphate monobasic and 40% acetonitrile HPLC grade.  The column used was an 
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alkylamide derivatized  SUPELCOSIL ABZ+ Plus column (25 cm X 4.6 mm, 5 µm) with 
an alkylamide gurad column SUPELCOSIL™ ABZ+Plus Supelguard® Cartridge (5 cm X 
4.6 mm, 5 µm.  The flow rate was set at 1 mL/min and UV detection at 254 nm. 
The free fraction was calculated by dividing the ultrafiltrate concentration by the 
initial concentration in serum. 
 
2.2.9 Model Prediction: 
 
Clearance was predicted according to the ontogeny model described in the 
background (Alcorn and McNamara 2002d).  The model assumptions are: 
1. Drug has a low extraction ratio. 
2. Infant and adult share the same enzymes and transporters in metabolizing the 
same drug. 
3. Microsomal protein content normalized to liver weight is constant and 
independent of age. 
4. Km for an enzyme-substrate system remains constant throughout 
development. 
5. Vmax reflects the amount of functional enzyme and is proportional from one 
substrate to the next. 
6. Hepatic Clearance is governed by hepatic metabolic enzymes and not hepatic 
transporters. 
The assumption that Km does not vary with age was tested in the previous 
section.  The assumption that microsomal protein content normalized to liver weight was 
examined by plotting microsomal protein content (mg/g liver) against age and a one-way 
analysis of variance (ANOVA) was performed to determine any significant difference 
between age groups.  If a significant difference exists, Dunnett’s post-hoc test was 
performed to compare different age groups to adults (112-day group). 
Midazolam is a drug cleared by hepatic Cyp3a metabolism(Gorski, Hall et al. 
1994; Thummel, Shen et al. 1994).  Although, it was shown to be a substrate for P-gp, P-
gp does not affect the permeability of midazolam intracellularly (Tolle-Sander, Rautio et 
al. 2003) since it is a highly permeable drug (log P= 2.68).  Hence, midazolam satisfies 
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most of the requirements for clearance prediction by the above model.  However, 
midazolam clearance is affected by hepatic blood flow as well as intrinsic clearance 
(intermediate extraction  drug).  To be able to circumvent hepatic blood flow, oral 
clearance (Clpo) will be calculated for midazolam as follows: 
 
 
 
 
where F is the oral bioavailability, FH is the fraction extracted by the liver and FG is the 
fraction extracted by gut or intestine.  Assuming that FG=1 then F=FH , then F and oral 
clearance can be calculated as follows: 
 
 
 
 
Thus oral systemic clearance can be calculated from in vitro data. 
The following equations describe the ontogeny model approach to calculate 
intrinsic clearance as described in the background: 
 
 
                                                                                                                                       
where 
 
Clearance will be calculated according to the following 2 models: 
 
 
 
 
Model 2 is the ontogeny model approach.  Model 1 assumes that microsomal protein 
normalized to liver weight and body weight is independent of age and hence RHSF=1. 
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2.2.10 Prediction Evaluation: 
 
The predicted clearance for the 7 and 21 day age groups will be compared to the 
clearance values determined in vivo.   Since only two age groups were characterized, a 
correlation analysis was inappropriate.  Using a standard statistical analysis (e.g. 
Student’s t-test) to compare the observed and predicted was also inappropriate since a 
statistical significance would not indicate that the prediction was not biologically or 
clinically useful.  Hence, an approach was used such that if the predicted values fell 
within the 50-200% of the observed values then the prediction will be accepted as valid 
i.e. within twofold of the observed. 
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Chapter 5. Results 
1 In Vitro M/S: 
 
1.1 Atkinson and Begg Model Assessment  
 
The drugs used in the following correlations were not used in building the original 
model.  Figure 1 shows the Atkinson and Begg model (Atkinson and Begg 1990; Begg, 
Atkinson et al. 1992) M/S prediction for a set of acidic drugs.   The model is inadequate 
in predicting the observed M/S values for these acidic drugs.  A large number of drugs 
are grouped near the ordinate (M/S<0.1) making the relationship more difficult to 
observe.  However, the model did not perform well with this set of acidic drugs.  One 
explanation for the discrepancy for the observed and predicted is the assumption of 
passive diffusion as the mechanism of transfer.   Two of the drugs on the graph (acyclovir 
M/Sobs =3.0 and ciprofloxacin M/Sobs =1.7) had a greater M/Sobs  than the M/Spred.  The 
M/Spred for oxazepam was much greater (M/Spred =1.2) than the observed (M/Sobs =0.1).  
Figure 2 shows the Atkinson and Begg model (Atkinson and Begg 1990; Begg, Atkinson 
et al. 1992) M/S prediction for a set of basic drugs.  The model performed better in 
predicting the observed M/S values for these drugs.  Two of the drugs on the graph 
(acebutolol M/Sobs =5.7 and ranitidine M/Sobs =3.8) had a higher M/Sobs than M/Spred. 
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Figure 1: M/S predicted values using the model proposed by Atkinson and Begg 
(1990) , for a set of acidic drugs not included in building their model, vs. M/S observed 
values reported in the literature for those same drugs (acyclovir, amoxicillin, captopril, 
cefadroxil, ciprofloxacin, clonazepam, doxorubicin, enalapril, indomethacin, ketorolac, 
naproxen, oxazepam, piroxicam).  The red data points are those used in the Fleishaker 
model evaluation in the above section.  The line of unity is depicted.  (r2 = 0.4780).  The 
inset represents the area surrounded by the rectangle at the origin of the graph. 
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Figure 2: M/S predicted values using the model proposed by Atkinson and Begg 
(1990) for basic drugs, for a set of drugs not included in building their model, vs. M/S 
observed values reported in the literature for those drugs (chlorpromazine, clonidine, 
fluoxetine, fluoxetine, imipramine, labetalol, metoprolol, quinidine, ranitidine, 
terbutaline, timolol, trimethoprim, acebutolol, quinine, nicotine).  The red data points are 
those used in the Fleishaker model evaluation in the above section.  The line of unity is 
depicted. (r2= 0.7663)  
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1.2 In Vitro M/S Calculation: 
 
The skim to whole milk ratio (S/W), free fraction in serum (fs) and free fraction in 
milk (fm) from the above experiments for ciprofloxacin, citalopram, nicotine, acyclovir 
and ascorbic acid are shown in Table 3. 
With the possible exception of citalopram, most of the measured parameters have 
small intersubject variability.  The larger variability seen in the S/W ratio for citalopram 
can be explained in terms of greater lipophilicity of citalopram (logP= 2.51, ACD labs 
v.6.0) and the intersubject variability of the fat content in milk reflected by crematocrit 
values (average 6.75% and coeffeicient of variation 13.4%)(Figure 3). 
The measured S/W ratio was low for citalopram and was inversely related to the 
crematocrit values indicating partitioning into milk fat.  The ratio fun.s/fun,m  was 1.58.  
The observed M/S values (1.8, 1.52, 3.00) fell within the confidence interval of the 
predicted value (M/Spred = 1.83) (Figure 4) indicating that the high M/S ratio could 
largely be attributed to partitioning into milk fat as well as ion-trapping in milk.  
The M/Sobs for ciprofloxacin has been reported to be 1.6 whereas the predicted 
value is 0.85 (Figure 5).  The predicted value was almost half of that observed.  However, 
using a more stringent criterion of the 50-200% confidence interval (Edwards, Rudy et al. 
2003), the M/Sobs ratio lies within that range (0.679-4.59).  The S/W ratio and fun.s/fun,m 
were close to 1.  Ciprofloxacin was more bound in serum than in milk.  Accordingly, the 
M/Sobs can not be readily explained by physicochemical properties measured. 
The 95% CI for M/Sobs for nicotine (2.60- 3.24) overlapped with the 95% CI for 
the 50-200% M/Spred (0.58-2.9), with the M/Sobs value (2.92) being outside that range 
(Figure 6).  M/Spred was 1.29.  The S/W ratio was equal to 1, the fun.s/fun,m was equal to 1.4 
and the fs/f,m was equal to 0.9.  The high M/S observed might partially be, but not fully, 
explained by ion-trapping (nicotine being a base) in milk and the slightly higher binding 
to milk proteins.  
For acyclovir the M/Sobs was reported in the range of 2.2 to 3.3; whereas the 
diffusion model prediction (M/Spred) was 1.01 (Figure 7).   The S/W ratio, fun.s/fun,m  and 
fs/f,m were all equal to 1.  There is no explanation for the high M/Sobs in terms of the 
measured parameters. 
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Ascorbic acid in vitro data predict an M/S ratio of 0.63, which was tenfold less 
than the observed value of 6.4 (n=57) (Figure 8).  As an acid its accumulation in milk 
cannot be explained by ion-trapping (fun.s/fun,m = 0.6).  Moreover, there was insignificant 
binding in both serum and milk and almost no partitioning into milk fat was observed 
(S/W=1). 
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Table 3: Measured parameters included skim to whole milk partitioning ratio 
(S/W), fraction unbound to serum (fs) and skim milk (fm) as well as estimated fraction 
unionized in serum (fun,s) and milk (fun,m) in human samples obtained from 8 lactating 
female volunteers. 
Conc 1
(µg/ml)
Citalopram
Mean 0.28 9.57 0.58 0.48 0.77 0.01 0.004 3
SD 0.10 0.06 0.12
Ciprofloxacin
Mean 0.21 8.38 0.91 0.72 0.91 0.91 0.94 4
SD 0.09 0.05 0.06
Nicotine
Mean 0.028 8 1.04 0.88 0.97 0.2 0.14 5
SD 0.08 0.04 0.03
Acyclovir
Mean 6.5 9.51 1.01 0.99 0.97 0.99 1 6
SD 0.05 0.06 0.04
Ascorbic Acid
Mean 17.6 4.37 1.03 1.05 0.98 0.0009 0.0015 7
SD 0.04 0.09 0.04
fm fun,s fun,m RefpKa2 S/W fs
 
1-Therapeutic serum concentration as obtained from the references. 
2-pKa values were obtained from ACD labs v. 6.0 
3- (Jensen, Olesen et al. 1997; Spigset, Carieborg et al. 1997; Rampono, 
Kristensen et al. 2000; Schmidt, Olesen et al. 2000) 
 4-(Giamarellou, Kolokythas et al. 1989) 
5-(Luck and Nau 1984; Dahlstrom, Lundell et al. 1990) 
6-(Lau, Emery et al. 1987; Meyer, de Miranda et al. 1988; Bork and Benes 1995; 
Sheffield, Fish et al. 2002) 
7-(Ortega, Quintas et al. 1998) 
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Figure 3: Correlation of skim to whole milk concentration ratio of citalopram 
with crematocrit in human subjects (n=8). 
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Figure 4: Citalopram.   Predicted M/S (lower and upper limits of the 95% 
confidence intervals of the 50% and 200% values of predicted M/S respectively).   
  Predicted M/S (95% CI).    Observed M/S (Jensen, Olesen et al. 1997; Spigset, 
Carieborg et al. 1997; Rampono, Kristensen et al. 2000; Schmidt, Olesen et al. 2000). 
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Figure 5: Ciprofloxacin.    Predicted M/S (lower and upper limits of the 95% 
confidence intervals of the 50% and 200% values of predicted M/S respectively).    
Predicted M/S (95% CI).   Observed M/S (Giamarellou, Kolokythas et al. 1989).  
 
 
 
Figure 6: Nicotine.   Predicted M/S (lower and upper limits of the 95% 
confidence intervals of 50% and 200% values of predicted M/S respectively).  
Predicted M/S (95% CI).   Observed M/S (95% CI) (Luck and Nau 1984; Dahlstrom, 
Lundell et al. 1990). 
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Figure 7: Acyclovir.  Predicted M/S (lower and upper limits of the 95% 
confidence intervals of the 50% and 200% values of predicted M/S respectively).   
Predicted M/S (95% CI).    Observed M/S (Lau, Emery et al. 1987; Meyer, de 
Miranda et al. 1988; Bork and Benes 1995; Sheffield, Fish et al. 2002). 
 
 
 
Figure 8: Ascorbic acid.   Predicted M/S (lower and upper limits of the 95% 
confidence intervals of the 50% and 200% values of predicted M/S respectively).   
Predicted M/S (95% CI).    Observed M/S (Ortega, Quintas et al. 1998). 
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2  In Vitro and In Vivo Cyp3a Ontogeny: 
 
2.1 RNA Integrity Results: 
 
 RNA integrity was checked to ensure that the RNA samples analyzed for 
ontogeny patterns were not degraded and thus undermining the results obtained.  RNA 
integrity results from the University of Kentucky Microarray Core Facility were reported 
in terms of RNA integrity number (RIN), a parameter designed by Agilent Technologies 
to report the degree of integrity of the sample.  Fluorescence versus time of ribosomal 
RNA peaks as well as RNA bands were also reported.  During analysis the RNA samples 
in the chip flow through micro-channels and are separated according to size and detected 
by fluorescence, hence a fluorescence chart is generated for RNA peaks as well as RNA 
bands in the sample compared to a ladder.  The sharper the RNA peaks, the less 
fragmented is the RNA in the sample, as shown by the RNA bands, the higher the RIN 
number, and the better the quality of the sample (Figure 9).  The highest possible RIN 
number is 10.  For the liver samples, only one sample failed to show a RIN number even 
though the RNA peaks were sharp and the bands showed no fragmentation; this sample 
was not excluded.  The RIN for liver RNA samples ranged from 9.6 to 10 with an 
average of 9.9.  For the intestinal mucosa RNA samples, rat number 3 in the 21 day age 
group was excluded from RNA integrity analysis and subsequent PCR reactions due to 
the very low amounts of RNA recovered from the sample.  Rat number 1 in the 112 day 
age group had a RIN of 6.1 and the RNA peak was broad and the bands showed 
fragmentation, hence the sample was excluded from further analysis.  One more sample 
(Rat number 3, 7 day age group) had a RIN of 8.3 but RNA integrity was not 
compromised and hence was not excluded.  The rest of the intestinal mucosa RNA 
samples had RIN ranging from 9.2-10 with an average of 9.7. 
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Figure 9: RNA integrity results for 2 samples.  The graphs show RNA peaks 
detected by fluorescence, the y-axis representing fluorescence units (FU) and the x-axis 
representing scanning time in seconds.  To the right of each graph is a plot of RNA bands 
to show whether there is fragmentation.  A is RNA from intestinal mucosa of a 112 day 
old rat.  RIN was 6.1 and the sample was excluded from analysis.  The 28s peak is broad 
and RNA bands on the right show fragmentation.  B is RNA liver sample from a 112 day 
old rat.  RIN was reported to be 10.  The RNA fluorescence peaks are sharp and the RNA 
bands to the right show no fragmentation.  
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2.2 Quantitative PCR Primer Optimization Results: 
 
 The conditions for each primer are listed under the methods section.  Representative PCR 
time course, gels and standard curves generated for each gene under those conditions are 
presented in Figures 10- 12. 
 
 
 
 
 
Figure 10:  A representative PCR time course for Mdr1a standard curve using rat 
brain cDNA. 
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Figure 11: Ethidium bromide stained agarose gels for quantitative PCR products 
using primers and conditions listed in the methods section.  Single bands were detected at 
the appropriate size for each product. 
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Figure 12: Standard curves for quantitative PCR using primers and conditions 
listed in the methods section.  A-Cyp3a1 using male rat liver cDNA (r2=0.988).  B-
Cyp3a2 using male rat liver cDNA (r2=0.989).  C-Mdr1a using male rat brain cDNA 
(r2=0.995).  D-Mdr1b using male rat liver cDNA (r2=0.988).  E- Villin using male rat 
intestinal mucosa cDNA (r2=0.996).  
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2.3 Quantitative PCR Results for Liver and Intestinal Samples: 
 
2.3.1 Hepatic Expression of Cyp3a1 and Cyp3a2, Mdr1a and Mdr1b Genes: 
 
The development of mRNA expression of Cyp3a1, Cyp3a2, Mdr1a and Mdr1b in 
the male Sprague-Dawley rat liver was determined using quantitative-PCR of cDNA 
reverse transcribed from the RNA at 1, 7, 21, 42, 77 and 112 days, 4 animals per age 
group.  The developmental pattern of Cyp3a1 expression (Figure 13) was high at birth 
and decreased by 1 week of age to adult levels and was stable throughout different age 
groups.  The variability was highest for the 1 day age group and minimal in the rest of the 
age groups. 
Cyp3a2 mRNA expression (Figure 14) was low at one day of age and increased 
untll almost reached adult levels at 42 days.  However, the 21 day age group showed an 
average expression lower than the 7 day and 42 day age groups and was significantly 
lower than the 112 day age group (P<0.05).  The only other age group that had 
significantly different Cyp3a2 mRNA expression than the 112 day old group was the 1 
day age group (P<0.01).  Variability was highest for the 77 and 112 day age groups.  A 
similar trend was seen in preliminary data (data not shown). 
Mdr1a liver expression (Figure 15) was high at one day of age and decreased 
subsequently.  The highest variability was noticed at 1 day of age and it was the only 
group that had significantly higher expression of Mdr1a mRNA than the 112 day age 
group (P<0.05).  
Mdr1b (Figure 16) expression was unique.  The expression was the same for all 
age groups except for the 42 day age group where the expression was the highest and 
most variable.  The expression at 42 days of age (puberty) was significantly higher than 
the 112 day age group (P<0.01).  This unique pattern for Mdr1b mRNA expression 
confirms the results obtained from preliminary experiments (data not shown). 
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Figure 13: Relative mRNA expression of Cyp3a1 in male Sprague-Dawley rat 
liver.  Normalization was done to total RNA used in the reverse transcription reaction and 
starting quantities are relative to a male rat liver standard curve dilutions from 0 to 10-4 
run on the same plate as the samples.  Starting quantities are expressed as mean ± 
standard deviation of 4 animals. (** P<0.01 when compared to 112 day group, one-way 
ANOVA followed by Dunnett’s test) 
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Figure 14:  Relative mRNA expression of Cyp3a2 in male Sprague-Dawley rat 
liver.   Normalization was done to total RNA used in the reverse transcription reaction 
and starting quantities are relative to a male rat liver standard curve dilutions from 0 to 
10-4 run on the same plate as the samples.  Starting quantities are expressed as mean ± 
standard deviation of 4 animals. (** P<0.01, * P<0.05 when compared to 112 day group, 
one-way ANOVA followed by Dunnett’s test) 
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Figure 15: Relative mRNA expression of Mdr1a in male Sprague-Dawley rat 
liver.  Normalization was done to total RNA used in the reverse transcription reaction and 
starting quantities are relative to a male rat brain standard curve dilutions from 0 to 10-4 
run on the same plate as the samples.  Starting quantities are expressed as mean ± 
standard deviation of 4 animals. (* P<0.05 when compared to 112 day group, one-way 
ANOVA followed by Dunnett’s test) 
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Figure 16: Relative mRNA expression of Mdr1b in male Sprague-Dawley rat 
liver.  Normalization was done to total RNA used in the reverse transcription reaction and 
starting quantities are relative to a male rat liver standard curve dilutions from 0 to 10-4 
run on the same plate as the samples. Starting quantities are expressed as mean ± standard 
deviation of 4 animals.  (** P<0.01 when compared to 112 day group, one-way ANOVA 
followed by Dunnett’s test) 
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2.3.2 Intestinal Mucosa Expression of Villin, Cyp3a1, Cyp3a2 , Mdr1a and 
Mdr1b Genes in Male Rat: 
 
Villin gene expression was used as a marker for epithelial intestinal mucosa 
(Maroux, Coudrier et al. 1988) to assess inter-animal and inter-age variability of the 
intestinal mucosa collected due to variability in the scraping method (Figure 17).  
Although inter-animal variability was pronounced especially for the 112 day group, the 
overall coefficient of variation across all animals was 15.5 % and thus the scraping 
method was considered adequate for intestinal mucosa collection and comparison across 
different age groups. 
Intestinal mucosa Cyp3a1, Cyp3a2, Mdr1a and Mdr1b mRNA expression levels 
were determined using quantitative PCR in 4 age groups 7, 21, 42 and 112 days.  Since 
both the liver and the intestinal samples were compared to the same standard curves 
although run on different plates, the magnitude of expression can still be compared. 
Unlike the liver, Cyp3a1 mRNA in intestinal mucosa (Figure 18) tended to increase with 
age and was more than 1000-fold lower than in the liver at 112 days old (significantly 
different P=0.0001). 
Cyp3a2 mRNA expression was detectable in all of the intestinal samples but was 
not quantifiable in the linear range of the quantitative-PCR reactions except for the 7 day 
age group, indicating much lower expression than in the liver.  Mean relative expression 
of Cyp3a2 in the liver ranged from 0.43 to 2.69 for the age groups.  In the intestine the 
highest expression was in the 7-day age group and the average was 0.0002.   
Mdr1a mRNA (Figure 19) increased with age.  The expression at 7, 21 and 42 
days were significantly lower than the expression at 112 days.  At 112 days, the intestinal 
mucosa mRNA relative levels for Mdr1a were more than 150 fold higher than in the 
liver.   
Relative Mdr1b expression (Figure 20) in the intestinal mucosa was comparable 
to the liver except for the 42 day old age group.  The 42 day age group Mdr1b intestinal 
expression seemed lower than the other age groups but was not significantly different 
from the 112 day age group when all the age groups where compared using one-way 
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ANOVA.  In contrast, the expression of hepatic Mdr1b in the 42 day age group was 
significantly higher than the rest of the age groups. 
 
 
Figure 17: Relative mRNA expression of villin in male Sprague-Dawley rat 
intestinal mucosa.  Normalization was done to total RNA used in the reverse transcription 
reaction and starting quantities are relative to a male rat intestinal mucosa standard curve 
dilutions from 0 to 10-4 run on the same plate as the samples.  Starting quantities are 
expressed as mean ± standard deviation of 3 animals for 21 and 112 day age groups and 
of 4 animals for the 7 and 42 day age groups. 
0 20 40 60 80 100 120
0
2
4
6
8
10
12
Age (days)
 V
ill
in
 R
el
at
iv
e 
R
N
A
Q
ua
nt
ity
N
or
m
al
iz
ed
 to
 T
ot
al
R
N
A
 
 
 
 
 
 
 
 
 
 
 
74 
 
Figure 18: Relative mRNA expression of Cyp3a1 in male Sprague-Dawley rat 
intestinal mucosa.  Normalization was done to total RNA used in the reverse transcription 
reaction and starting quantities are relative to a male rat liver standard curve dilutions 
from 0 to 10-4 run on the same plate as the samples.  Starting quantities are expressed as 
mean ± standard deviation of 3 animals except for the 42 day age group where n=4. 
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Figure 19: Relative mRNA expression of Mdr1a in male Sprague-Dawley rat 
intestinal mucosa.  Normalization was done to total RNA used in the reverse transcription 
reaction and starting quantities are relative to a male rat brain standard curve dilutions 
from 0 to 10-4 run on the same plate as the samples.  Starting quantities are expressed as 
mean ± standard deviation of 3 animals for 21 and 112 day age groups and of 4 animals 
for the 7 and 42 day age groups. (** P<0.01, * P<0.05 when compared to 112 day group, 
one-way ANOVA followed by Dunnett’s test) 
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Figure 20:  Relative mRNA expression of Mdr1b in male Sprague-Dawley rat 
intestinal mucosa.  Normalization was done to total RNA used in the reverse transcription 
reaction and starting quantities are relative to a male rat liver standard curve dilutions 
from 0 to 10-4 run on the same plate as the samples.  Starting quantities are expressed as 
mean ± standard deviation of 3 animals for 21 and 112 day age groups and of 4 animals 
for the 7 and 42 day age groups. 
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2.4 Expression of Cyp3a protein: 
 
2.4.1 Antibody specificity: 
 
The specificity of the antibodies purchased from Research Diagnostics, BD 
Gentest (Daiichi manufactured) and Chemicon was tested against rat Cyp3a1 and Cyp3a2 
Supersomes.  As shown in Figure 21, anti-rat Cyp3a1 from both Research Diagnostics 
and Chemicon were shown to be non specific, although the interaction with Cyp3a2 
protein seems to be weaker with Chemicon’s antibody.  Daiichi anti-rat Cyp3a2 was non 
specific as well.  Anti-rat Cyp3a2 from Chemicon was specific, bands were only detected 
for Cyp3a2 protein and none for Cyp3a1 protein.  To further confirm the Chemicon 
antibody specificity, Cyp3a1 and Cyp3a2 Supersomes mixtures were prepared where one 
of the proteins was constant in amount and the other was varied.  The interaction of the 
mixtures with each antibody was plotted against the net intensity of the bands.  Figure 22-
A shows that when the Chemicon anti-Cyp3a2 antibody was used, the net intensity of the 
bands increased when Cyp3a1 protein was constant and Cyp3a2 protein increased.  The 
net intensity was constant when Cyp3a2 protein was constant and Cyp3a1 protein varied 
in the mixture.  These data further confirm the specificity of anti-Cyp3a2 for Cyp3a2 
protein.  For the Cyp3a1 antibody (Figure 22-B), the net intensity increased when either 
of the proteins was increased and the other kept constant showing the lack of specificity 
of this antibody.  Due to the cross-reaction of the anti-Cyp3a1 antibody, Cyp3a1 protein 
ontogeny could not directly be addressed. 
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Figure 21:  Characterization of cross-reactivity of Cyp3a antibody.  Rat anti-
Cyp3a1 from Research Diagnostics and anti-Cyp3a2 from Daiichi and anti-Cyp3a1 and 
anti-Cyp3a2 from Chemicon were used to probe equal protein amounts (~1.16ng) of rat 
Cyp3a1 and Cyp3a2 Supersomes. 
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Cyp3a2 Varying Amounts with Constant 0.58 ng Cyp3a1 Amount. 
Cyp3a1 Varying Amounts with Constant 0.58 ng Cyp3a2 Amount. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 22: Interaction of Cyp3a1 and Cyp3a2 Supersomes mixtures with 
anti-rat Cyp3a2 (A) and anti-rat Cyp3a1 (B) antibodies from Chemicon. 
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2.4.2 Cyp3a2 Expression in the Liver: 
 
Western blotting for liver microsomal protein using a specific anti-rat Cyp3a2 
antibody was used for the determination of the ontogenic pattern of Cyp3a2 in the 
developing rat liver.  Age groups used were 1, 7, 21, 42, 77 and 112 days, 4 animals per 
group except for the 1 day group which had 3 animals.  Cyp3a2 protein content was 
normalized to the total amount of microsomes loaded and determined from a Cyp3a2 
Supersomes™ standard curve.  The results are plotted against age (Figure 23).  The 
amounts and standard curves were calculated based on duplicate loading of samples and 
standards except for the 42 day age group, which was determined based on only a set of 
loading.  At 21 days of age, the Cyp3a2 content was the lowest observed among the age 
groups under test and was significantly lower than in the 112 day age group.  Cyp3a2 
mRNA expression was also the lower at 21 days of age (Figure 14).  The expression at 
77 days of age was significantly higher than at 112 days.  Since anti-Cyp3a1 antibody 
was not specific, data from liver microsomal blots probed with anti-Cyp3a1 cannot 
provide useful information on Cyp3a1 ontogeny in male rat liver. 
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Figure 23: Cyp3a2 protein expression in male Sprague-Dawley rat liver 
microsomes (mean of 4 animals ± standard deviation).  Each animal sample was loaded 
in duplicate.  For the 42 day old sample, only one set of the duplicate loading was used 
for concentration calculation. (* P<0.05 when compared to 112 day group, one-way 
ANOVA followed by Dunnett’s test) 
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2.4.3 Cyp3a2 And Cyp3a1 Expression in the Intestine: 
 
Intestinal mucosa microsomal Cyp3a2 expression had much lower intensity than 
liver microsome Cyp3a2, despite the increased protein loading for intestine (10 µg) 
compared to liver (5 µg) (Figure 24).  Probing with the primary antibody anti-rat Cyp3a1 
from Chemicon, for age groups 7, 21 and 42 days, produced stronger bands than Cyp3a2. 
Although the antibody is non-specific, the lack of an adequate Cyp3a2 response in 7 day 
old rats indicates the presence of only Cyp3a1 protein.  Representative blots for 7 and 42 
days group are shown in Figure 25. 
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Figure 24: Cyp3a2 western blotting of liver and intestinal mucosa microsomes 
using Chemicon anti-Cyp3a2, N=4, each animal sample was loaded in duplicate.  The 
numbers above each band represents an animal microsome sample. 
 
 
 
 
 
  
 
 
 
 
 
 
112 day Intestine (10µg loading) 
 
112 day Liver (5µg loading) 
42 day Intestine (10µg loading) 
42 day Liver (5µg loading) 
 
 21 day Intestine (10µg loading) 
 
 21 day Liver (5µg loading) 
7 day Liver (5µg loading) 
  7 day Intestine (10µg loading) 
   1    2   3     4     1     2    3     4 
7 day intestine (10µg loading) 
42 day intestine (10µg loading) 
 1     2     3      4 
Figure 25: Cyp3a1 western blotting of male rat intestinal mucosa microsomes.  The 
numbers above each band represents an animal microsomal protein sample. 
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2.5 Developmental Activity of Cyp3a  
 
2.5.1 Developmental Activity of Cyp3a in Male Rat Liver: 
 
The in vitro activity of Cyp3a across developmental ages was determined by the 
4-hydroxylation of midazolam in male rat liver microsomes, 4-hydroxymidazolam being 
the major midazolam Cyp3a metabolite in male rat livers.  4-Hydroxymidazolam was 
measured in the reaction mixture using HPLC.  The 1-hydroxymidazolam metabolite did 
not interfere with the 4-hydroxymidazolam peak (Figure 26).  A representative standard 
curve is shown in Figure 27.  Time and protein linearity studies showed the reactions to 
be linear over a time frame of 1-10 minutes and protein amount of 15-75 µg per 200 µL 
reaction (Figure 28).  The reactions were carried out for 5 minutes using 50 µg 
microsomal protein and 60 µM midazolam as determined from preliminary studies.  The 
midazolam concentration of 60 µM was based on plotting the reaction velocity (V) 
against substrate concentration (0-500 µM).  The velocity starts to decrease at midazolam 
concentrations greater than 60 µM due to auto-inhibition which has been documented in 
the literature (Houston and Kenworthy 2000).  Vmax normalized to time and microsomal 
protein was initially low and came to a minimum at 21 days (weaning) and then increased 
to reach adult levels by day 77 (Figure 29).  The activity was significantly lower in all 
the age groups compared to 112 day old group except for 77 days. When Vmax was 
normalized to Cyp3a2 protein amount obtained from the western blot, Vmax was 
constant with age except for the 21 day age group which was significantly higher (Figure 
30).   
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Figure 26: HPLC chromatograms of 4-hydroxymidazolam (A) and                     
1- hydroxymidazolam (B).  Retention times 6.9 and 8.2 minutes respectively. 
1         2        3        4        5         6        7        8         9  
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Figure 27: HPLC standard curve of 4-hydroxymidazolam.  Five standards were 
determined in triplicate. 
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Figure 28: Linearity with time and protein amount of the 4-hydroxylation of 
midazolam by male rat liver microsomes.  Time linearity (A) was done at constant protein 
amount.  Protein linearity (B) was done for 5 minutes of incubation at midazolam 
concentration of 120 µM. 
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Figure 29: Vmax ontogeny for the 4-hydroxylation of midazolam in male rat 
liver.  Midazolam (60µM), 50µg  microsomal protein and 5 minutes incubation.  
(n=4, ** P<0.01, * P<0.05 when compared to 112 day group, one-way ANOVA followed 
by Dunnett’s test). 
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Figure 30: Vmax ontogeny for the 4-hydroxylation of midazolam in male rat 
liver normalized to Cyp3a2 protein.  Midazolam (60µM), 50µg microsomal protein and 5 
minutes incubation. (n=4, * P<0.05 when compared to 112 day group, one-way ANOVA 
followed by Dunnett’s test). 
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2.5.2 Developmental Activity of Cyp3a in Male Rat Intestine: 
 
 The reaction was determined to be linear within 5-15 minutes and 50-400 µg 
microsomal protein at 60 µM.  Midazolam 4-hydroxylation in intestinal mucosa 
microsomes was minimal under the current experimental conditions (200 µg protein, 10 
minutes and 60 µM midazolam).  Activity in the intestine was only noticed in several 
animals in the 42 and 112 day age groups and was only in the range of 30 pmol/min/mg 
protein (more than 80 fold lower than the liver) and none was seen in the 7 and 21 day 
age groups.  These results are consistent with the Cyp3a RNA and protein expression in 
the intestinal mucosa compared to the liver.  Hence, midazolam metabolism in the 
intestine by Cyp3a was considered negligible for modeling purposes. 
 
2.5.3 Km Vmax Development in Rat Liver: 
 
Km and Vmax for the 4-hydroxylation of midazolam in the pooled rat liver 
microsomes were modeled using Michaelis-Menten kinetics in GraphPad Prism.  The 
assay was performed at midazolam concentrations of 0-500 µM (Figure 31).  When the 
reaction velocity (V) is plotted against substrate concentration, the velocity starts to 
decrease at midazolam concentration greater than 60 µM due to auto-inhibition, which 
has been documented previously in the literature (Houston and Kenworthy 2000).  
Therefore, modeling was restricted to the range of 0-60 µM (Table 4, Figure 32).  Table 4 
lists fitted parameters of Michaelis-Menten kinetics.  The average and standard error are 
generated from the 95% confidence interval of fitting curves in Figure 32.  To determine 
whether Km’s significantly varied with age, the modeled Km values were statistically 
tested with Kruskal-Wallis test and the differences were not significantly different (P 
value = 0.4060).  Thus, the model assumption that Km does not vary with age appears to 
be valid.  To further confirm that Km does not change with age, the data was fit to the 
Michaelis-Menten kinetics using WinNonlin v.4.1 (Pharsight Corporation, Bedford, MA) 
twice.  One fit was done assuming different Km values and the other assuming a single 
Km value for all the age groups.  The resultant Vmax values from both fits are plotted in 
Figure 33. 
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Figure 31: Midazolam 4-hydroxylation by pooled male rat liver microsomes 
(pooled from 4 animals for each age group).  Midazolam Concentrations 0-500 µM.   
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Figure 32: Michaelis-Menten fit of midazolam 4-hydroxylation by pooled male 
rat liver microsomes.  Midazolam concentrations 0-60 µM. 
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Age Vmax ± SE Km ± SE
(days) (pmol/min/mg) (µM)
1 1910 ± 86 1.95 ± 0.41
7 1590 ± 34 9.36 ± 0.56
21 810 ± 45 6.00 ± 1.00
42 1450 ± 62 3.55 ± 0.58
77 2460 ± 80 2.34 ± 0.33
112 2970 ± 93 1.82 ± 0.28  
 
 
 
Figure 33:  Michaelis-Menten fit of Vmax of midazolam 4-hydroxylation by 
pooled male rat liver microsomes (mean ± standard deviation) using WinNonlin 
assuming different or same Km values.  Midazolam concentrations 0-60 µM.            
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Table 4: Michaelis-Menten fit parameters of midazolam 4-hydroxylation by 
pooled male rat liver microsomes (mean ± standard error) using GraphPad Prism. 
Midazolam concentrations 0-60 µM. 
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2.6 In Vivo Clearance Determination: 
 
 Oral midazolam (20 mg/kg) was administered to 7, 21 and 112 day rats and 
serum samples were collected by destructive sampling to be able to calculate in vivo 
clearance for the different age groups.  Serum samples were analyzed for midazolam 
using LC/MS/MS.  Standard curves of different ranges were needed to accommodate the 
concentration ranges in the different age groups.  A representative chromatogram and 
standard curve are shown in Figure 34.  The pharmacokinetic profiles are shown in 
Figure 35.  The model independent parameters were obtained by non-compartmental 
analysis in WinNonlin v 4.1 (Table 5).  Maximum concentration (Cmax) and area under 
the concentration-time curve (AUC) appeared to increase with age.  To characterize 
clearance more accurately the data was analyzed using NONMEM (University of 
California, San Francisco) by fitting to a one compartmental, first order absorption 
model.  Since destructive sampling was used the data is comprised of one observation per 
subject (rat), hence it would be more appropriate to employ population kinetics approach 
to analyze the data.  NONMEM employs nonlinear mixed effects method for population 
kinetics.  It adds the advantage of estimating interindividual variability.  The average oral 
clearance values obtained by NONMEM for 7, 21 and 112 day old rats are 3.7, 5.2 and 
64 L/hr/kg respectively (Table 6).  
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Figure 34: LC/MS/MS analysis of midazolam in rat serum using flurazepam as 
internal standard.  A-Representative standard curve.  B-Midazolam chromatogram.  C-
Flurazepam chromatogram. 
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Figure 35: Pharmacokinetic profiles of oral midazolam (20mg/kg) in male rats 
ages 7, 21 and 112 days (Four animals per time point, destructive sampling). 
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Table 5: WinNonlin non-compartmental estimates of model independent 
pharmacokinetic parameters of ora lmidazolam (20 mg/kg) in male rats. 
 
Age T1/2 Tmax Cmax AUC (0-∞) 
(days) (hr) (hr) (ng/mL) (hr*ng/mL) 
7 1.75 0.72 7244 7554 
21 0.65 1.57 2889 5377 
112 1.12 0.33 722 429 
 
 
 
 
Table 6: NONMEM calculated pharmacokinetic parameters (mean± SD) 
Age Cl/F V/F 
(days) L/hr/Kg L/Kg 
7 3.71±1.06 3.46±1.64 
21 5.2±1.66 4.31±0.69 
112 64±15 67±22 
 
 
2.6.1 Protein Binding: 
 
Protein binding of midazolam in serum was measured using an ultrafiltration 
method.  The unbound fractions of midazolam in rat serum for 7, 21 and 112 days are 
0.08, 0.05 and 0.09 respectively. 
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2.7 Model Prediction: 
 
To test the model assumption that microsomal protein does not vary with age, 
microsomal protein per gram liver was calculated and compared by one-way ANOVA to 
the adult (112-day) group.  All age groups were significantly different from the 112-day 
age group (Figure 36).  Micosomal protein normalized to liver weight increased with age 
except for the 21 day age group (weaning) that was higher than the rest of the age groups.  
Hepatic scaling factor was calculated and results are shown in Table 7.   Infant scaling 
factor (product of relative hepatic scaling factor and ontogeny scaling factor, Equation 
35) was calculated and its coefficient of variation was calculated according to the 
following formula for ratios (Table 8):                                                                                                                                                                             
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Where CV X/Y is the coefficient of variation of the ratio, X is the numerator set 
and Y is the denominator set , SD is the standard deviation, n is the number per group, X̅ 
and Y̅ are the averages for the X and Y sets respectively. 
The scaling factors were used to calculate the predicted clearance values 
according to Model1 and Model 2 (Equations 36 and 37) as described in the methods 
section.  Model 1 predicts clearance based on enzyme activity only assuming that 
microsomal protein does not vary with age.  Model 2 is the ontogeny model equation 
where prediction is based on the infant scaling factor.  The adult clearance value used for 
prediction is the 112 day age group average clearance obtained from the in vivo study (64 
L/hr/Kg).  Predicted values are displayed in Table 9.   
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Figure 36: Developmental pattern of microsomal protein content per gram liver 
in male Sprague-Dawley rats.  Mean ± Standard Deviation. (** P<0.01, * P<0.05 when 
compared to 112 day group, one-way ANOVA followed by Dunnett’s test) 
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Table 7: Hepatic scaling factor calculated for the different age groups (mean ± 
standard deviation). 
 
Age 
(days) HSF 
1 0.24 ± 0.05 
7 0.69 ± 0.11  
21 2.16 ± 0.13 
42 1.70 ± 0.25 
77 1.47 ± 0.17 
112 0.97 ± 0.12 
 
BW
LWLiver)MP(mg/gHSF =
98 
 
Table 8: Infant Scaling factor calculated for the different age groups.  CV is the 
coefficient of variation for the ISF value as calculated from Equation 38                                                                                         
                                                                                                              Equation 38 
 
Age ISF CV
(days)
1 0.19 0.20
7 0.45 0.13
21 0.97 0.16
42 0.82 0.14
77 1.79 0.14
112 1 0.18  
 
 
Table 9: Predicted oral clearance of midazolam in male rats.  Mean (95% 
confidence interval).  Model 1 predicts clearance based on enzyme activity only 
assuming that microsomal protein does not vary with age.  Model 2 is the ontogeny 
model equation where prediction is based on the infant scaling factor.   
 
Age          Cl/F (L/hr/Kg)
days Model 1 Model 2
7 42 (32-51) 29 (23-35)
21 28 (24-32) 62 (48-76)  
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2.8 Prediction Evaluation: 
 
After examining the microsomal protein across the different age groups it is clear 
that Model 1 would not be the model of choice for clearance prediction since microsomal 
protein changes with age and needs to be accounted for.  Model 2 (the ontogeny model) 
did not predict the in vivo oral clearance.  The criterion for accepting the prediction was 
that the predicted value falls within the 50-200% range of the observed value.  For the 7 
day age group the predicted value for oral clearance is 29 L/hr/Kg while the 50-200% 
range of the observed value is 1.86 – 7.42 L/hr/Kg.  For 21 day age group the predicted 
value is 61 L/hr/Kg and the 50-200% range of the observed value is 2.6 – 10.4 L/hr/Kg. 
Using the 50-200% criterion, the model failed to predict the in vivo clearance.  Hence 
looking at the model assumptions, if Km was not truly constant then ignoring its value in 
the prediction would bias the model.  Predicted clearance values were recalculated using 
Vmax and Km in the ontogeny scaling factor (OSF) for infants and adults and the model 
predictions were 5.73 and 19.05 L/hr/Kg for the 7 and 21 day age groups respectively. 
These values are more predictive of the observed oral clearance than when predicted by 
the other 2 models.  The other possibility is that FG  is lower in the adults (FG<<1) than in 
the pups causing both oral clearance (Cl/F) and volume of distribution (V/F) to be 
greater.   FG was assumed to be 1 in both pups and adults which might account for the 
prediction discrepancy. 
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Chapter 6. Discussion 
 
The risk resulting from infant exposure to xenobiotics has been a long debated 
issue.  Most of the drugs on the market have no indications for infant use and the 
consequences of their use in infants are largely unknown.  Exposure to drugs or 
environmental chemicals through breast milk is well documented in the literature.  Due to 
the lack of a standardized approach in assessing infant risk, the risk (to the infant) versus 
benefit (for the mother) ratio is sought before deciding to dose a mother with a drug while 
breastfeeding.  Since in most of the cases, the actual dose reaching the infant and the 
infant’s ability to clear such doses is unknown, short term and long term adverse effects 
in the infant are difficult to predict.  Rigorous clinical trials of drug exposure in neonates 
or in breastfeeding mother-infant pairs have many ethical and logistical drawbacks and 
hence are very rarely done.  Most of the information in the literature is derived from case 
report studies or is a compilation of retrospective data from existing cases under 
treatment.  Hence there is no control over experimental variables or circumstances 
occurring during treatment that might influence the outcomes, adding variability to the 
data, thereby hindering scientists and clinicians from reliable conclusions.  Alternatives 
have thus been sought to try to answer some of the questions about risk assessment of 
infant exposure to drugs in the neonate.  
First, the parameters influencing infant exposure are determined through indices 
designed to identify the critical factors influencing the underlying processes (Equation 3): 
 
 
 
An exposure index  assumes that the drug-target interaction and toxicity in the neonate 
are related to serum concentration and are similar to the adult (Ito and Koren 1994). 
Infant serum concentration is dependent on dose ingested in the milk, bioavailability and 
infant clearance.  The infant dose is in turn dependent on the amount of milk ingested and 
milk concentration of a drug.  The milk concentration is a result of maternal serum 
concentration and drug distributional properties that make up the maternal milk to serum 
Equation 39 
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ratio (M/S).  Maternal serum concentration is a variable that might be readily determined 
in a controlled setting.  
The milk to serum ratio is most accurate if determined experimentally under 
steady-state conditions, which are rarely performed.  As a result, several approaches have 
been proposed in the literature over the years to predict the M/S ratio (Rasmussen 1958; 
Rasmussen 1959; Meskin and Lien 1985; Fleishaker, Desai et al. 1987; Atkinson and 
Begg 1990; Agatonovic-Kustrin, Ling et al. 2002).  Out of these approaches, two have 
been chosen to be further evaluated in the current work.  Both of these approaches 
assume passive diffusion into milk based on physiochemical properties of the drug.   
The Atkinson and Begg approach has a distinct advantage of being empirical; no 
additional experimental work is required to make M/S predictions.  The approach stems 
from existing literature data.  If the model can predict observed M/S ratio in humans then 
it would be of a great value when observed values are not available. 
 The Fleishaker model provides a fundamental baseline model (passive diffusion) 
which might be able to identify those drugs undergoing active transport into milk by 
comparing the value predicted by the model to observed M/S in vivo.  The basis for 
choosing the Fleishaker model (Fleishaker, Desai et al. 1987) is that it is derived from 
first principles and considers all the relevant physiochemical properties of the drug from 
a mechanistic approach.  Moreover, it can explain interindividual variability in serum and 
milk protein binding and milk composition.  The disadvantage of this approach is the 
cumbersome nature of the in vitro experiments needed and the logistics of obtaining 
human samples in order to perform the work.  
Another critical component of the exposure index is the infant clearance of a drug. 
For the vast majority of drugs, this systemic clearance for infants is largely unknown. 
Most of the data in the in vivo literature that has been reported is from sick infants under 
therapy, and frequently the details of their conditions are unknown or not reported.   To 
provide a more mechanistic perspective, some in vitro studies have examined enzyme 
activity (both phase I and II) in livers from children of various ages (Pacifici, Bencini et 
al. 1986; Pacifici, Franchi et al. 1988; Pacifici, Franchi et al. 1988; Cappiello, Giuliani et 
al. 1991; Treluyer, Jacqz-Aigrain et al. 1991; Pacifici, Kubrich et al. 1993; Barker, Hume 
et al. 1994; Gilissen, Hume et al. 1994; Cresteil 1998; Sonnier and Cresteil 1998; de 
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Wildt, Kearns et al. 1999; de Wildt, Kearns et al. 1999).  However, even these in vitro 
experiments involved livers from infants where the exact circumstances of sample 
retrieval and storage are not very well documented (Stevens, Hines et al. 2003).  In most 
of the cases this in vitro data is not directly extrapolated to in vivo clearance concepts.  
An ontogeny model (Alcorn and McNamara 2002d) was proposed from our laboratory 
whereby the in vitro data could be extrapolated to in vivo data through the use of scaling 
factors and adult clearance values.  Such a model, if validated, would prove to be very 
beneficial for the approximation of initial estimates of clearance in neonates.  To 
extensively evaluate the model assumptions in infants presents tremendous logistical and 
ethical issues associated with human experimentation that is dramatically complicated 
when considering these vulnerable age groups.  Therefore, we examined the in vitro – in 
vivo model in rats.  Clearly, rats are not humans; however, they are extensively used in 
preclinical studies for evaluation of metabolic pathways, toxicity and drug interactions 
due to many shared similarities.   Moreover, the use of the rat will allow for a more 
detailed evaluation of the assumptions in the clearance ontogeny model.  In addition to 
examining the basic model assumptions, the ontogeny of RNA, protein and function was 
followed for a major drug metabolizing enzyme (Cyp3a). 
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1 In Vitro M/S Ratio 
 
1.1 Atkinson and Begg Model 
 
An empirical model that accurately predicts M/S ratios for passively diffusing 
drugs based on physiochemical properties without need for experimental data would be 
of great benefit.  Atkinson and Begg’s model (Begg, Atkinson et al. 1992; Begg and 
Atkinson 1993) was evaluated for this purpose.  For our analysis, drugs were selected that 
have not been incorporated into the orginal model building or evaluation.  The drugs had 
reported observed M/S ratios and the other parameters were either from the literature or 
predicted by ACD labs software.  The model did not accurately predict the observed 
milk-to-serum ratios (Figures 1 and  2).  One explanation for the discrepancy in the 
observed and predicted is the assumption of passive diffusion as the dominant mechanism 
of drug transfer into and out of the milk.   Two of the drugs (acyclovir M/Sobs =3.0 and 
ciprofloxacin M/Sobs =1.7) indeed have an active transport component as described earlier 
for the Fleishaker model.   The M/Spred for oxazepam was much greater (M/Spred =1.2) 
than the observed (M/Sobs =0.1).  For the basic drugs, two of the drugs (Figure 2) 
(acebutolol M/Sobs =5.7 and ranitidine M/Sobs =3.8) may have an active transport 
component in their transfer mechanism.  However, the M/Spred (2.5) for nicotine was 
similar to M/Sobs (2.9), although nicotine might have an active transport component to its 
transfer into milk.  A review of the model in the literature (Larsen, Ito et al. 2003) found 
no correlation between the values of milk-to serum ratios of a number of drugs predicted 
by Atkinson and Begg’s model and those observed in lactating women.  This review 
lumps together acidic and basic drugs as well as drugs known to be transported by active 
transport.  When we reanalyzed the data, the r2 for acidic drugs improved from 0.01 to 
0.7 when acyclovir and ciprofloxacin, both known to be actively transported into milk, 
were removed from the correlation.  In addition, the calculated M/S ratios in this review 
were more than twice M/Sobs for many of the basic drugs (citalopram, flecainide, 
fentanyl, fluoxetine, labetalol, loaratadine, hydroxychloroquine, metoclopramide, 
paroxetine, propranolol, diltiazem, chloroquine, venlafaxine and verapamil.).  When these 
drugs were removed from the correlation along with cimetidine (known to be actively 
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transported) and quazepam, both of which had M/S observed twice or more M/S 
predicted, the r2 improved from 0.0058 to 0.59.  The review was criticized for using logP 
instead of apparent logP at pH 7.2 and for incorporating drugs used to build the model 
(Doogue, Gardiner et al. 2004; Ilett and Hackett 2004).  However, the authors noted that 
even when using the apparent log P, predictions were not improved.  In the evaluation 
presented here, the correlation for acidic drugs was worse than for basic drugs where the 
M/S predicted values where actually higher in many cases than the observed values, 
making the model unsuitable for predicting M/S ratios when no in vivo data exists.  One 
reason for the poor correlation is the active transport of some of the drugs, thus violating 
the basic assumption of the model that drugs appear in milk via passive diffusion.   
Another reason is the variability of the physicochemical parameters reported in the 
literature (logP, log D, serum protein binding) and used for M/S ratio predictions.  
Outliers might also exist for the relationship proposed to predict milk protein binding 
further complicating the prediction.  Since building the model also involved values of 
physiochemical parameters from the literature for a relatively limited number of drugs, 
the regression relationship used for prediction might be biased by these values.  It seems 
that a more vigorous evaluation of the regression relationship is required as well as the 
model suggested for millk protein binding using a larger set of drugs provided that proper 
M/Sobs data in the literature is available. 
 
1.2 Fleishaker Model 
 
Breastmilk is an important source of infant nutrition and inadvertently a route of 
xenobiotic exposure for neonates.  The M/S ratio and its determinants play a major role in 
determining the extent of this exposure.  The ability to determine the factors governing 
this ratio will improve the predictability of infant exposure.  The Atkinson and Begg 
empirical model could not predict observed M/S ratios; hence a mechanistic approach is 
needed.  The model studied here is the Fleishaker model which predicts M/S ratios based 
on the physiochemical properties of the drug obtained by in vitro experiments (unbound 
fractions in serum and milk and skim to whole milk ratio), or calculated (fraction 
unionized).  The drugs selected for this model investigation have relatively high 
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observed M/S (M/Sobs) ratios as reported in the literature.  If the passage of these drugs 
into milk is dictated by passive diffusion pathways, then those high M/S ratios would be 
explained in terms of their physicochemical properties.  These include extensive 
partitioning into fat milk for lipophilic drugs (S/W ratio<1), by ion trapping in case of 
basic drugs (fun,s/fun,m >1) assuming that only the unionized drug can diffuse through the 
mammary epithelial tissue and into milk or by greater binding to milk proteins than to 
serum proteins (fs/fm>1).   Previously, our laboratory (Alcorn and McNamara 2002) has 
used a subjective cutoff  which considered active transport to be playing a significant role 
for those drugs for whom the observed M/S was twofold larger than the values predicted 
by the diffusion model.  Thus the 95% confidence interval of the 50% and 200% values 
of the predicted M/S was calculated (Alcorn and McNamara 2002) to account for active 
transport as well as any variability associated with the observed M/S ratios, especially 
when observed in a single case study.  If the observed value or its 95% confidence 
interval fall within that range or significantly overlap with it, then passive diffusion can 
be considered the major pathway for transport of drug into milk.  Otherwise, active 
transport can be assumed to play the key role i.e. at least 50% of passage into milk. 
Active transport of drugs into milk has been previously described in the literature 
(Lau, Emery et al. 1987; McNamara, Burgio et al. 1992b; Schadewinkel-Scherkl, 
Rasmussen et al. 1993; Oo, Kuhn et al. 1995; McNamara, Meece et al. 1996b; Gerk, 
Kuhn et al. 2001; Gerk, Oo et al. 2001; Oo, Paxton et al. 2001; Alcorn and McNamara 
2002; Edwards, Rudy et al. 2003).   An important role of Breast Cancer Resistance 
Protein (BCRP/ABCG2) in active transport of drugs into milk has been established 
(Jonker, Merino et al. 2005; Merino, Jonker et al. 2005; Merino, Alvarez et al. 2006; van 
Herwaarden, Wagenaar et al. 2007) for most of the drugs that were previously described 
to have an active transport component such as nitrofurantoin, cimetidine and acyclovir.  
BCRP is a member of the ATP Binding Cassette (ABC) family of transporters.  Active 
transport is achieved by the energy obtained by ATP (adenosine tri-phosphate) 
hydrolysis.  In addition to tumor cells, BCRP is present on the apical membrane in 
normal human tissues, in the liver, intestine, placenta, mammary glands and brain 
(Maliepaard, Scheffer et al. 2001; Cooray, Blackmore et al. 2002).  
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Citalopram M/S ratio was consistent with simple diffusion.  The predicted M/S 
ratio was 1.8 (Figure 4) and the observed values were 1.8, 1.52 and 3.00 (Jensen, Olesen 
et al. 1997; Spigset, Carieborg et al. 1997; Rampono, Kristensen et al. 2000; Schmidt, 
Olesen et al. 2000).  As a base and lipophilic drug, the M/S ratio is readily explained by 
partitioning into milk lipids and ion trapping.  The high variability observed in the 
predicted milk to serum ratio can be partially attributed to variability in milk fats as 
measured by the crematocrit values (Figure 3).  No evidence of active transport of 
citalopram is found in the literature. 
Ciprofloxacin predicted value (0.85) was about half that observed (1.6) 
(Giamarellou, Kolokythas et al. 1989)(Figure 5).  This would suggest a contribution of 
active transport to the drug appearance into milk. However, applying a more stringent 
criterion of the confidence interval of 50-200% of the observed value to account for any 
experimental variability in vitro or interindividual variability in vivo, the predicted M/S 
ratio is with in that range.  There is evidence in the literature of active transport 
mechanisms for ciprofloxacin both in vitro and in vivo (Griffiths, Hirst et al. 1993; 
Griffiths, Hirst et al. 1994; Merino, Alvarez et al. 2006).  Active transport of 
ciprofloxacin into milk was demonstrated in BCRP (BCRP-/-) knockout mice, where the 
M/S value was twice that in wild type mice when compared to knockout mice.  This 
would suggest that the 50-200% criterion is perhaps too stringent to predict active 
transport.  The ratio of the M/S in the wild type versus knockout mice was similar to the 
ratio between the value predicted by the Fleishaker model and the observed in vivo value. 
The observed nicotine M/S value in humans was outside the 50-200% range, with 
the 95% confidence intervals overlapping suggesting a role for active transport (Figure 
6).  Nicotine has been shown to accumulate in vitro in isolated rabbit choroid plexus by 
both an active saturable process and an unsaturable process (Spector and Goldberg 1982) 
and by a transport system in LLC-PK1 cells (Takami, Saito et al. 1998).  Nicotine has 
been also shown to interfere with the renal organic cation transport of amantadine in 
isolated male rat kidney tubules (Wong, Smyth et al. 1992).  However, no specific 
transporter has been identified yet for its active transport into milk or in other tissues. 
Acyclovir has an observed M/S ratio that is two to three-fold the predicted one 
(Figure 7).  This agrees with previous data from this lab investigating acyclovir 
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distribution in rat milk (Alcorn and McNamara 2002), suggesting a significant role of 
active transport processes for the appearance of acyclovir in human milk.  There is a 
report that rat multispecific organic anion transporter 1 (rOAT1) can transport acyclovir, 
and other antiviral nucleoside analogs (Wada, Tsuda et al. 2000), however, OAT1 does 
not appear to be expressed in human lactating mammary cells (Alcorn, Lu et al. 2002).  
In a recent study (Jonker, Merino et al. 2005), breast cancer resistance protein knock-out 
mice (BCRP-/-) were shown to have a significantly lower acyclovir M/S ratio when 
compared to wild type mice.  In the same study (Jonker, Merino et al. 2005) lactating 
human mammary epithelial cells were shown to express BCRP protein, indicating that 
acyclovir transport mechanism into human milk is most probably mediated by BCRP as 
in mice. 
Ascorbic acid in vitro data predict an M/S ratio which is tenfold less than the 
observed value (Figure 8).  As an acid, its accumulation in milk cannot be explained by 
ion-trapping.  Moreover, there was insignificant binding in both serum and milk and 
almost no partitioning into milk fat was observed, making it hard to explain its 
accumulation in milk by passive diffusion.  It has been shown that ascorbic acid is 
actively transported into human neutrophils and fibroblasts by means of a carrier and in a 
sodium-dependent fashion (Welch, Wang et al. 1995).  A human Na(+)-dependent 
vitamin C transporter 1 (SVCT1/SLC23A1) has been cloned and is specific for ascorbate 
with a Kt of approximately 75 microM (Wang, Dutta et al. 1999).   SVCT1 is expressed 
apically in human cells (Subramanian, Marchant et al. 2004).  SVCT1 was found to be 
expressed in human lactating mammary epithelial cells (Alcorn, Lu et al. 2002a). 
SVCT2/SLC23A2 and SVCT3/SLC23A3 are also human ascorbic acid transporters 
(Daruwala, Song et al. 1999; Strausberg, Feingold et al. 2002).  There is evidence from 
our lab that SVCT2/SLC23A2 mRNA is expressed in a purified population of human 
lactating mammary epithelial cells (unpublished data). 
Our results confirm that the model is valuable as an initial step in understanding 
mechanisms of drug transfer into milk in combination with animal models.   When the 
M/Sobs is at least twice the M/Spred, active transport is judged to play an important role in 
drug transfer. The rat, as an animal model, has proved to provide insight into transfer 
mechanisms into milk.  To date, drugs actively transported into milk seem to share 
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common mechanisms of transport in rats and humans.  Knockout mice are another 
valuable tool to prove the involvement of a certain transporter in drug transfer into milk. 
Further investigations are needed to identify the carriers of transport across mammary 
epithelial cells and to characterize the properties of these carriers in vitro and in vivo.  
Differences between animal models used and humans in these processes need to be well 
understood.  Such knowledge might enable the addition of an active transport component 
to the model further improving the ability to predict in vivo M/S ratios. 
The list of drugs for which evidence of active transport into milk exists, is by far 
shorter than the drugs currently on the market.  Then it is assumed that most of the drugs 
appear in milk by passive diffusion.  Hence, the model can be of a great value in 
preclinical studies when the M/S is unknown and when the candidate compound is not 
known to be a substrate for transporters.  
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2 Clearance Ontogeny 
 
2.1 Rat as an Animal Model 
 
Rat is widely used as an animal model in toxicology and in preclinical studies for 
new drug entities.  As a result, drug metabolism in the rat has been extensively studied.  
Expressed enzymes and antibodies for rat cytochrome P450 are commercially available 
making it a useful animal model.  Although rat and human enzymes share similarities, 
differences do exist in enzyme isoforms, substrate specificities, major metabolites of a 
substrate, inducers and inhibitors.  These similarities and differences have been 
documented in the literature (Eberhart, Gemzik et al. 1991; Guengerich 1997; Bogaards, 
Bertrand et al. 2000; Gibson, Plant et al. 2002; Zuber, Anzenbacherova et al. 2002; 
Martignoni, Groothuis et al. 2006). 
Guengerich (Guengerich 1997) classified the  major cytochrome P450 subfamilies 
involved in drug metabolism roughly into 4 classes according to the ability to extrapolate 
across species: 
1- Subfamilies where extrapolation seems to work, as for CYP2E1. 
2- Subfamilies where extrapolation has to be interpreted carefully as for 
CYP1A1    and CYP1A2. 
3- Subfamilies where extrapolation has to be interpreted more carefully as for 
CYP3A and CYP2D. 
4- Subfamilies where problems seem to arise during extrapolation as for 
CYP2A, CYP2B and CYP2C. 
Bogaards et al (Bogaards, Bertrand et al. 2000) compared the activities of 9 
cytochrome P450 enzymes in the liver microsomes of 7 animal species with that of 
humans.  Their approach was to compare Vmax (normalized to microsomal protein), Km 
and inhibitors.  The species that was closest to humans with respect to all of the studies 
parameters was considered a suitable animal model for this cytochrome P450 in humans.   
For Cyp3a , the 6-β-hydroxylation of testosterone was utilized.  Rats and mice were 
concluded to be the closest species and the most appropriate model for human CYP3A. 
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Although this study highlights the similarities between rat and human CYP3A, it is not 
conclusive for other CYP3A activities based on other substrates that may not share these 
similarities.  Eberhart et al (Eberhart, Gemzik et al. 1991) studied species differences in 
the Cyp3A dependent metabolism of digitioxin.  There were significant qualitative and 
quantitative differences between rat and human.  Martignioni et al (Martignoni, 
Groothuis et al. 2006) reviewed differences in cytochrome P450 mediated metabolism 
between humans and four other species.  They concluded that rat is not a good model for 
human Cyp3A since it is not induced by rifampicin.  Discrepancies in Cyp3A gene 
inducibility between species was explained by the differences in the Pregnane-X- 
Receptor (PXR) ligand-binding domain.  Zuber et al (Zuber, Anzenbacherova et al. 2002) 
highlighted the differences between rat and human CYP3A inducibility by rifampicin and 
metabolism of dihydropyridine calcium channel blockers.  All the similarities between 
the inducibility of human and rat CYP3A by phenobarbitone, pregnenolone-16-α-
carbonitrile and dexamethasone as well as the shared substrates were ignored.  Gibson et 
al (Gibson, Plant et al. 2002) reviewed the differences in regulation of Cyp3a between 
species.  They demonstrate that in addition to genetic differences, differences in the host 
cell environment e.g. transcription factors available, contribute to species differences in 
response to inducers.  Although differences exist between rat and human Cyp3a and their 
nuclear factors, the nuclear factors Pregnane-X-Recpetor (PXR), Constitutive Androstane 
Receptor (CAR),  Glucocorticoid Receptor (GR) are involved in xenobiotic regulation of 
human and rat Cyp3a.  
All the studies above did not provide conclusive evidence as to the suitability of 
one animal model to human cytochrome P450 metabolism.  It is clear that despite the 
differences between human and rat Cyp3a, the rat still serves as widely used animal 
model.  In this dissertation the rat was used to test the ontogeny model assumptions for 
possible future application in humans, however, one needs to keep the differences in 
mind.   It is possible that alternative animal models for ontogeny hepatic clearance may 
more closely mimic the human.  Nonetheless the rat affords a viable approach to test the 
assumptions of the underlying in vitro – in vivo model.  
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2.2 In Vitro Ontogeny of mRNA, Protein and Activity 
 
We hypothesized that mRNA and protein levels reflect activity levels during rat 
development and that Cyp3a and P-gp mRNA ontogeny follow similar patterns.  To test 
this hypothesis mRNA, protein and activity during different male rat developmental 
changes were followed. 
 
2.2.1 mRNA Ontogeny 
 
Ontogeny of Cyp3a1, Cyp3a2, Mdr1a and Mdr1b mRNA were followed in the rat 
liver and intestine.  In our data, Cyp3a1 mRNA ontogeny in male rat liver was 
significantly high at birth and had decreased to adult levels by one week of age.  The 
expression seemed stable throughout development (Figure 13), while in male rat 
intestinal mucosa, it increased with age with no statistical significance between the age 
groups (Figure 18).  Cyp3a1 ontogeny has been studied earlier.  Simmons and Kasper 
(Simmons and Kasper 1989) showed dramatic increase of Cyp3a1 mRNA after birth in 
the male rat liver that further increased slowly till 110 days of age.  However, the filter 
bound plasmid used for RNA hybridization was shown to be non-specific and the assay is 
at best semi-quantitative.  In the same study, the intestinal Cyp3a1 was found to be 8% of 
the maximal level in the liver and a developmental pattern was similar to that in the liver 
except that the surge in Cyp3a1 RNA was seen 24 hours before birth.  In a different study 
(Omiecinski, Hassett et al. 1990), hepatic Cyp3a1 mRNA was found as early as fetal day 
15 and increased at fetal day 22.  Levels from 3 weeks up to 46 days postpartum were 
similar.  The method used was autoradiography of  32P-labeled probe for southern 
blotting of PCR products, which is semi-quantitative,  and the sex of rats was not 
specified.  Ribeiro and Lechner (Ribeiro and Lechner 1992) showed sex- dependence of 
Cyp3a1 and Cyp3a2 mRNA expression, where Cyp3a1 and Cyp3a2 transcripts were 
absent in the female liver at 45 and 90 days of age.  Cyp3a1 mRNA expression  was found 
to be transiently high after birth up to 10 days of age but then at 25, 45 and 90 days the 
expression was low.  
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In the present study, Cyp3a2 expression seemed to increase with age (Figure 14). 
However when testing with one-way ANOVA only days one and 21 age groups were 
significantly lower than the day 112 age group.  Mahnke et al (Mahnke, Strotkamp et al. 
1997) found stable expression of Cyp3a2 transcripts in male Sprague-Dawley rats from 1 
week to 20 weeks of age.  In a second study (Ribeiro and Lechner 1992) Cyp3a2 mRNA 
expression was found to peak at 25 days in male Wistar rats.  In a third study (Rosati, 
Maniori et al. 2003) Cyp3a2 transcripts peaked at 60 days in Wistar rats.  Kawai et al 
(Kawai, Bandiera et al. 2000) showed no change in Cyp3a2 expression in male Sprague-
Dawley rats from 22 to 91 days of age.  Wright et al (Wright, Edwards et al. 1997) 
examined 21 and 84 day old rats and showed higher Cyp3a2 mRNA expression in the 21 
day old group.  Gonzalez et al (Gonzalez, Song et al. 1986) studied newborn 1, 2, 3, 4 
and 12 weeks male rats for Cyp3a2 mRNA expression, their results show increased 
expression from newborn to 1 week, slight depression at 4 weeks then a significant 
increase at 12 weeks compared to other age groups.  It is apparent that there are some 
discrepancies between the results from different studies, probably due to difference in the 
sensitivity of methods used, rat strain, and/or the age groups used to describe the 
ontogeny pattern.  The overall ontogeny pattern from our results (Figure 14) seemed to 
generally agree with the studies described above in the fact that Cyp3a2 mRNA increased 
with age and reached adult levels early in ontogeny.  Cyp3a2 mRNA expression pattern 
in the intestine could not be followed.  Cyp3a2 was detectable in all of the samples but 
not quantifiable in intestinal mucosa, indicating lower expression than the liver.  To date, 
no studies in the literature were found that followed Cyp3a2 mRNA development in the 
rat intestine.  One study was unable to detect Cyp3a2 transcripts in 63 day old male 
Wistar rat intestine (Takara, Ohnishi et al. 2003). 
Mdr1a developmental pattern in the liver showed a significantly different 
expression at 1 day of age when compared to 112 day old rats (adults) (Figure 15).  In a 
study by Rosati et al (Rosati, Maniori et al. 2003), Mdr1a expression in the liver in 
Wistar rats increased with age till 150 days and did not show the current pattern. 
Differences in methodology where densitometric analysis of PCR products was employed 
or when it was not specified whether male or female rats or both were used could be 
sources for discrepancies between results.  Mdr1a expression in the intestine showed a 
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different pattern (Figure 19).  Expression increased with age and all age groups had 
expression levels significantly different from the adult.  The adult levels were greater 
than 150 fold higher in the intestine than in the liver at 112 days.  Mdr1a has been 
previously shown to be more highly expressed in the intestine than in the liver in male 
Sprague-Dawley rats (Brady, Cherrington et al. 2002).  No ontogeny studies 
characterizing Mdr1a mRNA development in the rat intestine were found in the literature. 
Mdr1b expression in the liver showed a stable expression from birth to adulthood 
(112 days) except for the 42 day age group which was significantly higher in expression 
than the rest of the age groups (Figure 16).  The data from Rosati et al (Rosati, Maniori et 
al. 2003) showed Mdr1b expression levels peaking at 30 and 60 days and decreased at 
150 days, in agreement with our results.  In previous preliminary studies, we have also 
demonstrated that Mdr1b gene expression in male rat liver peaked at 42 days (data not 
shown).  Paradoxically, Mdr1b expression pattern was slightly different in the intestine 
and no significant difference was detected among the different age groups (Figure 20). 
There seemed to be lower expression at 42 days but this was not statistically significantly 
different from the adult.  The 42 day age group represents puberty in rats.  It is unclear 
whether hormonal changes at this stage influence Mdr1b expression in both liver and 
intestine.  Expression level in the liver and intestine was comparable. In a study by Brady 
et al (Brady, Cherrington et al. 2002) duodenal Mdr1b expression was about 3.6 higher 
than in the liver in male Sprague-Dawley rats.   
It is interesting to note that mRNA ontogeny for hepatic Cyp3a1, Cyp3a2, Mdr1a 
and Mdr1b did not follow a similar ontogeny pattern.  Due to their common substrates 
and role in drug disposition their common regulation was suggested (Westphal, 
Weinbrenner et al. 2000).  However, there is only partial overlap between substrates and 
modulators and the interplay between P-gp and Cyp3a is unpredictable except on a case 
by case basis (Kim, Wandel et al. 1999).  
PXR was shown to be involved in the induction of both Cyp3a and P-gp proteins 
(Mei, Richards et al. 2004).  Although we did not follow the protein ontogeny of P-gp, 
mRNA expression of Cyp3a1/2 and Mdr1a/b genes did not follow a similar pattern. 
Different hormones are probably responsible for gene regulation during development. 
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The role of these hormones for P-gp needs to be elucidated to explain the difference in 
ontogeny pattern when compared to Cyp3a. 
Cyp3a1 and Cyp3a2 share a 90% nucleotide homology (Gonzalez, Song et al. 
1986).  However, Cyp3a1 appears to be present in low levels throughout development 
while Cyp3a2 increases with age in male rats, indicating different regulation patterns 
throughout development.  Cyp3a2  has been shown to be regulated by growth hormone 
and testosterone levels in male rats (Ribeiro and Lechner 1992; Kawai, Bandiera et al. 
2000).  Growth hormone secretion is pulsatile in male adult rats, peaking every 3 to 4 
hours and with non-detectable troughs in-between.  In adult females, pulses are closer, 
irregular and of lower levels and there is always growth hormone detected in the 
circulation in between peaks (Thangavel, Garcia et al. 2004).  It has been implied that 
response to growth hormone is imprinted by sex hormones (Laz, Wiwi et al. 2004; 
Thangavel, Garcia et al. 2004).  Cyp3a1 was also found to be affected by growth hormone 
levels (Shimada, Nagata et al. 1989).  Cyp3a1 is induced by dexamethasone in rat liver 
while Cyp3a2 is not (Caron, Rioux et al. 2005).  Phenobarbital and pregnenolone-α-
carbonitrile induce both Cyp3a1 and Cyp3a2 (Debri, Boobis et al. 1995; Caron, Rioux et 
al. 2005; Jan, Mishin et al. 2006).  It is possible that the interplay of growth hormone and 
testosterone regulate the developmental changes in Cyp3a1 and Cyp3a2 differently 
leading to distinct expression of the genes in males and females and across different 
developmental stages. 
P-glycoprotein is known to be the product of Mdr1a and Mdr1b, but these genes 
appear to be regulated differently.   Not only do they exhibit a different developmental 
pattern in the liver but they also show a different tissue distribution pattern in adults and 
the relative distribution of Mdr1a and Mdr1b is different  (Brady, Cherrington et al. 2002; 
Mei, Richards et al. 2004).  Induction by cytochrome P-450 inducers is also different 
between the 2 gene products and within the same gene product in different tissues 
(Brady, Cherrington et al. 2002) which suggest different regulation mechanisms of the 
two genes.  Induction with dexamethasone showed concentration and tissue dependent 
responses in terms of magnitude and direction (induction/inhibition)(Mei, Richards et al. 
2004). 
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Cyp3a9, Cyp3a18 and Cyp3a62 are other Cyp3a isoforms expressed in rat liver 
and intestine (Takara, Ohnishi et al. 2003; Matsubara, Kim et al. 2004).  No commercial 
antibodies or expressed enzyme systems are available for any of them.  Substrate 
specificity is largely unknown.   Hence, ontogeny studies were not performed for these 
genes. 
 
2.2.2 Cyp3a2 Protein Ontogeny 
 
Cyp3a1 protein developmental expression was not followed due to the lack of 
commercial antibodies specific to rat Cyp3a1 as shown in the results.  Cyp3a2 protein 
expression was followed by western blotting using rat anti-Cyp3a2 from Chemicon. 
Cyp3a2 expression in male rat liver microsomes was not significantly different in most of 
the age groups compared to adults (112 days) (Figure 23).  The only 2 groups that were 
statistically significantly different were the 21 day old group which was lower and the 77 
day old group which was higher.  Visual inspection of intestinal mucosa microsomes 
western blots probed by the anti-Cyp3a2 antibody reveal increased levels with age 
(Figure 24). In a study by Wright et al (Wright, Edwards et al. 1997)  Cyp3a1 and 
Cyp3a2 expression in the liver were examined by specific antibodies (Debri, Boobis et al. 
1995) raised in rabbit, in 21, 42, 63, 84 and 105 day old groups.  The protein levels of 
Cyp3a2 were found to be depressed between 63 and 84 days in male Sprague-Dawley 
rats.  Cyp3a1 expression was stable throughout development.  Johnson et al (Johnson, 
Tanner et al. 2000) examined Cyp3a development in the liver and enterocytes in male 
Wistar rats at 1, 10, 15, 20, 25, 30, 40, 60, 80 and 365 days.  Using a polyclonal anti-
Cyp3a2 antibody, hepatic Cyp3a appeared to start high at birth, decrease until 20-40 days 
then gradually increase to reach adult levels.  These results are consistent with our data.  
It is not clear if they used an antibody that cross-reacted with Cyp3a1 as well or not.  
Intestinal Cyp3a2 protein seemed to increase at 20 days.  A study by Kawai et al (Kawai, 
Bandiera et al. 2000) showed a stable protein expression of Cyp3a2 between 22 and 91 
days of age.  Lee and Werlin (Lee and Werlin 1995) showed an increase in Cyp3a hepatic 
expression in male Sprague-Dawley rats by 20 days of age that persisted at 4 and 18 
months old.  Using a polyclonal anti-Cyp3a1 antibody Gonzalez et al (Gonzalez, Song et 
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al. 1986) could not detect Cyp3a protein atbirth , levels were elevated at 1 week of age 
and were maintained throughout development.  Due to differences in antibodies used and 
their specificities, there are some discrepancies between the ontogeny patterns of Cyp3a 
protein reported in different studies as well as ours.  An additional factor is the difference 
in age groups used.  Overall, Cyp3a2 protein starts lower at birth and increases with age 
early in development. 
 
2.2.3 Ontogeny of In Vitro Activity  
 
Midazolam was used as a probe for Cyp3a activity.  Both Cyp3a1 and Cyp3a2 
metabolize midazolam into 4-hydroxymidazolam and 1-hydroxymidazolam.  Unlike 
humans, 4-hydroxymidazolam is the major metabolite in the rat liver.  Kobayashi et al 
showed that 4-hydroxymidazolam production by Cyp3a2 is three-fold higher than by 
Cyp3a1 recombinant enzymes under similar conditions (Kobayashi, Urashima et al. 
2002).  Their study also showed that the 4-hydroxy metabolite was more specific to rat 
Cyp3a2 and Cyp3a1 compared to the 1-hydroxy metabolite, which was produced at very 
low levels by Cyp2C6, Cyp2C11 and Cyp2D2 using recombinant enzyme systems. These 
findings are consistent with other data in the literature (Kotegawa, Laurijssens et al. 
2002).  
The formation of 4-hydroxymidazolam was followed in rat liver and intestinal 
microsomes as a marker of the ontogeny of Cyp3a activity in vitro.  The Vmax (maximal 
enzyme activity) normalized to incubation time and microsomal protein was significantly 
lower in the liver microsomes of 1, 7, 21 and 42 day old male rats when compared to 
adults (112days) (Figure 29).  The 77-day old age group was not significantly different.  
The activity was also normalized to Cyp3a2 protein obtained by western blotting (Figure 
30).  It was constant for all the age groups except for the 21 day age group which was 
significantly higher.  It would be expected that activity per unit functional enzyme would 
be constant with age.  However, western blot detected total Cyp3a2 protein and not 
necessarily functional enzyme.  In the intestine, the ontogeny pattern was difficult to 
follow.  Using our current methods, 4-hydroxymidazolam formation was not detected in 
the 7 and 21-day age groups and was detected in only few animals in the 42 and 112 day 
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age groups.  Whether the assay sensitivity or the method of preparation of microsomes 
played a role in the inability to detect the metabolite is unknown.  However, these results 
are consistent with RNA and protein expression, where the intestinal mucosa was found 
to express both Cyp3a1 and Cyp3a2 at a much lower level than the liver.  To date, there 
are no specific substrates that would differentiate the activity of Cyp3a1 and Cyp3a2.  It 
is not known whether midazolam is also metabolized by rat Cyp3a9 and Cyp3a18.  There 
are no commercial sources for antibodies or recombinant enzymes that would have 
enabled us to answer this question.  The data presented here suggests that the 4-
hydroxylation of midazolam in male rat liver reflects the ontogeny pattern of Cyp3a2 and 
not Cyp3a1.  With the exception of the one day old age group, Cyp3a2 RNA and protein 
expression in the liver showed an overall pattern similar to activity (Figure 37).   It is not 
clear whether a difference in RNA regulation (e.g. half life of the transcript) or protein 
translation is responsible for the difference in the ontogeny pattern.  Since Cyp3a2 
protein and Vmax determinations are based on microsomal protein isolation and 
concentration determination, any variations in these processes or biological variation in 
the microsomal protein in the day 1 group will affect the ontogeny pattern at this point, 
which might be another explanation for this difference. 
Figure 37: Normalization of Cyp3a2 mRNA expression, Cyp3a2 protein 
expression and Cyp3a in vitro activity to the 112 day age group in male rat liver. 
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In the literature, Cyp3a activity development in the rat has been followed using 6-
β-hydroxylation of steroids (Gonzalez, Song et al. 1986; Wright, Edwards et al. 1997; 
Johnson, Tanner et al. 2000; Kawai, Bandiera et al. 2000).  The overall pattern showed an 
increase in activity with age in agreement with our results.  Although the 6-β-
hydroxylation of testosterone is specific to Cyp3a, testosterone is hydroxylated at a 
number of positions by a number of enzymes other than Cyp3a.  Cyps 2a1, 2a2, 2b2, 2c11 
and 2c13 are involved as well in testosterone metabolism in the rat liver (Arlotto, Trant et 
al. 1991).  The major metabolites of testosterone by rat Cyp3a1 and Cyp3a2 are the 2-β 
hydroxy and the 6-β-hydroxytestosterone (Arlotto, Trant et al. 1991).  In humans, 
testosterone is metabolized by Cyp3A into the 6-β-hydroxytsetosterone, 2-β-
hydroxytestosterone and 16-α-hydroxy testosterone (Rendic and Di Carlo 1997). 
Midazolam metabolism and not testosterone was used in the present study despite 
the fact that testosterone metabolsim has been traditionally used in the rat in in vitro 
ontogeny studies since testosterone metabolism is not specific to Cyp3a.  Since the in 
vitro activity data was used to extrapolate to the in vivo clearance, the same substrate was 
used in vitro and in vivo.  Only the 6-β-hydroxytestosterone metabolite needs to be 
followed to be able to characterize Cyp3a ontogeny in vitro and in vivo.  This would be 
feasible in vitro where the reaction conditions could be manipulated to produce 
quantifiable levels of the metabolite.  In vivo however, this might not be possible due to 
the limited amount of samples and due to the fact that testosterone is present 
endogenously.  The clearance of testosterone is a composite of several hepatic pathways 
rather than a single one in contrast to midazolam.  Using serum from neonatal animals 
adds the limitation of a small serum volume that would make it challenging in detecting 
and quantifying metabolites.  
In the study by Wright et al (Wright, Edwards et al. 1997), 6-β-hydroxylation of 
androstenedione was found to increase from 3 weeks of age to 6 weeks of age in male rat 
liver microsomes. The activity was maintained at 9 weeks then dropped at 12 and 15 
weeks.  The authors pointed out that this pattern was not mirrored by Cyp3a2 protein 
development in males and hence other Cyp3a forms (e.g. Cyp3a18) might be responsible 
for the activity.  Johnson et al (Johnson, Tanner et al. 2000) studied enterocytic and 
hepatic 6-hydroxylation of midazolam with age.  Hepatic microsomes showed an increase 
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in activity from birth till adulthood.  Enterocytic microsmal activity was low at birth, a 
surge was observed at weaning, then a plateau was observed up to 80 days if age and at 1 
year.  The overall intestinal activity marked by Vmax/Km was 50-fold lower than hepatic 
activity.   Gonzalez et al (Gonzalez, Song et al. 1986) presented a study that had a similar 
pattern of development.  The 6-β-hydroxylation of testosterone was absent at birth, 
increased at 1 and 2 weeks of age and continued increasing up to 12 weeks of age. Kawai 
et al (Kawai, Bandiera et al. 2000) examined the 2-β and 6- β-hydroxylation of 
testosterone in male rat liver.  The pattern was similar for both metabolites where activity 
peaked at 34 days. The mRNA pattern of Cyp3a2, Cyp3a9 and Cyp3a18 was followed in 
the same rats but the activity did not correspond to the mRNA pattern of any of the 
enzymes.  This pattern was different from our results and data presented in the literature. 
 
2.3 Ontogeny Model Assumptions 
 
2.3.1 Microsomal Protein 
 
One of the ontogeny model assumptions is that microsomal protein normalized to 
liver weight remains constant with age.  To test this assumption total microsomal protein 
was measured for each age group and normalized to liver weight (Figure 36).  Microsomal 
protein was found not to be constant with age.  It peaked at 21 days and then decreased 
afterwards.  The inconsistency of microsomal protein during development in male rat 
liver is documented in the literature.  The patterns reported were either increasing with 
age (Petermann and Hamilton 1958; Nakajima, Wang et al. 1992) or similar to the pattern 
observed in Figure 28 (Elbarbry and University of Saskatchewan. College of Graduate 
Studies and Research. 2006).  The implication of this finding is that microsomal protein 
normalized to body weight is necessary to know for calculating the infant scaling factor 
from in vitro data to be able to extrapolate adult clearance to infant clearance.   Hence, it 
would appear unwise to compare infant and adult in vitro activity measurements 
normalized to microsomal protein content alone. 
Possible explanation of the variability seen in microsomal protein is the 
variability in liver weight due to glycogen content, the variability of the microsomal 
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fraction collected by centrifugation which might include other subcellular fractions in 
addition to microsomes. 
 
2.3.2 Michaelis-Menten Affinity Constant (Km) 
 
The ontogeny model proposed a constant Km of a substrate-enzyme system 
across developmemtal stages.  To directly test this assumption, Michaelis-Menten 
profiles were constructed for the 4-hydroxylation of midazolm by male rat liver 
microsomes at different age groups (Figure 32).  Table 4 shows Km values obtained by 
fitting each profile to a one-binding site non-linear model.  Statistical analysis showed no 
significant difference between Km’s for the different age groups.  The Km’s listed are the 
apparent Km’s.  It is assumed that only the free drug is available for enzymatic 
metabolism.  Non-specific binding of midazolam to human and rat liver microsomes has 
been reported to be similar (Lu, Li et al. 2006).  At constant protein amount and assuming 
that non-specific binding does not vary with midazolam concentrations, the true Km 
would be the product of apparent Km and the free fraction of drug.  Assuming that non-
specific binding per gram microsomal protein does not vary with age, then similar to the 
apparent Km, the true Km across age groups is non-significantly different.  In contrast to 
our data, the Km CYP1A2-mediated methoxyresorufin-O-dealkylation was found to be 
significantly different at 5 and 7 days in male rat liver microsomes when compared to 
112 day animals (Elbarbry and University of Saskatchewan. College of Graduate Studies 
and Research. 2006).  The authors explained this discrepancy between age groups 
suggesting that other enzymes might be involved in the metabolism of methoxyresorufin 
at earlier stages of development and hence the Km of these age groups reflects the 
affinity to other enzymes in addition to Cyp1A2.  They also commented that non-specific 
binding might vary with age due to changes in microsomal protein content (Elbarbry and 
University of Saskatchewan. College of Graduate Studies and Research. 2006).  With 
midazolam, non-specific binding in rats and humans was similar (Lu, Li et al. 2006), 
despite microsomal protein differences that would make it less likely that non-specific 
binding varies with age in rats. 
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For the purpose of calculating the infant scaling factor from in vitro data, Km was 
considered constant with age and was not included in the calculation of the ontogeny 
scaling factor (OSF).  This Km cancels out when dividing the infant intrinsic clearance 
by adult intrinsic clearance and OSF becomes the ratio of Vmax in the infant to that in 
the adult.  If Km were different across age groups, the model would still be useful, 
however the OSF would be the ratio of intrinsic clearances in the neonate to that in the 
adult, where intrinsic clearance is the ratio of Vmax to Km. 
 
2.3.3 Other Model Assumptions 
 
In order to make the model most useful, another assumption that was not directly 
tested in this study is that the Vmax pattern would be similar from one substrate to the 
next for the same pathway.  Hence, one could measure changes in activity with a probe 
substrate in vitro and this should be indicative of in vivo activity for any other substrate.   
This assumption was tested in the literature for Cyp1a2 and Cyp2e1 in the male rat liver; 
the ontogeny of 2 substrates for each enzyme was found to correlate (Elbarbry and 
University of Saskatchewan. College of Graduate Studies and Research. 2006).  
Testosterone 6-β hydroxylation has been studied in the literature as a marker for Cyp3a 
ontogeny.  The general patterns described of an increase in activity with age was similar 
to our findings with midazolam, strongly suggesting that this model assumption holds 
true (Gonzalez, Song et al. 1986; Johnson, Tanner et al. 2000). 
Two of the model assumptions are related to the in vivo characteristics of the 
substrate under study.   First, the clearance of the drug is dictated by enzymatic 
metabolism in which uptake into the hepatocyte is not rate limiting (i.e., no uptake 
transporters involved).  Midazolam as a Cyp3a substrate fulfills this assumption in that its 
lipophilicity is such that it readily passes through cell membranes.   Hence Cyp3a 
metabolism, and not hepatic transporters, is responsible for midazolam clearance, so that 
changes in enzyme activity should be reflected in clearance.   Second, the in vitro model 
is constructed to predict intrinsic clearance, which is largely influenced by changes in 
Vmax.  Ideally, the drug would be a low extraction ratio drug and its systemic clearance 
following an intravenous dose would yield an estimate of intrinsic clearance with little or 
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no dependence on blood flow.  However midazolam has an intermediate extraction ratio 
in the rat (Uhing, Beno et al. 2004), entailing the partial dependence of midazolam 
clearance on hepatic blood flow.   As an alternative to the intravenous route of 
administration and to avoid the inclusion of hepatic blood flow estimate, oral clearance 
can be used in vivo as illustrated by Equation 30-Equation 34.   However, this requires 
that intestinal bioavailability (FG) is equal to 1.  This assumption is strengthened both by 
our in vitro data, and data from the literature (Kotegawa, Laurijssens et al. 2002; Uhing, 
Beno et al. 2004; Kanazu, Okamura et al. 2005).  Our in vitro data shows that mRNA, 
protein and in vitro activity of Cyp3a in the intestine was very much lower than in the 
liver. The in vitro activity in the intestine at 112 days was 100-fold less than that in the 
liver. 
 
2.4 Model Prediction 
 
Infant scaling factor (ISF) was calculated from in vitro data.  In vivo oral clearance 
of midazolam was measured in age groups 7 days (neonate), 21 days (weanling) and 112 
days (adult) to test the model prediction at two different developmental stages. Oral 
clearance of midazolam in 112 days (average weight 377g) was 64 L/hr/kg and similar to 
values reported in the literature.  The reported oral clearance of midazolam in male rats 
(weight 125- 350g)  in the literature ranged from 42 to 63 L/hr/kg (Kotegawa, Laurijssens 
et al. 2002; Strelevitz, Foti et al. 2006; Zhang, Tan et al. 2007).  There are currently no 
midazolam in vivo studies in the literature in male rats as young as 7 or 21 day old.  The 
predicted clearance for 7 and 21 day old rats was calculated according to Equations 
36 and 37.  Our criterion was that if the predicted clearance was 50-200% that of the 
measured in vivo clearance then the prediction was acceptable.  Neither the 7 nor the 21 
day predicted clearances fell in this range.  The predicted clearance values werer 8-fold 
(predicted 29 L/hr/Kg, observed 3.71 L/hr/Kg) and 12-fold (predicted 62 L/hr/Kg, 
observed 5.2 L/hr/Kg) higher than those observed for 7 and 21 day age groups, 
respectively.  Hence, the model was unable to predict in vivo oral clearance of midazolam 
using in vitro scaling factors. 
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The model assumes linear conditions where the unbound concentration (available 
for drug metabolism) is smaller than Km.  There is evidence in the literature of dose 
dependent kinetics for midazolam in rats and humans (Bornemann, Min et al. 1985; 
Higashikawa, Murakami et al. 1999).  In humans, a total dose of 30 mg was outside the 
linear range, where AUC increased disproportionately with the dose increase 
(Bornemann, Min et al. 1985).  In rats, intestinal and hepatic first-pass metabolism 
appeared to be dose –dependent (Higashikawa, Murakami et al. 1999).  These findings 
contradict one of the model assumptions. 
When predicted clearance was calculated using Km, the predicted values better 
reflected the observed clearance.  This might indicate the possibility of different Km 
values with age.  One explanation might be the difference in lipid composition of 
microsomes in different age groups that affects the drug availability to the enzyme and 
thus affecting apparent Km. 
A more viable explanation is that intestinal availability (FG) in adults is much less 
than 1 contradicting an underlying assumption of oral clearance prediction.  Although 
data from the literature (Kotegawa, Laurijssens et al. 2002; Uhing, Beno et al. 2004; 
Kanazu, Okamura et al. 2005) largely supported this assumption, there is some evidence 
to the contrary (Strelevitz, Foti et al. 2006).  Our in vitro data shows that mRNA, protein 
and in vitro activity of Cyp3a in the intestine was very much lower than in the liver.  The 
in vitro activity in the intestine at 112 days was 100-fold less than in the liver.  However, 
scaling factors for the intestine are mostly lacking in terms of surface area, protein 
content and enzyme distribution along the whole organ.  Such low activity might then be 
an indicator of significant intestinal metabolism if properly scaled.  Together with the fact 
that no activity was detected in the 7 and 21 day old rat intestine, this might be an 
evidence of significant intestinal first pass effect in the adults and not in the pups which 
was not accounted for in the prediction causing the model to fail. 
Our results do not discredit the model as a viable option for clearance prediction.  
Further experiments elucidating how Km and first pass metabolism vary or not with age 
along with dosing the rats with a lower dose of midazolam and using a different Cyp3a 
substrate would allow further evaluation of the model. 
Copyright © Maggie Magdi Abbassi 2007 
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Chapter 7. Summary and Conclusions 
 
Infant exposure to drugs in breast milk is determined by two important factors, the 
amount of drug ingested in the milk and the ability of the infant to clear the drug.  There is 
a dearth of information about both determinants.  Clinical trials set to explore either 
phenomenon suffer from ethical and logistical hindrances.  Hence, models are needed to 
predict the appearance of drugs in milk and the clearance in the neonate.  The aim of this 
dissertation was to examine models to predict milk to serum ratio of drugs in the mother 
and clearance in the neonate. 
The models studied for the M/S prediction were the Atkinson and Begg model 
and the Fleishaker model.  The Atkinson and Begg model is an empirical model that does 
not need any experimental determination of the parameters.  It assumes passive diffusion 
of the drugs into milk.  M/S is predicted by a multiple linear regression relationship of the 
physicochemical parameters affecting the diffusion of the unionized, unbound molecule 
into milk.  The model was shown to be inadequate for predicting both basic and acidic 
drugs. The multiple regression relationship might need to be further examined with a 
larger set of drugs to improve the model prediction. 
The Fleishaker model is a mechanistic model that relies on the in vitro 
determination of drug protein binding in milk and serum and the drug ratio in skim to 
whole milk.  The model is better suited to predict whether the drugs passively diffused 
into milk or were actively transported, based on comparison with observed values.  In its 
current form, the model is useful in understanding the mechanisms of drug transfer into 
milk when combined with observed values.  Further understanding of the active transport 
processes involved in drug transfer into milk might make it feasible to add an active 
transport component to the model and improve its predictive ability. 
The ontogeny of Cyp3a metabolism in the male rat was studied to understand the 
various aspects of development (mRNA, protein and activity) and to examine the 
assumptions of the clearance ontogeny model previously proposed by our laboratory.  
The mRNA expression development of Mdr1a and Mdr1b was followed as well, due to 
the importance of P-gp in clearance and the shared regulation and substrates of Cyp3a 
and P-gp.  The patterns of ontogeny were different in the liver versus the intestine for 
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each gene.  In general, the expression levels were lower in the intestine.  Cyp3a1 and 
Mdr1a expression in the liver were high at birth and decreased subsequently.  Cyp3a2 
mRNA expression increased with age.  Mdr1b expression in the liver was relatively low 
at all the age groups studied except for the 42 day old group, which was significantly 
higher.  In the intestine, Cyp3a1 and Mdr1a mRNA expression increased with age.  
Mdr1b expression was the same for all the age groups except for the 42 day old rats, 
which had slightly lower expression.  It was not possible to follow Cyp3a2 mRNA 
ontogeny in the intestine due to the very low expression.  It appears that each gene is 
differentially regulated across tissues.  However, Cyp3a1 and Mdr1a seem to have the 
same ontogeny pattern at the mRNA level within the same tissue.  The 42 day old age 
group had a unique expression of Mdr1b in both the intestine and liver when compared to 
the rest of the age groups.  Although there are some studies about the regulation of these 
genes in the rat liver and intestine, the actual triggers of these ontogeny patterns remain to 
be studied. 
Cyp3a2 protein ontogeny in the male rat liver increased with age.  In the intestine 
the expression was lower.  Cyp3a1 protein was not followed due to the lack of a 
commercially available specific antibody. 
Midazolam 4-hydroxylation by the male rat liver and intestinal microsomes was 
used as probe for in vitro Cyp3a activity.  The intestinal activity, when detectable, was 
100 fold lower than in the liver, in agreement with the mRNA and protein expression, 
which were lower in the intestine.  The Vmax for 4-hydroxymidazolam formation 
increased with age in the male rat liver.  Cyp3a2 mRNA expression, protein expression 
and Cyp3a in vitro activity in the male rat liver had the same ontogeny pattern when 
normalized to the adult (112 days) with the exception of the 1 day old where protein and 
activity were correlated and only RNA was low.  Modeling of such a pattern might 
enable the prediction of activity from protein or mRNA levels. 
The ontogeny model assumptions studied were whether microsomal protein does 
not change with age and if Km is constant for an enzyme-substrate system.  The 
microsomal protein normalized to liver weight was found to change with age, 
necessitating that the scaling factors used to extrapolate in vitro activity to in vivo 
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clearance take microsomal protein into account.  The Km was not different across the age 
groups for the 4-hydroxylation of midazolam by the male rat liver microsomes. 
When applying the model prediction to the 7 and 21 day old age groups, the 
model did not predict the measured in vivo clearance of midazolam.  The model grossly 
overpredicted clearance based on in vitro data.  A possible reason for the difference 
between the predicted and observed values is that intestinal bioavailability in the intestine 
is much lower in the adults than in the pups, which was not accounted for in the model.   
These results are inconclusive as to whether the model is useful in predicting in 
vivo clearance.   Further studies are needed to test the model prediction of drugs cleared 
by Cyp3a in the male rat.   In vitro, the use of hepatocytes rather than microsomes might 
better mimic in vivo conditions.  In vivo, a different Cyp3a substrate and testing the 
model prediction in more age groups would be of great value. 
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Table 12: Predicted M/S (M/P’ phase) from the Atkinson and Begg model and 
observed M/S values from the literature. 
Drug 
M/P' 
phase 
(predicted) 
M/S 
obs 
Acyclovir 0.70 3.00 
Amoxicillin 0.11 0.02 
Captopril 0.01 0.01 
Cefadroxil 0.07 0.01 
Ciprofloxacin 0.82 1.60 
Clonazepam 0.00 0.33 
Doxorubicin 0.78 1.20 
Enalapril 0.02 0.02 
Indomethacin 0.04 0.37 
Ketorolac 0.17 0.02 
Naproxen 0.28 0.01 
Oxazepam 0.72 0.10 
Piroxicam 0.13 0.02 
Chlorpromazine 0.86 2 
Clonidine 2.22 2 
Fluoxetine 0.38 0.38 
Fluoxetine 0.38 0.68 
Imipramine 1.10 1.6 
Labetalol 1.11 1.5 
Metoprolol 2.63 2.9 
Quinidine 0.74 0.71 
Ranitidine 2.24 3.8 
Terbutaline 2.31 2 
Timolol 1.29 0.8 
Trimethoprim 1.06 1.25 
Acebutolol 3.10 5.7 
Quinine 0.54 0.31 
Nicotine 2.51 2.92 
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References used for calculations: (Ardenne and Reitnauer 1975; Corrocher, 
Tedesco et al. 1975; Yokoyama, Kono et al. 1975; Dahl and Strandjord 1977; Eeg-
Olofsson, Malmros et al. 1978; Spyker, Thomas et al. 1978; Wiles, Orr et al. 1978; 
Gugler, Kurten et al. 1979; Sovner and Orsulak 1979; Kafetzis, Siafas et al. 1981; 
Pickoff, Kessler et al. 1981; Boreus and de Chateau 1982; Ita, Singhvi et al. 1982; 
Lonnerholm and Lindstrom 1982; Fidler, Smith et al. 1983; Laskin 1983; Ostensen 1983; 
Kulas, Lunell et al. 1984; Lindberg, Boreus et al. 1984; Lindeberg, Sandstrom et al. 1984; 
Luck and Nau 1984; Dayer, Leemann et al. 1985; Egan, Costanza et al. 1985; Kearns, 
McConnell et al. 1985; Lunell, Kulas et al. 1985; McGourty, Silas et al. 1985; Sjovall, 
Alvan et al. 1986; Hartikainen-Sorri, Heikkinen et al. 1987; Lau, Emery et al. 1987; 
Duchin, McKinstry et al. 1988; Lowenthal, Matzek et al. 1988; Meyer, de Miranda et al. 
1988; Ostensen, Matheson et al. 1988; Borgstrom, Nyberg et al. 1989; Wischnik, Manth 
et al. 1989; Dahlstrom, Lundell et al. 1990; Dostal, Weaver et al. 1990; Isenberg 1990; 
Redman, Kelly et al. 1990; Sallee and Pollock 1990; Donnelly and Macphee 1991; 
Hutabarat, Unadkat et al. 1991; Lebedevs, Wojnar-Horton et al. 1991; Rush, Snyder et al. 
1991; Brocks and Jamali 1992; Verme, Ludden et al. 1992; Benowitz and Jacob 1993; 
Gladziwa and Klotz 1993; MacFadyen, Meredith et al. 1993; Oberbauer, Krivanek et al. 
1993; Piscitelli, Rodvold et al. 1993; Altamura, Moro et al. 1994; Olkkola, Brunetto et al. 
1994; Wells, Mortensen et al. 1994; Bork and Benes 1995; Foye, Lemke et al. 1995; 
McNamara, Meece et al. 1996; Venkatesan, Mathur et al. 1997; Yoshida, Smith et al. 
1997; Yoshida, Smith et al. 1998; Yoshida, Smith et al. 1998; Kristensen, Ilett et al. 
1999; Zhu, Jiang et al. 2002) 
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Table 13: Relative mRNA expression of Cyp3a1 in male Sprague-Dawley rat 
liver. 
Age (days).Rat number Mean 
1.1 6.10 
1.2 6.35 
1.3 5.28 
1.4 8.18 
7.1 0.71 
7.2 1.12 
7.3 0.76 
7.4 0.84 
21.1 1.08 
21.2 1.09 
21.3 1.54 
21.4 1.67 
42.1 0.86 
42.2 0.81 
42.3 1.00 
42.4 0.81 
77.1 1.24 
77.2 0.96 
77.3 0.81 
77.4 0.93 
112.1 0.90 
112.2 1.30 
112.3 1.24 
112.4 1.13 
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Table 14: Relative mRNA expression of Cyp3a2 in male Sprague-Dawley rat 
liver. 
Age (days).Rat number Mean 
1.1 0.49 
1.2 0.43 
1.3 0.41 
1.4 0.40 
7.1 2.50 
7.2 1.98 
7.3 1.94 
7.4 1.86 
21.1 1.45 
21.2 1.36 
21.3 1.76 
21.4 1.72 
42.1 2.19 
42.2 2.67 
42.3 2.42 
42.4 2.43 
77.1 3.20 
77.2 2.78 
77.3 2.10 
77.4 3.71 
112.1 1.24 
112.2 2.65 
112.3 3.92 
112.4 2.93 
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Table 15: Relative mRNA expression of Mdr1a in male Sprague-Dawley rat liver. 
Age (days).Rat number Mean 
1.1 0.09 
1.2 0.42 
1.3 0.32 
1.4 0.39 
7.1 0.09 
7.2 0.08 
7.3 0.11 
7.4 0.14 
21.1 0.31 
21.2 0.16 
21.3 0.21 
21.4 0.22 
42.1 0.17 
42.2 0.17 
42.3 0.19 
42.4 0.15 
77.1 0.09 
77.2 0.16 
77.3 0.09 
77.4 0.06 
112.1 0.01 
112.2 0.07 
112.3 0.17 
112.4 0.19 
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Table 16: Relative mRNA expression of Mdr1b in male Sprague-Dawley rat liver. 
Age (days).Rat number Mean 
1.1 0.14 
1.2 0.33 
1.3 0.38 
1.4 0.23 
7.1 0.15 
7.2 0.06 
7.3 0.10 
7.4 0.10 
21.1 0.30 
21.2 0.20 
21.3 0.56 
21.4 0.13 
42.1 1.44 
42.2 1.43 
42.3 1.02 
42.4 2.07 
77.1 0.22 
77.2 0.25 
77.3 0.20 
77.4 0.43 
112.1 0.27 
112.2 0.31 
112.3 0.50 
112.4 0.41 
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Table 17: Relative mRNA expression of villin in male Sprague-Dawley rat 
intestinal mucosa.  
 
Age (days).Rat number Mean 
7.1 4.76 
7.2 7.07 
7.3 3.81 
7.4 4.58 
21.1 5.21 
21.2 5.78 
21.4 6.84 
42.1 9.06 
42.2 6.83 
42.3 5.35 
42.4 6.64 
112.2 4.66 
112.3 11.20 
112.4 5.56 
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Table 18: Relative mRNA expression of Cyp3a1 in male Sprague-Dawley rat 
intestinal mucosa. 
Age (days).Rat number Mean 
7.1 0.0003 
7.2 0.0004 
7.3 0.0003 
7.4 0.0003 
21.1 0.0004 
21.2 0.0002 
21.4 0.0005 
42.1 0.0008 
42.2 0.0003 
42.3 0.0003 
42.4 0.0003 
112.2 0.0009 
112.3 0.0009 
112.4 0.0005 
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Table 19: Relative mRNA expression of Mdr1a in male Sprague-Dawley rat 
intestinal mucosa. 
Age (days).Rat number Mean 
7.1 1.09 
7.2 N/A  
7.3 3.87 
7.4 3.36 
21.1 1.71 
21.2 5.20 
21.4 2.67 
42.1 10.60 
42.2 7.90 
42.3 10.75 
42.4 4.82 
112.2 13.25 
112.3 23.75 
112.4 14.95 
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Table 20: Relative mRNA expression of Mdr1b in male Sprague-Dawley rat 
intestinal mucosa.  
Age (days).Rat number Mean 
7.1 0.08 
7.2 0.28 
7.3 0.12 
7.4 0.15 
21.1 0.14 
21.2 0.26 
21.4 0.12 
42.1 0.13 
42.2 0.02 
42.3 0.05 
42.4 0.02 
112.2 0.27 
112.3 0.26 
112.4 0.13 
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Table 21: Cyp3a2Protein expression male Sprague-Dawley rat liver microsomes 
determined by western blot (ng Cyp3a2 protein/5µg liver microsomal protein). 
 
Age 
(days).Rat 
number 
Mass  
1.1 0.77 
1.2 1.22 
1.3 1.09 
7.1 0.78 
7.2 0.83 
7.3 0.62 
7.4 0.61 
21.1 0.20 
21.2 0.23 
21.3 0.36 
21.4 0.21 
42.1 1.24 
42.2 0.82 
42.3 0.49 
42.4 0.66 
77.1 1.59 
77.2 1.77 
77.3 1.90 
77.3 0.92 
112.1 0.88 
112.2 1.02 
112.3 0.89 
112.4 0.92 
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NONMEM ANALYSIS 
NONMEM 7 day age group data format: 
 
#ID AMT Time DV MDV 
50 300 0 0 1 
50 0 0.083 43.576 0 
59 250 0 0 1 
59 0 0.083 107.822 0 
60 300 0 0 1 
60 0 0.1 320.728 0 
51 350 0 0 1 
51 0 0.117 107.798 0 
58 250 0 0 1 
58 0 0.267 194.857 0 
47 200 0 0 1 
47 0 0.283 1201.77 0 
48 250 0 0 1 
48 0 0.283 775.369 0 
49 200 0 0 1 
49 0 0.283 1862.67 0 
89 350 0 0 1 
89 0 0.5 1082.81 0 
90 300 0 0 1 
90 0 0.5 2568.5 0 
88 250 0 0 1 
88 0 0.55 544.23 0 
101 250 0 0 1 
101 0 0.667 5404.19 0 
100 250 0 0 1 
100 0 0.683 3994.36 0 
99 300 0 0 1 
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99 0 0.717 7244.29 0 
91 200 0 0 1 
91 0 1.033 1443.88 0 
92 300 0 0 1 
92 0 1.033 2357.29 0 
103 300 0 0 1 
103 0 1.05 1014.46 0 
102 250 0 0 1 
102 0 1.083 1165.95 0 
94 250 0 0 1 
94 0 1.5 2087.91 0 
93 250 0 0 1 
93 0 1.533 844.148 0 
104 300 0 0 1 
104 0 1.567 936.258 0 
105 250 0 0 1 
105 0 1.583 972.694 0 
96 250 0 0 1 
96 0 2.033 1885.65 0 
95 200 0 0 1 
95 0 2.05 1317.55 0 
107 300 0 0 1 
107 0 2.067 1104.67 0 
106 300 0 0 1 
106 0 2.083 3984.67 0 
108 200 0 0 1 
108 0 3.017 452.107 0 
109 250 0 0 1 
109 0 3.017 791.594 0 
97 300 0 0 1 
97 0 3.05 420.169 0 
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98 250 0 0 1 
98 0 3.067 908.407 0 
45 300 0 0 1 
45 0 4.017 779.95 0 
46 300 0 0 1 
46 0 4.033 695.948 0 
62 250 0 0 1 
62 0 4.05 1531.76 0 
61 250 0 0 1 
61 0 4.083 744.928 0 
54 300 0 0 1 
54 0 6.017 158.64 0 
53 300 0 0 1 
53 0 6.05 49.248 0 
63 250 0 0 1 
63 0 6.05 455.925 0 
52 200 0 0 1 
52 0 6.067 55.322 0 
55 250 0 0 1 
55 0 8.033 14.375 0 
64 300 0 0 1 
64 0 8.033 97.297 0 
65 300 0 0 1 
65 0 8.033 552.739 0 
56 250 0 0 1 
56 0 8.05 27.504 0 
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NONMEM Control File for 7 day age group: 
 
Created by MAGGIE ABBASSI  
$PROBLEM POPULATION DATA ANALYSIS OF MIDAZOLAM 
$INPUT  ID AMT TIME DV AGE1 AGE2 MDV ; FITTING OF 
DESTRUCTIVE SAMPLING IN 7 DAY OLDS 
                ; DATE CONTROL FILE CREATED 06-1-07 
                ; INITIAL ESTIMATE OF CL AND KA OBTAINED FROM 
AVERAGE INDIVIDUAL ANALYSIS               
;------------------------- 
;  UNITS                 | 
;  Time - hours          | 
;  Dose - mcg            | 
;  Cp  - ng/ml = mcg/L   | 
;  Clearances/F - L/hour | 
;  Volumes/F - L         | 
;------------------------- 
$DATA  MIDAZOLAM.7DAY.AGE.DATA.TXT IGNORE= # 
$SUBROUTINES ADVAN2 TRANS2 
$PK 
      
      TVCL  =THETA(1) 
      CL    = TVCL*EXP(ETA(1)) 
      TVV  = THETA(2) 
      V   = TVV*EXP(ETA(2)) 
      CLRA  = 0 
      TVKA=THETA(3) 
      KA=THETA(3) 
       
      S2    = V 
      K     = CL  / V ;  
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      DUM   = 0 
$ERROR IPRED= F 
      Y     = IPRED*(1+ERR(1)) 
      IRES  = DV - F 
  
 
$THETA  
 (0, 0.0274,10) ;[CL]   
 (0, 0.0945 ,10) ;[V] 
 (0, 0.357, 1);[KA] 
 
$OMEGA 
 (0.1) 
 (0.1) 
$SIG 
 0.3 FIX   
 
$ESTIMATION METHOD=1 PRINT=1 MAXEVAL=9999 NOABORT 
SIGDIGITS=3 POSTHOC 
        MSFO=msfo.outputfile 
         
$COVA 
$TABLE ID  AMT  TIME  IPRED  IRES 
       NOPRINT ONEHEADER FILE=table.txt 
$TABLE ID  CL   V  KA   
       FIRSTONLY NOPRINT ONEHEADER NOAPPEND FILE=etatable.txt 
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NONMEM output for 7 day age group:  
 
ID AMT TIME IPRE IRES Observed PRED RES WRES 
50 0.00 0.08 166.86 -123.29 43.58 357.66 -314.09 -0.68 
59 0.00 0.08 170.14 -62.32 107.82 298.05 -190.23 -0.50 
60 0.00 0.10 344.66 -23.93 320.73 423.96 -103.23 -0.19 
51 0.00 0.12 282.46 -174.66 107.80 569.36 -461.57 -0.64 
58 0.00 0.27 428.63 -233.78 194.86 804.31 -609.46 -0.65 
47 0.00 0.28 1126.10 75.64 1201.80 671.71 530.06 0.68 
48 0.00 0.28 790.62 -15.25 775.37 839.63 -64.26 -0.07 
49 0.00 0.28 1742.20 120.48 1862.70 671.71 1191.00 1.53 
89 0.00 0.50 1287.90 -205.11 1082.80 1691.00 -608.16 -0.35 
90 0.00 0.50 2322.40 246.13 2568.50 1449.40 1119.10 0.75 
88 0.00 0.55 823.38 -279.15 544.23 1267.50 -723.23 -0.57 
101 0.00 0.67 4892.70 511.48 5404.20 1377.10 4027.10 3.10 
100 0.00 0.68 3495.40 499.00 3994.40 1389.10 2605.20 2.00 
99 0.00 0.72 6601.20 643.04 7244.30 1695.10 5549.20 3.55 
91 0.00 1.03 1340.50 103.36 1443.90 1213.40 230.44 0.24 
92 0.00 1.03 2121.60 235.65 2357.30 1820.20 537.12 0.37 
103 0.00 1.05 1402.30 -387.83 1014.50 1821.30 -806.81 -0.55 
102 0.00 1.08 1337.00 -171.01 1165.90 1518.40 -352.48 -0.29 
94 0.00 1.50 1774.40 313.55 2087.90 1435.50 652.45 0.62 
93 0.00 1.53 1202.30 -358.15 844.15 1423.70 -579.58 -0.56 
104 0.00 1.57 1410.50 -474.23 936.26 1693.30 -757.06 -0.61 
105 0.00 1.58 1235.40 -262.75 972.69 1405.00 -432.29 -0.42 
96 0.00 2.03 1589.60 296.04 1885.70 1204.30 681.37 0.73 
95 0.00 2.05 1151.40 166.18 1317.60 956.88 360.67 0.49 
107 0.00 2.07 1267.30 -162.59 1104.70 1425.50 -320.81 -0.29 
106 0.00 2.08 3352.90 631.75 3984.70 1416.20 2568.50 2.33 
108 0.00 3.02 504.90 -52.80 452.11 604.03 -151.93 -0.25 
109 0.00 3.02 780.56 11.04 791.59 755.04 36.55 0.05 
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97 0.00 3.05 615.67 -195.50 420.17 890.33 -470.16 -0.53 
98 0.00 3.07 859.62 48.79 908.41 735.25 173.15 0.24 
45 0.00 4.02 741.60 38.35 779.95 517.44 262.51 0.42 
46 0.00 4.03 667.70 28.24 695.95 512.63 183.32 0.29 
62 0.00 4.05 1425.00 106.76 1531.80 422.97 1108.80 2.15 
61 0.00 4.08 701.78 43.15 744.93 414.87 330.06 0.65 
54 0.00 6.02 158.00 0.64 158.64 153.56 5.08 0.02 
53 0.00 6.05 89.19 -39.94 49.25 150.44 -101.19 -0.45 
63 0.00 6.05 448.19 7.73 455.92 125.37 330.56 1.76 
52 0.00 6.07 68.49 -13.17 55.32 99.24 -43.92 -0.30 
55 0.00 8.03 22.19 -7.81 14.38 36.08 -21.71 -0.37 
64 0.00 8.03 96.29 1.01 97.30 43.30 54.00 0.77 
65 0.00 8.03 551.22 1.52 552.74 43.30 509.44 7.29 
56 0.00 8.05 29.10 -1.60 27.50 35.69 -8.19 -0.14 
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NONMEM: Clearance (L/hr), V (L), Ka for 7 day age group 
 
ID CL V KA 
45 0.05 0.05 0.64 
46 0.05 0.05 0.64 
47 0.05 0.02 0.64 
48 0.05 0.04 0.64 
49 0.04 0.01 0.64 
50 0.05 0.09 0.64 
51 0.05 0.09 0.64 
52 0.06 0.03 0.64 
53 0.06 0.03 0.64 
54 0.05 0.04 0.64 
55 0.06 0.03 0.64 
56 0.06 0.04 0.64 
58 0.05 0.08 0.64 
59 0.05 0.07 0.64 
60 0.05 0.05 0.64 
61 0.04 0.06 0.64 
62 0.02 0.05 0.64 
63 0.04 0.08 0.64 
64 0.05 0.06 0.64 
65 0.03 0.11 0.64 
88 0.05 0.07 0.64 
89 0.05 0.06 0.64 
90 0.05 0.02 0.64 
91 0.05 0.03 0.64 
92 0.05 0.03 0.64 
93 0.06 0.05 0.64 
94 0.04 0.03 0.64 
95 0.04 0.04 0.64 
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96 0.04 0.04 0.64 
97 0.06 0.03 0.64 
98 0.05 0.05 0.64 
99 0.02 0.01 0.64 
100 0.03 0.01 0.64 
101 0.02 0.01 0.64 
102 0.06 0.05 0.64 
103 0.06 0.07 0.64 
104 0.06 0.05 0.64 
105 0.06 0.05 0.64 
106 0.02 0.02 0.64 
107 0.06 0.04 0.64 
108 0.06 0.04 0.64 
109 0.05 0.04 0.64 
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NONMEM 21 day age group data format: 
 
#ID AMT Time DV MDV 
68 850 0 0 1 
68 0 4.03 303.1 0 
69 850 0 0 1 
69 0 3.98 182.4 0 
70 850 0 0 1 
70 0 0.3 408.69 0 
71 950 0 0 1 
71 0 0.3 253.56 0 
72 800 0 0 1 
72 0 0.1 14.98 0 
73 1050 0 0 1 
73 0 0.08 576.23 0 
74 850 0 0 1 
74 0 0.52 1999.86 0 
75 1000 0 0 1 
75 0 0.52 1244.48 0 
76 900 0 0 1 
76 0 1.03 2266.43 0 
77 1050 0 0 1 
77 0 1 2801.07 0 
78 950 0 0 1 
78 0 1.53 1032.63 0 
79 800 0 0 1 
79 0 1.52 1340.98 0 
80 800 0 0 1 
80 0 2.03 2722.52 0 
81 950 0 0 1 
81 0 2.03 390.49 0 
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82 950 0 0 1 
82 0 3.02 1033.14 0 
83 950 0 0 1 
83 0 3.05 1515.82 0 
84 1000 0 0 1 
84 0 6.08 11 0 
85 850 0 0 1 
85 0 6 17.31 0 
86 850 0 0 1 
86 0 8 7.71 0 
87 1050 0 0 1 
87 0 8 0.98 0 
112 950 0 0 1 
112 0 4.05 632.89 0 
113 950 0 0 1 
113 0 4.05 617.23 0 
114 750 0 0 1 
114 0 0.27 293.47 0 
115 1100 0 0 1 
115 0 0.25 867.06 0 
116 1000 0 0 1 
116 0 0.1 18.62 0 
117 1050 0 0 1 
117 0 0.08 37.8 0 
118 1050 0 0 1 
118 0 0.53 1033.25 0 
119 950 0 0 1 
119 0 0.55 1920.13 0 
120 1050 0 0 1 
120 0 1.02 2414.99 0 
121 850 0 0 1 
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121 0 1.03 1115.75 0 
122 700 0 0 1 
122 0 1.3 738.61 0 
123 1100 0 0 1 
123 0 1.52 2265.75 0 
124 950 0 0 1 
124 0 1.57 2888.92 0 
125 950 0 0 1 
125 0 1.98 1353.6 0 
126 800 0 0 1 
126 0 2.02 987.94 0 
127 600 0 0 1 
127 0 3.05 355.97 0 
128 750 0 0 1 
128 0 3.1 1771.65 0 
129 700 0 0 1 
129 0 6.05 1.23 0 
130 900 0 0 1 
130 0 6.05 18.29 0 
131 950 0 0 1 
131 0 8 4.1 0 
132 750 0 0 1 
132 0 8 15.14 0 
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NONMEM Control File for 21 day age group: 
 
; Created by MAGGIE ABBASSI  
$PROBLEM POPULATION DATA ANALYSIS OF MIDAZOLAM 
$INPUT  ID AMT TIME DV MDV ; FITTING OF DESTRUCTIVE 
SAMPLING IN 21 DAY OLDS 
                ; DATE CONTROL FILE CREATED 06-1-07 
                ; INITIAL ESTIMATE OF CL AND KA OBTAINED FROM 
winNonlin ANALYSIS               
;------------------------- 
;  UNITS                 | 
;  Time - hours          | 
;  Dose - mcg            | 
;  Cp  - ng/ml = mcg/L   | 
;  Clearances/F - L/hour | 
;  Volumes/F - L         | 
;------------------------- 
$DATA  MIDAZOLAM.21DAY2.DATA.TXT IGNORE= # 
$SUBROUTINES ADVAN2 TRANS2 
$PK 
      
      TVCL  =THETA(1) 
      CL    = TVCL*EXP(ETA(1)) 
      TVV  = THETA(2) 
      V   = TVV*EXP(ETA(2)) 
      CLRA  = 0 
      TVKA=THETA(3) 
      KA=THETA(3) 
       
      S2    = V 
      K     = CL  / V ;  
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      DUM   = 0 
$ERROR IPRED= F 
      Y     = IPRED*(1+ERR(1)) 
      IRES  = DV - F 
  
 
$THETA  
 (0, 0.169,10) ;[CL]   
 (0, 0.158 ,10) ;[V] 
 (0, 0.357, 1);[KA] 
 
$OMEGA 
 (0.1) 
 (0.1) 
$SIG 
 0.3 FIX   
 
$ESTIMATION METHOD=1 PRINT=1 MAXEVAL=9999 NOABORT 
SIGDIGITS=3 POSTHOC 
        MSFO=msfo.outputfile 
         
$COVA 
$TABLE ID  AMT  TIME  IPRED  IRES 
       NOPRINT ONEHEADER FILE=table.txt 
$TABLE ID  CL   V  KA   
       FIRSTONLY NOPRINT ONEHEADER NOAPPEND FILE=etatable.txt 
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NONMEM output for 21 day age group:  
 
ID TIME IPRE IRES Observed PRED RES WRES 
73 0.08 420.45 155.78 576.23 375.09 201.14 0.88 
117 0.08 319.80 -282.00 37.80 375.09 -337.29 -1.47 
72 0.10 295.91 -280.93 14.98 349.41 -334.43 -1.57 
116 0.10 369.88 -351.26 18.62 436.76 -418.14 -1.57 
115 0.25 991.45 -124.39 867.06 1017.40 -150.36 -0.24 
114 0.27 663.89 -370.42 293.47 732.81 -439.34 -0.99 
70 0.30 816.44 -407.75 408.69 892.71 -484.02 -0.90 
71 0.30 884.90 -631.34 253.56 997.73 -744.17 -1.24 
74 0.52 1382.20 617.66 1999.90 1213.80 786.10 1.07 
75 0.52 1394.80 -150.29 1244.50 1428.00 -183.47 -0.21 
118 0.53 1427.40 -394.16 1033.30 1511.40 -478.18 -0.52 
119 0.55 1497.20 422.97 1920.10 1388.10 531.99 0.63 
77 1.00 2043.40 757.64 2801.10 1700.60 1100.40 1.00 
120 1.02 1917.90 497.13 2415.00 1697.00 718.00 0.65 
76 1.03 1709.90 556.54 2266.40 1452.80 813.63 0.86 
121 1.03 1297.30 -181.51 1115.80 1372.10 -256.34 -0.29 
122 1.30 943.30 -204.69 738.61 1061.00 -322.37 -0.44 
79 1.52 1216.70 124.30 1341.00 1114.80 226.21 0.28 
123 1.52 1872.20 393.52 2265.80 1532.80 732.94 0.65 
78 1.53 1195.20 -162.57 1032.60 1318.00 -285.40 -0.30 
124 1.57 2116.50 772.43 2888.90 1294.70 1594.20 1.66 
125 1.98 1225.10 128.54 1353.60 1044.80 308.76 0.36 
126 2.02 934.04 53.90 987.94 859.46 128.48 0.18 
80 2.03 2158.60 563.91 2722.50 854.39 1868.10 2.63 
81 2.03 711.22 -320.73 390.49 1014.60 -624.09 -0.74 
82 3.02 946.53 86.61 1033.10 517.66 515.48 0.96 
83 3.05 1388.80 127.04 1515.80 506.20 1009.60 1.90 
127 3.05 346.77 9.20 355.97 319.71 36.26 0.11 
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128 3.10 1642.00 129.65 1771.70 384.93 1386.70 3.40 
69 3.98 190.73 -8.33 182.40 218.35 -35.95 -0.13 
68 4.03 290.93 12.17 303.10 209.62 93.48 0.36 
112 4.05 607.56 25.33 632.89 230.48 402.41 1.40 
113 4.05 592.24 24.99 617.23 230.48 386.75 1.34 
85 6.00 23.31 -6.00 17.31 38.97 -21.66 -0.36 
129 6.05 13.56 -12.33 1.23 30.71 -29.48 -0.61 
130 6.05 24.00 -5.71 18.29 39.48 -21.19 -0.34 
84 6.08 21.90 -10.90 11.00 42.72 -31.72 -0.47 
86 8.00 7.63 0.08 7.71 6.51 1.20 0.10 
87 8.00 3.63 -2.65 0.98 8.04 -7.06 -0.49 
131 8.00 4.76 -0.66 4.10 7.27 -3.17 -0.24 
132 8.00 14.99 0.15 15.14 5.74 9.40 0.92 
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NONMEM: Clearance (L/hr), V (L), Ka for 21 day age group: 
 
ID CL V KA 
68 0.21 0.19 0.92684 
69 0.26 0.19 0.92684 
70 0.26 0.21 0.92684 
71 0.27 0.22 0.92684 
72 0.25 0.23 0.92684 
73 0.24 0.17 0.92684 
74 0.21 0.17 0.92684 
75 0.25 0.19 0.92684 
76 0.19 0.18 0.92684 
77 0.19 0.18 0.92684 
78 0.27 0.19 0.92684 
79 0.22 0.19 0.92684 
80 0.09 0.16 0.92684 
81 0.33 0.19 0.92684 
82 0.16 0.20 0.92684 
83 0.12 0.19 0.92684 
84 0.32 0.18 0.92684 
85 0.30 0.18 0.92684 
86 0.23 0.19 0.92684 
87 0.33 0.18 0.92684 
112 0.15 0.20 0.92684 
113 0.15 0.20 0.92684 
114 0.26 0.21 0.92684 
115 0.25 0.20 0.92684 
116 0.25 0.23 0.92684 
117 0.25 0.22 0.92684 
118 0.27 0.20 0.92684 
119 0.22 0.18 0.92684 
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120 0.20 0.18 0.92684 
121 0.27 0.19 0.92684 
122 0.28 0.19 0.92684 
123 0.19 0.19 0.92684 
124 0.13 0.17 0.92684 
125 0.21 0.19 0.92684 
126 0.23 0.19 0.92684 
127 0.23 0.19 0.92684 
128 0.08 0.18 0.92684 
129 0.34 0.18 0.92684 
130 0.30 0.18 0.92684 
131 0.28 0.19 0.92684 
132 0.19 0.20 0.92684 
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NONMEM 112 day age group data format: 
 
#ID AMT Time DV MDV 
2 7500 0 0 1 
2 0 0.166667 168.2494 0 
3 7000 0 0 1 
3 0 0.333333 194.935 0 
4 7000 0 0 1 
4 0 0.5 230.8778 0 
5 7500 0 0 1 
5 0 1 193.6514 0 
6 7500 0 0 1 
6 0 1.5 22.08481 0 
7 7500 0 0 1 
7 0 2 48.30726 0 
8 7500 0 0 1 
8 0 3 2.12 0 
9 7500 0 0 1 
9 0 4 5.674165 0 
10 7500 0 0 1 
10 0 6 20.82152 0 
12 7500 0 0 1 
12 0 0.166667 98.10196 0 
13 8500 0 0 1 
13 0 0.333333 36.23911 0 
14 8500 0 0 1 
14 0 0.5 254.0732 0 
15 7500 0 0 1 
15 0 1 68.97136 0 
16 7500 0 0 1 
16 0 1.5 204.6975 0 
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17 8500 0 0 1 
17 0 2 33.68613 0 
18 7500 0 0 1 
18 0 3 7.790713 0 
19 7500 0 0 1 
19 0 4 5.176053 0 
20 7000 0 0 1 
20 0 6 26.65926 0 
21 7500 0 0 1 
21 0 2 158.3851 0 
23 7500 0 0 1 
23 0 0.166667 90.69091 0 
24 7500 0 0 1 
24 0 0.333333 192.5114 0 
25 7500 0 0 1 
25 0 0.5 284.6366 0 
26 7500 0 0 1 
26 0 1 244.9198 0 
27 7500 0 0 1 
27 0 1.5 33.24913 0 
28 7000 0 0 1 
28 0 2 69.69412 0 
29 7000 0 0 1 
29 0 3 13.77647 0 
30 7000 0 0 1 
30 0 4 3.36 0 
31 7000 0 0 1 
31 0 6 12.36589 0 
33 7500 0 0 1 
33 0 0.166667 49.51896 0 
34 7500 0 0 1 
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34 0 0.333333 722.4294 0 
35 8000 0 0 1 
35 0 0.5 353.8323 0 
36 7500 0 0 1 
36 0 1 51.95315 0 
37 7500 0 0 1 
37 0 1.5 91.89146 0 
38 7500 0 0 1 
38 0 2 18.99279 0 
39 7500 0 0 1 
39 0 3 9.252923 0 
40 8000 0 0 1 
40 0 4 5.08 0 
41 7650 0 0 1 
41 0 6 25.40474 0 
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NONMEM Control File for 112 day age group: 
 
; Created by MAGGIE ABBASSI  
$PROBLEM POPULATION DATA ANALYSIS OF MIDAZOLAM 
$INPUT  ID AMT TIME DV MDV ; FITTING OF DESTRUCTIVE 
SAMPLING IN 112 DAY OLDS 
                ; DATE CONTROL FILE CREATED 06-1-07 
                ; INITIAL ESTIMATE OF CL AND KA OBTAINED FROM 
winNonlin ANALYSIS               
;------------------------- 
;  UNITS                 | 
;  Time - hours          | 
;  Dose - mcg            | 
;  Cp  - ng/ml = mcg/L   | 
;  Clearances/F - L/hour | 
;  Volumes/F - L         | 
;------------------------- 
$DATA  MIDAZOLAM.112DAY2.DATA.TXT IGNORE= # 
$SUBROUTINES ADVAN2 TRANS2 
$PK 
      
      TVCL  =THETA(1) 
      CL    = TVCL*EXP(ETA(1)) 
      TVV  = THETA(2) 
      V   = TVV*EXP(ETA(2)) 
      CLRA  = 0 
      TVKA=THETA(3) 
      KA=THETA(3) 
       
      S2    = V 
      K     = CL  / V ;  
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      DUM   = 0 
$ERROR IPRED= F 
      Y     = IPRED*(1+ERR(1)) 
      IRES  = DV - F 
  
 
$THETA  
 (0, 17.57,100) ;[CL]   
 (0, 28.47 ,100) ;[V] 
 (0, 0.357, 10);[KA] 
 
$OMEGA 
 (0.1) 
 (0.1) 
$SIG 
 0.3 FIX   
 
$ESTIMATION METHOD=1 PRINT=1 MAXEVAL=9999 NOABORT 
SIGDIGITS=3 POSTHOC 
        MSFO=msfo.outputfile 
         
$COVA 
$TABLE ID  AMT  TIME  IPRED  IRES 
       NOPRINT ONEHEADER FILE=table.txt 
$TABLE ID  CL   V  KA   
       FIRSTONLY NOPRINT ONEHEADER NOAPPEND FILE=etatable.txt 
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NONMEM output for 112 day age group:  
 
ID TIME IPRE IRES DV PRED RES WRES 
2 0.17 152.91 15.34 168.25 129.72 38.53 0.36 
12 0.17 113.80 -15.69 98.10 129.72 -31.62 -0.30 
23 0.17 110.46 -19.77 90.69 129.72 -39.03 -0.37 
33 0.17 94.40 -44.89 49.52 129.72 -80.20 -0.76 
3 0.33 180.80 14.13 194.93 165.63 29.30 0.23 
13 0.33 138.23 -101.99 36.24 201.13 -164.89 -1.07 
24 0.33 185.05 7.46 192.51 177.46 15.05 0.11 
34 0.33 623.42 99.01 722.43 177.46 544.97 4.00 
4 0.50 200.03 30.85 230.88 172.99 57.89 0.46 
14 0.50 229.99 24.08 254.07 210.06 44.01 0.29 
25 0.50 234.05 50.58 284.64 185.35 99.29 0.74 
35 0.50 279.17 74.67 353.83 197.71 156.13 1.09 
5 1.00 158.32 35.34 193.65 137.77 55.88 0.61 
15 1.00 118.63 -49.65 68.97 137.77 -68.80 -0.75 
26 1.00 182.66 62.27 244.92 137.77 107.15 1.17 
36 1.00 114.56 -62.61 51.95 137.77 -85.82 -0.94 
6 1.50 51.03 -28.95 22.09 86.32 -64.23 -0.95 
16 1.50 156.76 47.94 204.70 86.32 118.38 1.75 
27 1.50 57.16 -23.91 33.25 86.32 -53.07 -0.78 
37 1.50 89.16 2.73 91.89 86.32 5.58 0.08 
7 2.00 49.36 -1.05 48.31 52.20 -3.89 -0.07 
17 2.00 40.82 -7.13 33.69 59.16 -25.47 -0.41 
21 2.00 133.94 24.45 158.39 52.20 106.19 1.93 
28 2.00 63.85 5.85 69.69 48.72 20.98 0.41 
38 2.00 28.91 -9.92 18.99 52.20 -33.21 -0.60 
8 3.00 5.75 -3.63 2.12 18.74 -16.62 -0.50 
18 3.00 9.45 -1.66 7.79 18.74 -10.95 -0.33 
29 3.00 14.18 -0.41 13.78 17.49 -3.71 -0.12 
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39 3.00 10.58 -1.33 9.25 18.74 -9.49 -0.29 
9 4.00 5.73 -0.05 5.67 6.71 -1.03 -0.06 
19 4.00 5.26 -0.09 5.18 6.71 -1.53 -0.09 
30 4.00 3.58 -0.22 3.36 6.26 -2.90 -0.18 
40 4.00 5.21 -0.13 5.08 7.15 -2.07 -0.11 
10 6.00 20.81 0.01 20.82 0.86 19.96 5.57 
20 6.00 26.65 0.01 26.66 0.80 25.86 7.74 
31 6.00 12.36 0.01 12.37 0.80 11.56 3.46 
41 6.00 25.39 0.01 25.41 0.88 24.53 6.72 
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NONMEM: Clearance (L/kg), V (L), Ka for 112 day age group: 
 
ID CL V KA 
2 25.41 20.83 3.86 
3 25.32 22.45 3.86 
4 24.40 20.60 3.86 
5 22.21 22.09 3.86 
6 33.21 19.34 3.86 
7 26.28 24.45 3.86 
8 30.31 19.15 3.86 
9 26.17 24.25 3.86 
10 15.92 42.78 3.86 
12 25.83 28.82 3.86 
13 26.51 38.87 3.86 
14 24.93 22.15 3.86 
15 30.28 27.73 3.86 
16 14.22 20.02 3.86 
17 29.07 21.67 3.86 
18 28.62 21.18 3.86 
19 26.42 23.87 3.86 
20 13.78 44.45 3.86 
21 11.93 21.92 3.86 
23 25.86 29.76 3.86 
24 25.52 23.74 3.86 
25 23.43 18.33 3.86 
26 19.18 19.32 3.86 
27 32.00 20.48 3.86 
28 22.14 27.18 3.86 
29 26.69 23.66 3.86 
30 27.31 22.59 3.86 
31 18.29 39.19 3.86 
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33 25.98 35.24 3.86 
34 13.77 5.33 3.86 
35 22.03 15.85 3.86 
36 31.56 28.02 3.86 
37 25.01 25.18 3.86 
38 30.62 20.05 3.86 
39 28.20 21.72 3.86 
40 26.64 23.55 3.86 
41 14.76 43.91 3.86 
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